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Abstract 
The use of biomacromolecules, e.g. peptides and antibodies, as therapeutics, so-called 
‘biologics’, is experiencing an increase in interest as more and more small molecule 
therapeutics fail to meet the regulatory requirements for human use.  
 
To expedite the examination of such biologics as useful therapeutics, positron-emission 
tomography (PET) is being used as an early stage non-invasive in vivo imaging modality to 
rule in, or to rule out, candidates from the drug discovery pipeline. To realise this goal, small, 
reactive radiolabelled compounds, termed prosthetic groups, are often used to label the 
biologic of interest. Furthermore, prosthetic groups may also be incorporated into small 
molecule therapeutics, thus enabling rapid elucidation of candidates in a pre-clinical 
environment from a single appropriate prosthetic group precursor/apparatus set up. 
 
Diaryliodonium salts have been considered as useful precursors to prosthetic groups, as this 
class of compound may facilitate the one-step introduction of a nucleophilic radiolabel, e.g. 
[18F]fluoride ion, onto any position of a given arene. However, direction of the radiolabel 
onto the target arene is generally dictated by stereoelectronics, where the nucleophile is 
substituted upon the least electron-rich arene. To achieve this effect, electron-rich arenes, 
such as 2-thienyl, are employed. However, a potentiated product where the second arene is 
also electron-rich is the poorly characterised 2-[18F]fluorothiophene. To ensure that the 
products of radiofluorination processes reported herein are correctly assigned, an authentic 
sample of 2-[19F]fluorothiophene has been prepared on a 750 mmol scale (Scheme A). 
 
 
Scheme A: Synthesis of 2-[19F]fluorothiophene. 
 
Unambiguous verification of the detection of 2-[18F]fluorothiophene has herein been 
achieved for the first time by radiofluorination of the highly electrophilic electron-rich 
dithienyliodonium trifluoroacetate, using a microfluidic apparatus. 
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Microfluidic apparatus is a technology which is experiencing an emergence as a useful 
means of probing the conditions advantageous to the production of radiolabeled material. We 
investigated the use of such apparatus in the optimised preparation of regioisomers of a key 
prosthetic group, [18F]fluorobenzaldehyde ([18F]FBA). The successful optimisation of the 
radiolabeling process has delivered 4-[18F]FBA in excellent radiochemical yields (>95%), as 
well delivering the associated regioisomer, 3-[18F]FBA, which is unavailable by convention 
means, by use of diaryliodonium salt precursors (Scheme B). 
 
Scheme B: Radiosynthesis of 4-[18F]FBA and 3-[18F]FBA from diaryliodonium salt precursors. 
 
Another prosthetic group considered bears the thiol reactive maleimide. An appropriate 
synthesis of a suitable diaryliodonium salt precursor (Scheme C) is reported herein. 
  
 
Scheme C: Synthesis of the precursor to the prosthetic group N-(4-[18F]fluorophenyl)maleimide. 
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1 Chapter One: Introduction 
 
Imaging agents, which have been labelled with positron (β+) emitters, are playing an 
increasingly important role in drug discovery/development and in the diagnosis of 
disease, for example in the early stage detection of biological abnormalities, such as 
tumours, both malignant and benign.1-5 Information regarding biochemical 
mechanisms, metabolic processes, and receptor function cannot typically be obtained 
by medical imaging techniques such as X-ray and magnetic resonance imaging 
(MRI). These techniques generally yield information about a subject’s anatomy and 
therefore provide little detail of molecular or metabolic events. The nuclear medicine 
imaging techniques Positron Emission Tomography (PET) and Single Photon 
Emission Computed Tomography (SPECT), provide a means of obtaining this 
information. 
 
1.1 Positron Emission Tomography 
 
PET is a non-invasive in vivo medical imaging technique which is used to detect 
compounds which have been labelled with a positron emitting radioisotope. There 
are many advantages to this procedure, such as the ability to quantitatively determine 
the biodistribution of a given imaging agent, and therefore determine the 
pharmacokinetic profile of that imaging agent.6 A picture and a representation of 
what occurs inside a PET scanner (Figure 1) are provided below. 
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Figure 1: A PET scanner (left), and a schematic representation of what occurs inside the 
scanner when a positron emitting isotope decays (right).3 The line-of-coincidence (LoC) is 
represented where both gamma photons are emitted in opposing directions. 
 
The subject is injected with the imaging agent of choice, e.g. an imaging agent 
labelled with fluorine-18, and after a period of rest, around 30 to 40 minutes in case 
of [18F]FDG (see section 1.4) then moved into the PET scanner. Fluorine-18 decays 
in the body largely by positron emission (97% - remainder via electron capture) 
forming oxygen-18, a positron and a neutrino (ν) (Scheme 1). 
 
18F                   18O + β+ + ν 
 
Scheme 1: Radioactive decay of the radioisotope fluorine-18. 
 
γ Photons are emitted as a consequence of an annihilation event which occurs 
between antimatter, (the positron emitted by decay of the radioisotope) and matter (a 
nearby electron).7 Very large numbers of these annihilation events need to occur in 
order to produce a PET image of sufficient quality. The energy at which a positron is 
emitted from a decaying isotope is a critical parameter regarding the resolution of the 
PET image, as, ideally, the annihilation event should occur as close as possible to the 
imaging agent. A high energy positron will travel further in matter, and therefore the 
annihilation event will occur further away from the site of interest, leading to a PET 
image of lower resolution. Signal to noise ratio (SNR) will also impact upon the 
resolution and therefore the quality of a PET image, though methods to take this into 
account, such as the noise equivalent count rate aim to mitigate this effect.7 The PET 
scanner is essentially a ring of photon detectors, or cameras, which detect the two 
gamma (γ) photons emitted at approximately 180° to each other as a result of the 
positron annihilation event. Many γ photons leave the body along a line of 
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coincidence (LoC) (Figure 1). By exploiting the LoC, i.e. using software algorithms 
to construct an image, it is possible to detect, with an acceptable degree of accuracy, 
where the annihilation event took place and hence the in vivo location for the 
fluorine-18 radiolabeled imaging agent. 
 
The quality of an image obtained by PET scanning can also be affected by an 
phenomenon known as Compton Scattering,8 whereby a γ photon emitted from the 
annihilation event interacts with an electron in the outer shell of a nearby atom. The γ 
photon’s path is changed, causing a slight loss in energy. In the majority of cases, the 
γ photon’s path is altered to such an extent that it is scattered out of the field of a 
detector and is therefore not counted; this is process is known as attenuation. When 
the effect of Compton Scattering is applied to subjects under study, it follows that an 
increase in subject size increases the relative amount of attenuation, consequently the 
number of lines of coincidence are decreased resulting in the diagnostic benefit of the 
scan being compromised (Figure 2).9 
 
 
Figure 2:9 The effect of Compton Scattering on the quality of PET images obtained from slim 
(left), average (middle) and heavy (right) patients. 
 
As the two γ photons produced in an annihilation event travel independently, it is 
possible that one γ photon may be attenuated, leaving the other γ photon without a 
partner in its LoC. If a γ photon is scattered and remains in the field of view, a 
scattered LoC can be observed (Figure 3). Scattered photons can be detected by 
measuring the energy deposited onto the crystal, as scattered photons will have a 
lower energy than non-scattered photons. The energy differences can be measured to 
±5% which removes most of the scattered events and improves the accuracy of the 
image produced.10 Another detection problem arises due to accidental coincidences, 
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which may occur when two non-partnered γ photons reach the detectors within the 
coincidence timing window (τ), simulating an authentic LoC (Figure 3). The number 
of accidental coincidences can be reduced by reducing τ.10 
 
 
Figure 3:10 Non-collinear LoC (dotted line) observed due to scattering (left) and accidental 
coincidences (right). 
 
The first medical applications, utilising a positron emitting radioisotope for medical 
applications, were carried out in 1951 by Sweet11 and Wren and co-workers,12 with 
the first human studies carried out in 1974.13, 14 The first scanner for human use was 
termed PETT III, for Positron Emission Transaxial Tomography III, however, the 
name was reduced to PET once it became apparent images could be obtained other 
than those only in the transaxial plane (Figure 4). 
 
 
Figure 4: The first PET machine for human use, termed PETT III.14 
 
Since 2000, PET has been integrated with a technique termed X-ray computed 
tomography (CT).15 CT provides detailed anatomical information about the subject, 
the data obtained can then be combined with the data obtained from a PET scan, the 
combined technique is known as PET-CT.2 
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PET has been used extensively as an imaging modality in the fields of oncology,2 
neurology,16 including the characterisation of Alzheimer’s and Parkinson’s disease, 
and cardiology.17 It is widely anticipated that PET will be widely used as an in vivo 
pharmacological imaging modality, and therefore play a major role in drug 
development.18 Data obtained from a PET image will allow drug developers to better 
understand the mode of action of lead compounds, their biodistribution, in addition 
to guiding the correct dosages for that compound. 
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1.2 Positron Emitting Isotopes used in PET 
 
Commonly used positron emitters in PET include, 11C, 13N, 15O, 18F, 64Cu and 68Ga 
(Table 1). The radioactive isotopes (interchangeably termed radionuclides) of carbon, 
nitrogen, and oxygen are an attractive choice to the radiochemist, as these elements 
are already present in many biologically active molecules and, as a result, the 
incorporation of their radionuclide equivalents does not compromise the in vivo 
activity.3 
Some of the radionuclides presented in Table 1 can be produced in a cyclotron. A 
cyclotron is a small particle accelerator that is capable of producing high energy 
beams of charged species, such as protons, which when directed at a particular target 
source, afford the corresponding radionuclide. Other radionuclides, such as gallium-
68, may be produced in a generator.  
 
Radionuclide Half-life (t1/2) Decay Product % (β+ decay) EMAX (β+) (KeV) 
11C 20.3 min 11B 100 961 
13N 9.97 min 13C 100 1190 
15O 2.04 min 15N 100 1732 
18F 109.7 min 18O 97 634 
64Cu 12.8 h 64Ni 19 656 
68Ga 67.6 min 68Zn 89 1899 
81Rb 4.57 h 81Kr 96 335 
89Zr 71.4 h 89Y 22 897 
124I 4.17 days 124Te 23 603 
 
Table 1: Radionuclides used in PET and their properties.19 
Careful consideration of the choice of the radioisotope to be used for the PET study 
is required for several reasons. Firstly, the half-life of the radioisotope determines its 
effectiveness at studying certain biological processes. For instance, using oxygen-15 
to measure a slow biological process, such as protein synthesis, would not be very 
useful as the half-life of oxygen-15 is too low at only 2.04 minutes. Consequently, 
most of the oxygen-15 radiolabeled imaging agent would have decayed before any 
useful data could be obtained. In this instance, it would be more appropriate to use a 
radionuclide with a longer half-life such as fluorine-18 (t1/2 = 109.7 min). Secondly, 
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the positron emitted from different decaying radionuclides does so at several 
different energies (Table 1). The energy at which a positron is emitted from a 
decaying radioisotope is a critical parameter regarding the resolution of the PET 
image, as, ideally, the annihilation event should occur as close as possible to the 
origin of the positron. A high energy positron will travel further, and therefore the 
annihilation event will also occur further away from the site of the 
radiopharmaceutcial leading to greater uncertainty in its location and hence a lower 
resolution PET image. 
 
Cyclotrons, of which a number are available, enable the production of positron 
emitting radionuclides by bombarding a particular target with accelerated charged 
particles (Figure 5). Cyclotron technology is an extremely complex topic and is 
beyond the scope of this chapter, however, an explanation of the essential features is 
provided. For an in-depth discussion of cyclotron technology, the reader is directed 
elsewhere.20 
 
 
Figure 5: ABT mini-cyclotron in the raised position (left) showing the vacuum chamber and a 
simplified schematic representation of what occurs when the cyclotron is in operation. 
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The first cyclotron was developed in 1934 by E. O. Lawrence and M. S. 
Livingston,21 both of whom subsequently developed the first medical cyclotron in 
1938 (Figure 6).22 
 
 
Figure 6:22 M. S. Livingston (left) and E. O. Lawrence (right) next to the first medical cyclotron, 
manufactured in 1938. 
 
Some of the most important radionuclides for PET, and their corresponding targets, 
which are produced in cyclotrons are presented in Table 2. 
 
 
 
Radionuclide t1/2 (min) Nuclear Reaction Target Product Decay Product 
11C 20.3 14N(p ) 11C N2(+O2) [11C]CO2 11B 
N2(+H2) [11C]CH4  
13N 9.97 16O(p ) 13N H2O [13N]NOx 13C 
  H2O+EtOH [13N]NH3  
15O 2.04 15N(d,n) 15O N2(+O2) [15O]O2 15N 
18F 109.7 20Ne(d )18F Ne(+F2) [18F]F2 18O 
  18O(p,n)18F [18O]H2O 18F-  
Table 2: PET radionuclides and their corresponding targets. 
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1.3 Pharmaceuticals Containing Fluorine 
 
Only since 1957 have pharmaceuticals been synthesised which contain fluorine,23 
since then, over 150 fluorinated pharmaceutical compounds have been developed, 
covering around 20% of today’s market.23-26 Many of the world’s top 
pharmaceuticals also contain fluorine,25 such as fluoxetine, atorvastatin and 
ciprofloxacin (Figure 7). 
  
 
Figure 7: Examples of drugs containing fluorine. 
 
The chart below shows how the incorporation of fluorine into drugs has developed 
between 1957 and 2006 (Figure 8).27 
 
 
Figure 8: Number of drugs released, and those which contain fluorine, 1957-2006.27 
 
Fluorine has many physical and pharmacokinetic properties which may be exploited 
to the medicinal chemists’ advantage.28 For instance, fluorine can in many cases 
enhance metabolic stability of nearby functionalities to oxidation by cytochrome 
P450 enzymes.29 Often, fluorine is used to replace hydrogen atoms in drug 
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compounds suffering from undesired metabolism, even though the size and 
electronic nature of the two atoms are very different. Furthermore, there is a 
difference in bond length between C-H (1.09 Å) and C-F (1.41 Å), with the C-F bond 
being more akin to a C-O bond (1.43 Å).29 Even though, successful H to F 
substitutions are known,30 such as Ezetimib (also with fluorine substitution of one of 
the methoxy groups) (Scheme 2)31 and fluoroquinolines (Scheme 3).32 
 
 
Scheme 2: H to F substitution, shown in red, which was found to block metabolic processes at 
the site of substitution as a result of structure activity relationship (SAR) studies. 
 
 
Scheme 3: H to F substitution, shown in red and determined as a result of structure activity 
relationship (SAR) studies, aided in facilitating activity vs a wide range of Gram-positive 
bacteria as well as increasing oral efficacy.  
 
A measure of lipophilicity can be achieved by using the logarithmic coefficient for 
distribution (logD) of a compound between octanol and water, at pH 7.4. As logD 
increases, the lipophilicity of the compound in question increases.33 A general trend 
discovered across a series of 300 pharmaceutical compounds was that the logD of the 
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drug is raised upon switching an atom of hydrogen with fluorine,30 thus making the 
drug more lipophilic. It should be noted that this is a general trend, but that logD 
values may decrease when fluorine is substituted near an oxygen,34 or nitrogen35 
atom.  
 
Addition of fluorine to a compound often affects the pKa of the functional groups in 
that compound. Rules have been developed which help predict the change in pKa of a 
basic amine as a consequence of being near a fluorine atom.36 If there are sufficient 
fluorine atoms present, the amine can remain sufficiently un-protonated at 
physiological pH, thus increasing the bioavailability of the compound. This increase 
in bioavailability was observed in a study using human 5-HT1D receptor inhibitors, as 
the incorporation of fluorine into a 5-HT1D receptor ligand was found to significantly 
reduce the pKa of the compound, and this reduction of basicity was shown to have a 
dramatically beneficial influence on oral absorption, although the effect on a 
compound’s oral bioavailability could not always be accurately predicted         
(Scheme 4).37 
 
 
Scheme 4: A decrease in compound pKa, found to be beneficial to the study, was observed across 
a range of human 5-HT1D receptors via sequential H to F substitutions (shown in red). 
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1.4 Fluorine-18 in Positron Emission Tomography 
 
Of the several positron emitters available, fluorine-18 is termed the ‘radionuclide of 
choice’ and is also the most used radionuclide in PET. There are several reasons why 
fluorine-18 has many advantages over its β+-emitting counterparts listed in Table 1. 
Fluorine-18 has a half-life (t1/2) of 109.7 minutes, which is a convenient timescale to 
perform a multistep radiosynthesis, purification and radiopharmaceutical formulation. 
Additionally, the t1/2 of fluorine-18 enables one to probe physiological processes 
which have appropriate kinetics, such as metabolic processes. A fluorine-18 imaging 
agent can be transported to an imaging centre several hours away and retain a level 
of activity required for a PET scan, in a process termed centralised distribution. For 
instance, a 5 GBq dose of a fluorine-18 imaging agent could be delivered to an 
imaging centre four hours away and still comprise a dose suitable for a PET scan 
(Figure 9). Carbon-11 based imaging agents suffer from the limitation that 
centralised distribution is not an option, due to its very short half-life; therefore, if 
feasible, patients may have to travel to a site where such  an  imaging agent is 
available.38 
 
Figure 9: Half life graph showing the exponential decay of fluorine-18 (the dashed line indicate 
the approximate activity needed for a useful PET scan with [18F]FDG). 
 
Fluorine-18 emits a relatively low energy positron (0.635 MeV) which has a short 
range in tissue before annihilation with an electron (~2.3 mm), closely matching the 
spatial resolution of most modern PET cameras. Consequently, an image obtained 
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with a fluorine-18 imaging agent will provide an image of the highest resolution 
relative to other PET radionuclides. 
 
The development of the radiopharmaceutical 2-deoxy-2-[18F]fluoro-D-glucose 
(commonly known as [18F]FDG), which was first synthesised (for further synthetic 
details see sections 1.6.2 and 1.7.3) by Ido and co-workers in 1978,39 provided a 
means of measuring glucose metabolism in vivo and established fluorine-18 as a key 
isotope for use in PET studies. Glucose is transported around the body, where it is 
eventually phosphorylated by the enzyme hexokinase, to glucose-6-phosphate 
(Scheme 5, pathway A). In the case of [18F]FDG, once phosphorylated, the resultant 
2-fluoroglucose-6-phosphate is no longer able to participate further in the natural 
reaction cascade do to incorporation of fluorine-18 in place of the naturally occurring 
–OH moiety (Scheme 5, pathway B).  
 
Scheme 5: Incorporation of the fluorine-18 atom blocks further metabolism of [18F]FDG. 
 
Accordingly, concentrations of the radiolabel build-up within a cell which is 
associated with, for instance, high hexokinase activity. The increased concentration 
is a marker for an area with high levels of energy metabolism, areas such as the brain, 
heart, or some tumour types. Clinical data has shown that [18F]FDG uptake in some 
cancer cells correlates with tumour growth and the tumour degree of metastasis.3 
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Hence [18F]FDG remains a universally popular choice for imaging certain tumour 
types, in addition to investigating cardiovascular and neurological issues.  
 
1.4.1 A Further Comparison of Fluorine-18  Relative to Other 
Radionuclides used in Positron-Emission Tomography 
 
Comparative imaging studies between carbon-11 and fluorine-18 imaging agents 
have been reported, whereby fluorine-18 has outperformed its carbon-11 counterpart, 
not only due to resolution, but also due to increased counting statistics; i.e. the 
greater t1/2 of fluorine-18 enables greater image data acquisition.
40, 41 Image 
comparison by in vivo imaging of the non-human primate’s 5-hydroxytyptamine (5-
HT) system, a system responsible for anxiety and mood-related illnesses, by binding 
to the critical 5-HT1A receptor, responsible for playing a key role in the regulation of 
the 5-HT system, has revealed that the fluorine-18 imaging agent provides twelve 
times more image data and superior detection sensitivity in brain regions with lower 
5-HT1A densities, relative to its carbon-11 counterpart (Figure 10).
41 
 
 
Figure 10:41 Comparison between [18F]Mefway and [11C]WAY100635 in the rhesus monkey 
brain. Three transaxial slices highlight imaging agent binding. 
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1.5 Practical Aspects of Synthetic Radiochemistry 
The synthesis of radiolabeled compounds which are applied in pre-clinical and 
clinical environments, places stringent requirements upon the operators of a 
radiopharmaceutical production facility (Figure 11). 
 
Figure 11: The Sir Bobby Robson Foundation PET Tracer Production Unit, Newcastle 
University. 
 
Synthetic radiochemistry, for many reasons, needs to be treated differently to 
standard bench synthetic chemistry. The handling of radioactive material needs to be 
carried out in a safe and controlled fashion, in a laboratory which has appropriate 
facilities for this purpose. Furthermore, many radioactive materials, such as fluorine-
18, have a half-life which is restrictive on the total time spent on synthesis and 
purification of a target compound. The reasons outlined above have resulted in a 
requirement for automated synthetic apparatus, which facilitates rapid incorporation 
of radionuclides into a target molecule. The apparatus needs to be placed behind an 
appropriate shield, often, a so-called hot cell is used (Figure 12). Due to the use of 
shielding, radiation levels in the laboratory are maintained at a safe level, enabling 
the automated equipment to be controlled by the radiochemist from within the 
radiopharmaceutical facility. 
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Figure 12: Hot-cells (Gravatom) within the Sir Bobby Robson Foundation PET Tracer 
Production Unit at Newcastle University. 
 
1.5.1 Automated Apparatus used in Synthetic Radiochemistry 
 
The time constraint introduced by a radionuclide’s inherent half-life has resulted in 
the development and use of automated apparatus which enables the rapid production 
of radiolabeled targets; achievable even when using the appropriate precursor on the 
μmol scale. Development of automated systems for PET imaging agent synthesis 
began in the late 1970’s and the early 1980’s, and to this day many of the innovations 
from this period are used in modern radiochemistry facilities. For instance, the 1982 
radiosynthesis of [11C]glucose utilised automated equipment comprising: 19 Teflon 
coated solenoid valves, 2 reactors, 2 heaters, 4 reagent vials, a vacuum pump, a 
purification column including 2 Sep-pak cartridges and 4 photo-sensors.42 A modern 
system, such as the modular Advion NanoTek microfluidic synthesis system used in 
Newcastle University, still requires significant assembly by the radiochemist and is 
made up of similar components (contains 4 modules which consist of 3 reagent 
pumps, 2 concentrator vials, reactors and a distribution hub). 
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1.5.1.1 Automated Microfluidic Radiosynthesis Platforms 
 
An increasing number of microfluidic systems have been used in radiochemistry; 
some are commercial whilst others have been bespoke apparatus. For excellent 
reviews on this topic the reader is directed elsewhere,43, 44 and a general overview is 
provided below. Microfluidic apparatus can be divided into three major sub-groups, 
namely, capillary-based systems, hybrid devices and lab-on-a-chip systems. 
 
Capillary-based systems include the Advion NanoTek45 and comprise of a simple 
hardware setup, using syringe pumps and automated switching valves in conjunction 
with well understood micro-bore tubing and connectors, resulting in laminar flow 
across the microfluidic flow apparatus (Figure 13). Microfluidic synthesis systems 
have provided many advantages in the research and development of radiotracers, 
such as low reaction times, minimal use of often very expensive precursors, high 
levels of isotope incorporation and the ability to perform multiple reactions using a 
single batch of isotope. 
 
 
Figure 13: A commercially available microfluidic synthesis system (NanoTek®, Advion 
Biosciences, Inc., Ithaca, NY). 
 
Hybrid devices occupy the middle-ground between capillary-based systems and lab-
on-a-chip systems, and are often bespoke in design, utilising conventional hardware 
such as syringe pumps with monolithic chip devices. Elizarov and co-workers 
recently described such a system, used in the synthesis of the ubiquitous imaging 
agent [18F]FDG in doses suitable for preclinical use (Figure 14).46 Hybrid systems 
 18 
 
are utilised to avoid the macro-scale to micro-scale change in technology which is 
needed to utilise capillary-based systems, e.g. during the sequestration of fluorine-18 
from the target water obtained from the cyclotron. They also do not suffer from the 
use of volumes <5 µL like their continuous flow counterparts. However, none have 
been utilised for routine clinical production, with the design of the aforementioned 
hybrid device unsuitable for some human studies due to the properties of the material 
used in the novel reactor.46 
 
 
Figure 14:46 A schematic of a hybrid microfluidic device (left) used in the synthesis of [18F]FDG. 
The apparatus (right) is presented with dyes loaded into the capillaries for clarity; the fluid 
network is shown in green, valves in red and vent in yellow. 
 
Finally, lab-on-a-chip devices possess a high level of functionality integrated around 
a central microfluidic core. An example of this apparatus has been demonstrated by 
van Dam and co-workers in the novel synthesis of [18F]FDG using electrowetting-on-
dielectric (EWOD) microfluidic apparatus (Figure 15).47 EWOD devices are a 2D 
system which manipulate droplets using their inherent surface tension.48 A standard 
setup comprises a pair of parallel plates, plate one consists of a plate patterned with 
electrodes and coated with dielectric and non-wetting layers. The dielectric layer is 
an electrical insulator which may be polarised by an applied electric field. Plate two 
acts a cover chip which is coated with a conductor (to act as a ground electrode), 
dielectric and non-wetting layers.47 Droplets are sandwiched between the parallel 
plates, with subsequent manipulations such as droplet transport, splitting and 
merging achieved by applying an electrical potential to individual or multiple 
electrodes.49 As liquid manipulations are performed electronically, the requirement 
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for moving parts such as pumps and valves is eliminated, thus simplifying the chip 
and the external control system. Additional electronically controlled functions can 
also be incorporated into the chip, such as sensors to monitor liquid volumes50 and 
composition51 as well as heating elements and temperature sensors for heating or 
evaporating solvent.52 
 
 
Figure 15:47 (A) A schematic of an EWOD microchip with four concentric heaters (inset) with a 
maximum volume of 17 μL. Inset shows magnified area of the heater with four concentric 
individually controlled resistive heating rings. (B) Schematic side view of the EWOD chip 
sandwiching a reaction droplet between two plates coated with indium tin oxide (ITO) 
electrodes, a dielectric layer (silicon nitride) and a hydrophobic layer. 
 
However, hybrid devices and lab-on-a-chip systems suffer from major drawbacks. 
Hybrid devices, to date, comprise a reactor medium constructed from 
poly(dimethylsiloxane) (PDMS), a material known to be incompatible with a range 
of organic solvents as well as being able to interact with and absorb reagents.53 Lab-
on-a-chip systems are currently in an early developmental stage, carrying associated 
developmental risks, as well as suffering from a lack of compatibility with GMP 
regulations which is critical to translate radiopharmaceutical production from a 
preclinical environment to the clinic.44 Capillary-based devices, such as the Advion 
NanoTek, do not suffer from these limitations and have demonstrated clinical utility 
in the repeated synthesis of [18F]fallypride,54 which was administered to twelve 
patients as part of a clinical trial in the US.55 Additionally, further imaging agents 
synthesised using capillary-based devices have been approved for human use, such 
as [18F]FLT56 and [18F]HX4 (Figure 16).57 
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Figure 16: The structures of compounds approved for human use synthesised using microfluidic 
apparatus; [18F]Fallypride is the only compound used so far in a clinical trial.55 
 
1.5.1.2 Further Automated Radiosynthesis Platforms  
 
Apart from the recent example of [18F]fallypride, highlighted above, microfluidic 
systems have primarily been used for pre-clinical production. The majority of 
clinically used imaging agents are synthesised using batch reactors in association 
with cassette based devices e.g. FASTlab (GE Healthcare),58 Elixys (Sofie 
Biosciences)58 and Scintomics GRP cassette module (Scintomics GmbH)58 amongst 
others. For clinical production a cassette based device (Figure 17) is particularly 
useful from a regulatory standpoint, as centralised and controlled manufacture of the 
requisite cassette is enabled, and subsequently the cassette can be distributed to PET 
centres in various regions. Additionally, as the cassettes are disposable and replaced 
after each imaging agent synthesis, fluid paths and validation of a cleaning process is 
not required. From a synthetic chemistry standpoint, the central manufacture of 
cassettes which also include all of the reagents required to produce a particular 
imaging agent reduces the work and error associated with a production run. The 
disadvantages of the batch based approach are apparent in a research and 
development scenario, as a limited number of reaction parameters can be 
investigated per dose of radioisotope. The greater quantity of precursor required to be 
used in a batch process may not always be feasible, e.g. due to availability and cost 
limitations, e.g. certain peptides may only be available in small amounts.  
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Figure 17: A FASTlab loaded with a disposable cassette (GE Healthcare), used for the clinical 
production of PET imaging agents.  
 
1.6 Fluorine-18 Labelling Strategies 
 
There are two major routes to incorporate fluorine-18 into a compound: direct and 
indirect labelling. Direct labelling incorporates fluorine-18 into the molecule of 
interest in a single step thereby minimising the degree of automation required to 
furnish the final product. Inclusion of fluorine-18, using either of these approaches, 
can be carried out using two different sources for the fluorine-18, the first is [18F]F2 
(electrophilic) and the second [18F]fluoride (nucleophilic). Indirect labelling involves 
the use of prosthetic groups and mitigates any tolerance issues between the molecule 
to be radiolabeled and the radiolabelling process, e.g. many large biomolecules can 
not tolerate the conditions required to label with fluorine-18 directly. Prosthetic 
groups are primarily small molecules, bound to a fluorine-18 label, which possess at 
least one further reactive functional group, e.g. an aldehyde. These groups then go on 
to react with appropriate pendant functionality on the target molecule, such as the 
primary amine moiety present at the N-terminus of a peptide. This sequence results 
in a minimum two-step process as part of the complete synthesis of the imaging 
agent. 
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1.6.1 Preparation of Electrophilic Fluorine-18 
 
Electrophilic fluorinations involve, at some stage, the use of [18F]F2. The major 
drawback in using [18F]F2 is a consequence of its preparation in unavoidably low 
specific activity (SA), relative to 18F-. [18F]F2 is prepared by bombardment of one of 
two targets, neon, or [18O]H2O and then removal of the generated fluorine-18 from 
the target with carrier F2. Both of these irradiation targets clearly have major 
limitations in that dilution with fluorine-19 occurs. Additionally, using a neon target 
results in the nuclear reaction 20Ne(d, )18F, a process which intrinsically yields low 
specific activity [18F]F2. The aforementioned process was used historically, but is not 
widely used nowadays.  
 
A technique which produces [18F]F2 in high specific activity (high, that is, relative to 
previous [18F]F2 production methods) is by use of an electric discharge with 
[18F]fluoride and has been demonstrated to yield [18F]F2 in specific activities up to 
100 GBq/μmol.59  
 
If [18F]F2 is used as the fluorinating agent, a mixture of labelled products will 
generally be obtained. This is attributable to the fact that [18F]F2 lacks specificity due 
to its highly reactive nature. In an attempt to avoid the lack of specificity, more 
selective electrophilic reagents have been developed by reaction of an appropriate 
precursor with [18F]F2. 
 
1.6.2 Electrophilic Fluorine-18 Reagents 
 
 
One of the most important PET imaging agents, which is still the most commonly 
used imaging agent to this day, is [18F]fluorodeoxyglucose ([18F]FDG) 12 which was 
originally prepared by electrophilic fluorination of 11 using [18F]acetyl hypofluorite 
(Scheme 6).60 
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Scheme 6: Preparation of [18F]FDG using [18F]acetyl hypofluorite. 
 
However, [18F]FDG is more commonly synthesised using nucleophilic fluorine-18, 
as doses of [18F]FDG in much higher specific activity (SA) can be obtained by a 
nucleophilic approach (see section 1.7.3). 
 
The N-F reagent [18F]Selectfluor™ has been prepared (Scheme 7) as its bistriflate 
salt by reaction of compound 161 with [18F]F2 generated by an electrical discharge.
59 
 
 
Scheme 7: Preparation of [18F]Selectfluor™ bistriflate. 
 
[18F]Selectfluor™ has been synthesised as its bistriflate salt, as opposed to the 
bistetrafluoroborate salt, as this would introduce complications arising from isotopic 
exchange ([18F]fluoride will exchange with the fluorine atoms in the 
tetrafluoroborate counter-ion releasing [19F]fluoride into the reaction). Conveniently, 
the bistriflate salt reacts with similar substrates as its bistetrafluoroborate counterpart 
without the additional complications of diluting the sample with fluorine-19. 
[18F]Selectfluor™ has been used in electrophilic fluorodestannylation reactions with 
electron-rich aromatic compounds, such as 2, mediated by silver triflate, yielding 
fluorine labelled electron-rich aromatics such as [18F]3 (Scheme 8).61
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Scheme 8: Electrophilic fluorodestannylation of an electron-rich aryl stannane. 
 
N-[18F]Fluorobenzenesulfonamide ([18F]NFSi), is another important electrophilic N-
F fluorinating reagent, prepared by reaction of 4 with [18F]F2 (Scheme 9).
62 
 
 
Scheme 9: Preparation of [18F]NFSi. 
 
To demonstrate the scope of the reagent, [18F]NFSi has been used to successfully 
fluorinate silyl enol ether 5 generating fluorine-18 labelled ketone [18F]6, and to 
fluorinate allyl silane 7 affording allylic fluorine-18 labelled [18F]8 (Scheme 10).62 
 
 
Scheme 10: Electrophilic fluorination reactions utilising [18F]NFSi. 
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1.7 Production of Nucleophilic Fluorine-18 
 
Many of the most valuable PET imaging agents are routinely produced using 
nucleophilic fluorine-18 (abbreviated as 18F-). As fluorine-19 carrier is not used in 
the preparation of 18F-, high SA of 100-400 GBq/μmol of 18F- can be achieved. High 
SA may be a requirement of the imaging agent in question, e.g. where images are to 
be obtained from sites of low receptor concentration, such as certain neuronal 
receptors.63 If a low SA imaging agent was used for this application, the resultant 
image would be of poor quality, as the non-radioactive fluorine-19 containing 
compound would compete with the imaging agent at the site of interest giving 
misleading information on the density of the receptor. For receptors that are only 
present at very low densities their presence may be missed completely. 
The availability of high SA 18F- is clearly a major advantage of nucleophilic 
fluorination, as the maximum SA one can obtain using electrophilic fluorine is 
around 100 GBq/μmol.59 The most common method of production of 18F-, can be 
broken down into several stages.64 18F- is obtained by irradiation of [18O]H2O, where 
the nuclear reaction 18O(p,n)18F is particularly high yielding, even at low proton 
energies. 18F- is then sequestered onto an ion exchange resin, such as a QMA 
cartridge, enabling the recovery of the excess [18O]H2O. Elution of the trapped 
18F- is 
achieved with a weak base, such as potassium carbonate in a water/acetonitrile 
solution. In this state, the 18F- is hydrated and therefore poorly nucleophilic so to 
facilitate the removal of water, and thus enhance the nucleophilic reactivity of the 
18F-, a phase transfer agent is employed. Kryptofix-222® (K222) may be used in this 
role, as it forms a strong complex with the potassium cation, consequently exposing, 
and hence making reactive, the 18F- ([18F]KF.K222) (Figure 18). 
 
 
Figure 18: Exposed [18F]fluoride due to complexation of the potassium with K222. 
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An alternative phase transfer agent is tetrabutylammonium bicarbonate which 
generates [18F]tetrabutylammonium fluoride, [18F]TBAF as the reactive species.65 
18F- is trapped onto an ion exchange resin, which is then eluted with 
tetrabutylammonium bicarbonate, which functions simultaneously as the source of a 
weak base and an organic soluble cation for the  18F-. Experiments conducted using 
[19F]fluoride have shown that for some reactions [19F]TBAF increases reaction yields 
compared to [19F]KF.K222 over ten minute reaction times.
66 
 
A further, recently developed alternative exists: [18F]tetraethylammonium fluoride, 
[18F]TEAF.67 [18F]TEAF has been shown to have equivalent fluorination properties 
relative to the phase transfer agents discussed above,67, 68 and in particular benefits 
over [18F]KF.K222 when used in conjunction with microfluidic apparatus due to 
reduced blockages of the apparatus’ capillary tubing.69, 70 
 
1.7.1 Reactions with Nucleophilic Fluorine-18: Balz-
Schiemann and Wallach Reaction 
 
 
The Balz-Schiemann and Wallach reactions are historically important reactions 
regarding the nucleophilic synthesis of fluoroarenes. The Balz-Schiemann reaction 
concerns the transformation of an aryl diazonium salt which thermally decomposes, 
in the presence of a source of fluoride, forming the corresponding fluoroarene 
(Scheme 11).71 
 
 
Scheme 11: A radiosynthesis using Balz-Schiemann reaction. 
 
As highlighted earlier (see section 1.6.1) it must be noted that this reaction suffers 
from several severe limitations. If a fluoride labile anion is used, such as BF4
-, the 
maximum theoretical radiochemical yield one could obtain is 25%, this is a 
consequence of the presence of isotopic dilution due to fluorine-19 carrier. BCl4
- has 
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been used in an attempt to avoid adding carrier, with little success, as this results in 
chloroarene formation which have subsequently proven to be difficult to separate 
from the target fluoroarenes under the time constraints of the fluorine-18 half-life.72  
 
The Wallach reaction also involves decomposition of a reactive intermediate, in this 
instance, of diazene compound in the presence of acid (Scheme 12).73 
 
 
 
Scheme 12: The diazene intermediate formed during the Wallach reaction. 
 
As above this reaction suffers from low RCYs, even though attempts have been 
made to optimise the reaction by modification of the reaction solvent, acid and 
reaction equivalents.74 As both the Balz-Schiemann and Wallach reactions suffer 
serious flaws when applied to radiosynthesis, many new methodologies have been 
developed to incorporate [18F]F- into an imaging agent. 
 
1.7.2 Reactions with Nucleophilic Fluorine-18: Nucleophilic 
Aromatic Substitution Reactions 
 
Nucleophilic aromatic substitution (SNAr) radiochemistry provides a direct one-step 
route to radiolabeled aromatic compounds, on the premise that the aromatic ring on 
which substitution is to occur is activated in the ortho or para position by an 
electron-withdrawing moiety.64 Reactions conditions associated with this class of 
transformation are typically harsh, with temperatures in the range of 100–180 °C, 
DMSO as the solvent, a base and potentially a kryptand.64 Commonly employed 
leaving groups in such reactions include trialkylamine, mesylate, tosylate, triflate, or 
halogens (Scheme 13). 
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Scheme 13: Production of [18F]fluoroarenes using SNAr chemistry. 
 
The trialkylamine moiety is an excellent leaving group, but suffers from unwanted 
side reactions, and may, in the case of trimethylammonium derivatives form 
[18F]fluoromethane, a radioactive gas, as a side product instead of the intended 
fluoroarene. The influence of aromatic versus aliphatic substitution has been 
evaluated by a detailed mechanistic study, which has found that p-substituted arenes, 
with a high Hammet σ constant, favour the formation of the fluorinated arene over 
[18F]fluoromethane (Figure 19).63 
 
 
 
Figure 19:63 The influence of p-substituents on the competitive formation of [18F]fluoroarenes 
and [18F]fluoromethane where trimethylamine is the leaving group. 
 
An example of this procedure of direct SNAr chemistry has been applied in the 
synthesis of the imaging agent [18F]Flumazenil, where the careful choice of precursor 
9 demonstrates the success of the fluorination of a weakly activated arene          
(Scheme 14).75 
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Scheme 14: Direct SNAr radiosynthesis of [18F]Flumazenil. 
 
The disadvantage of a direct nucleophilic approach is that any other sites, also 
susceptible to nucleophilic attack by [18F]fluoride ion, need to be protected, such as 
ROH, RCO2H and RNH2, due to the ability of fluoride to abstract labile protons from 
these functional groups. Consequently, additional synthetic steps to protect this 
functionality are required to prepare the precursor and once the fluorine label has 
been introduced then remove the protecting groups, and therefore the RCY of the 
radiosynthesis is likely to suffer. 
 
1.7.3 Reactions with Nucleophilic Fluorine-18: Aliphatic 
Nucleophilic Substitution Reactions 
 
Aliphatic nucleophilic substitution with 18F- follows the reactivity of a typical SN2 
reaction, with higher yields obtained at a primary carbon, and the reactions are 
typically performed in polar aprotic solvents. 
 
[18F]FDG, the aforementioned ubiquitous imaging agent, is widely used in PET 
studies. The synthetic route to [18F]FDG by nucleophilic means proceeds by an 
aliphatic nucleophilic substitution reaction (Scheme 15).76 A synthetic process has 
now been fully automated for this reaction, and takes around 30 minutes for a 
complete radiosynthesis and purification. However, this synthesis of [18F]FDG does 
suffer from the same disadvantage that was highlighted by SNAr chemistry, i.e. the 
requirement of additional steps (protection/deprotection of 10 and 11, the latter being 
critical in the radiosyntheis) where sensitive functionalities are present in the imaging 
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agent. However, the excellent RCY and SA obtained more than outweigh the 
disadvantages. 
 
 
Scheme 15: Synthesis of [18F]FDG. 
 
Not all nucleophilic aliphatic substitution reactions rely on multi-step syntheses. A 
synthesis of the selective dopamine transport ligand [18F]LBT-999 has been achieved 
in a one-step process from the aliphatic halide precursor 12 (Scheme 16).77 
 
 
Scheme 16: One step radiosynthesis of [18F]LBT-999.  
 
Nucleophilic 18F- can also be used to open some cyclic systems, such as 13a or 13b 
to afford [18F]fluoro-3'-deoxy-3'-L-fluorothymidine, [18F]FLT (Scheme 17).78 The 
nucleoside [18F]FLT is used as a cellular proliferation marker.79  
 
 
Scheme 17: Opening of cyclic systems 13a and 13b with 18F-. 
 
 31 
 
Unfortunately, ring opening chemistry can’t be routinely exploited in the case of 
epoxides, as an acid catalyst is typically required.80 It is necessary to take specific 
precautions, as quantities of dilute hydrofluoric acid could be generated between a 
source of fluoride and a source of protons. Although hydrofluoric acid is a weak acid 
in a dilute solution,81 it is highly corrosive, and will dissolve a wide range of 
materials. 
 
1.7.4 Reactions with Nucleophilic Fluorine-18: Substituion 
Reactions upon Heteraromatics 
 
The main class of heteroarenes for which the SNAr chemistry with 
18F- has been 
examined are pyridines.82 A consequence of the occurrence of the pyridinyl moiety 
in many natural products such as compounds which bind to nicotinic receptors.3 
Compounds possessing these features could therefore be modified to incorporate a 
radiolabel, and function as PET imaging agents. The synthesis of several classes of 
fluoropyridines (Figure 20) using conventional fluorine-19 chemistry has been 
demonstrated, and could potentially be exploited to prepare fluorine-18 counterparts.  
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Figure 20: Fluoropyridines accessed using conventional fluorine-19 nucleophilic substitution 
chemistry. 
 
Epibatidine is a natural pyridinyl containing compound which is isolated from the 
skin of Epipedeobates Tricolour, a poisonous frog. It is a potent nicotinic 
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acetylcholine receptor agonist.83 The 2-[18F]fluoroepibatidine radiolabeled compound 
is prepared by nucleophilic aromatic substitution of the corresponding aryl bromide 
precursor 14 (Scheme 18).84 There are currently no useful 4-[18F]fluoropyridine 
based imaging agents, even though the synthesis of this class of compounds proceeds 
with similar efficacy as their 2-[18F]fluoropyridine counterparts.64 
 
 
 
Scheme 18: One-step synthesis of 2-[18F]fluoroepibatidine. 
 
The synthesis of 3-[18F]fluoropyridines requires an electron-withdrawing moiety, 
such as amido or cyano moieties, to be present para- to the desired fluorination site 
(Scheme 19).85. Bromo or chloro atoms may be successfully utilised as leaving 
groups in this case. 
 
N
X
R
[18F]KF.K222
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X = Cl, Br
R = CONH2, CN
RCY = 67-98%
 
 
Scheme 19: A general one-step synthesis to 3-[18F]fluoropyridines. 
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1.8 Reactions with Nucleophilic Fluorine-18: Click Chemistry 
Approaches 
 
The advantages that click chemistry possess are very relevant to the radiochemist, i.e. 
rapid, selective and relatively simple reactions which often only require mild 
conditions. The rapid formation of a triazole ring by a Huisgen cycloaddition (a 1,3-
dipolar cycloaddition) of azide 15 with an alkyne,86 has been described as “the cream 
of the crop” of click chemistry.87 The cycloaddition reaction has been put to 
excellent use in the formation of a library of 2-[18F]fluoroethyltriazoles (Scheme 
20).88 
 
 
Scheme 20: Click-chemistry used to synthesise 2-[18F]fluoroethylazides. 
 
The Huisgen 1,3-dipolar cycloaddition requires the presence of a Cu(I) catalyst, else, 
the reaction would take many hours to complete.86 Therefore an excess of Cu(I) and 
azide are employed in the radiosynthetic approach, meaning the conjugation step 
takes around 10 minutes at room temperature in a water/MeCN/DMF buffered 
solution (pH 6.0).88 The terminal alkynes used in the reaction may include acidic 
functionality, ester, amide, amino and phenyl moieties, demonstrating that this 
reaction has an excellent functional group tolerance and therefore scope for future 
investigations regarding this type of chemistry.  
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1.9 Reactions with Nucleophilic Fluorine-18: Reactions with 
Diaryliodonium Salts 
 
The major limitations that standard nucleophilic aromatic substitution of arenes with 
18F- suffers are that they are poor at labelling electron-rich arenes, and poor at 
accessing all regioisomers of a particular fluoroarene, due to mechanistic 
considerations. Therefore, in many of the previous synthetic examples outlined 
above, only arenes possessing an electron-withdrawing moiety, and certain 
regioisomers of the arene, have been fluorinated. It may be desirable to incorporate 
the radiolabel into an electron-rich arene, in which case SNAr with 
18F- would prove 
troublesome. Also, during the evaluation of an imaging agent it may be found that a 
different regioisomer is required, which cannot be accessed by standard SNAr 
methodologies. Diaryliodonium salts (Figure 21) provide a potential solution to this 
problem. 
 
 
Figure 21: The general structure of a diaryliodonium salt. 
 
Diaryliodonium salts were first reported in 1995 as precursors to radiofluorinated 
arenes,89 and since then have received considerable attention for their utility both in 
radiochemistry and in cross-coupling reactions.85 Both electron-deficient and 
electron-rich arenes can be fluorinated using diaryliodonium salts,90 in addition, all 
regioisomers of a particular arene may be accessed, thus providing two distinct 
advantages over standard SNAr chemistry. Additionally, diaryliodonium salts present 
the radiochemist with two useful selectivity features. Firstly, the selectivity of the 
fluorination of diaryliodonium salts tends to proceed according tothe so-called 
“ortho-effect”, this effect results in preferential radiofluorination of the more 
sterically demanding arene.91 A second mode of selectivity was determined by 
computational studies regarding the regioselectivity of nucleophilic attack by 
fluoride upon alkynyliodonium salts92, 93 and heteroaromatic diaryliodonium salts.94 
These studies found that the electronic nature of substituents around the iodine atom 
 35 
 
are the most important features in determining regioselectivity; if there is no ortho 
substituent present on either ring, the ring with the lowest electron density will be 
preferentially fluorinated. The study with heteroaromatic diaryliodonium salts also 
provided experimental evidence which supported this regioselectivity theory.94 
 
It has been proposed that the mechanism of fluorination of a diaryliodonium 
proceeds in a “turnstile” fashion (Scheme 21).85  
  
 
Scheme 21: The proposed “turnstile” mechanism for the radiofluorination of a diaryliodonium 
salt.85 
 
This mechanism helps to account for the ortho selectivity discussed above, as the 
bulkier arene (Ar2 in Scheme 21) lies in the more favoured equatorial position. 18F- 
attacks the positive iodine centre, forming a trivalent intermediate which then 
collapses forming the products. 
 
Reactions of this type are typically carried out under milder conditions than their 
SNAr counterparts, and may even be able to take place in the presence of large 
quantities of water.95 
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1.10 Chemistry of Diaryliodonium Salts 
 
Diarylodonium salts are a class of compounds first synthesised in the late 19th 
century.96 In these compounds iodine possesses a non-standard bonding number and 
therefore, according to IUPAC nomenclature, described by notation. For instance, 
hydrogen iodide, HI, is classified as an iodane. However, due to the non-standard 
bonding present in H3I, the iodane is described as a λ3-iodane, H5I as a λ5-iodane and 
so on. The more common λ-iodanes are of the type Ar2IL, and are termed diaryl-λ3-
iodanes. Therefore, it is more correct to describe diaryliodonium salts as diaryl-λ3-
iodanes, even though the former nomenclature is still the most common descriptor. It 
is important to note that the use of the term “salt” is not very accurate as two discreet 
ions are not always present. Single-crystal X-ray crystallographic methods have 
determined that the compounds adopt a trigonal bipyramidal structure, and the two 
axial ligands share a hypervalent bond (Figure 22).97 As consequence of a node in the 
non-bonding orbital of the hypervalent bond being located on iodine, the iodine atom 
is highly electrophilic.  
 
 
 
Figure 22: Diaryliodonium salt geometry, and a simplified molecular orbital diagram of the 
pseudo-axial hypervalent bond. 
 
In solution, there is much debate about whether or not diaryliodonium salts retain the 
trigonal bipyramidal configuration which they adopt in the solid state; many 
speculate that the nature of the counter anion X, and the solvent, could affect the “T-
shape” structure which was determined in the solid phase.97  
 
It has been reported that the successful fluorination of diaryliodonium salts varies, 
especially where both arenes of the diaryliodonium salt are electron rich.98, 99 
Aromatic radicals may be generated from a hypervalent iodine compound, as a 
consequence of homolytic fission of an aryl iodine bond. As the process of homolytic 
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fission is spontaneous and random, particularly at elevated temperatures, the level of 
radicals present in the reaction vessel may differ between reactions, and may 
therefore cause a lack of reproducibility. Aromatic radical species may undergo 
further side reactions, leading to undesired products, leading to not only a lower yield 
but complicating the purification of the desired fluoroarene. Fortunately, it has been 
shown that the addition of radical scavengers, such as galvinoxyl and TEMPO 
(Figure 23), can improve the reproducibility and the material yield of the fluorination 
process, where both arenes of the diaryliodonium salt are electron-rich.100   
 
 
Figure 23: Radical scavengers used in the fluorination of diaryliodonium salts.  
 
1.10.1 Synthesis of Diaryliodonium Salts 
 
Diaryliodonium salts can be synthesised by several different means, often in two to 
three steps.101 Oxidation of an iodoarene to an iodine(III) precursor, followed by 
reaction with an organometallic reagent is a popular choice. A typical approach to 
the initial oxidation of the iodoarene is to use sodium perborate mono or tetrahydrate 
as the oxidant, in acetic acid, furnishing a aryliodobisacetate (Scheme 22).102 
 
 
Scheme 22: Transformation of a substituted iodobenzene to a substituted diacetoxyiodobenzene. 
 
The diacetoxyiodoarene can then be reacted with an organometallic reagent, such as 
an arylstannane in the presence of an acid, to prepare a diaryliodonium salt. As it is 
possible to generate a diacetoxyiodoarene and an organostannane at any given 
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position of an arene, it is possible to synthesise all regioisomers of a particular 
diaryliodonium salt. This means that upon reaction with a nucleophile, such as 18F-, 
all regioisomers of a radiolabeled arene can be accessed if careful choices are made 
about the arenes involved and the position of any substituents (Scheme 23). 
 
 
 
Scheme 23: Synthesis of a general diaryliodonium salt. 
 
1.10.2 Diaryliodonium Salt Chemistry Applied to Imaging 
Agents and Prosthetic Groups  
 
Many examples above have so far been concerned with the direct labelling of an 
imaging agent precursor, using either electrophilic or nucleophilic means. An 
excellent use of diaryliodonium salts is that they are compatible with both direct, and 
indirect radiolabeling approaches. For example, the synthesis of the imaging agent 
[18F]DAA1106 was achieved by direct nucleophilic radiofluorination of 
diaryliodonium salt precursor 16 (Scheme 24).103 
 
 
Scheme 24: Direct radiosynthesis of [18F]DAA1106 from a diaryliodonium salt precursor. 
 
By varying the position of the iodonium group on the target arene, further 
regioisomers of [18F]DAA1106 could be obtained, as the electron-rich anisole moiety 
directs fluorination towards the target arene. 
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Many imaging agents have been studied as only their ortho or para regioisomers, as 
unsuccessful attempts have been made to synthesise meta regioisomers by 
nucleophilic means.104 It is possible to access meta substituted fluorinated arenes 
with diaryliodonium salts,105 for the reasons discussed above. A practical application 
of this approach has been demonstrated in the synthesis of meta-[18F]fluoropyridine, 
[18F]18 from 3-pyridyliodonium salt 17 (Scheme 25).91 If this chemistry were to be 
applied to the synthesis of other fluorine-18 labelled radiopharmaceuticals then 
optimisation of imaging agent structure could be achieved, akin to SAR in 
conventional drug discovery. 
 
 
 
Scheme 25: Synthesis of meta-[18F]fluoropyridine, [18F]18. 
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1.11  Radiolabelling Biomacromolecules with Fluorine-18 Prosthetic 
Groups 
The therapeutic use of biomacromolecules, a field termed biologics, are playing a 
progressively important role in medicine relative to small molecule therapeutics due 
to several key advantages.106 For instance, due to the specific action of a protein, a 
desired pharmacological effect can be attained without impairment of normal 
biological processes. Furthermore, the complex nature of proteins means the 
requisite pharmacological effect often cannot be obtained by the use of a simple 
small molecule. The total US market for biologics was ~$48 billion in 2009,107 
~$51.3 billion in 2010,108 and ~$53.8 billion in 2011.109 The biologics market has 
seen continued and sustained growth in sales since 2005, which then had sales of 
around $33 billion (Figure 24).107 
 
 
Figure 24: Continued growth in biologics sales in the US between 2007-2011.109 
 
The biologics market is expected to continue to grow in future, as many more 
biologics are undergoing clinical trials for a range of disorders.106 Additionally, the 
success rate of these therapeutics are now higher than that of small-molecule drugs, 
with a 32% and 13% approval rate respectively between 1993 and 2004.107 
 
Additionally, the application of biologics as radiopharmaceuticals is also gaining 
interest in the field of nuclear medicine.110-112 Unfortunately, direct radiolabelling of 
biomacromolecules with fluorine-18 is not always practical, save in certain 
circumstances, due to the harsh conditions which are often employed, for instance, in 
SNAr radiolabeling processes. New methodologies have therefore been developed, 
whereby the radiolabel is introduced onto a small molecule (the prosthetic group) 
which bears the reactive functionality required to conjugate to a suitability 
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functionalised biomacromolecule precursor. A range of prosthetic groups are 
available which facilitate the indirect labelling of a range of biomacromolecules such 
as oligonucleotides (Scheme 26). 
 
 
Scheme 26: Fluorine-18 radiolabelling of oligonucleotides with fluorine-18 radiolabeled 
prosthetic groups. 
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Furthermore, many prosthetic groups are available which facilitate the indirect 
labelling of a range peptides/proteins (Scheme 27). 
 
Scheme 27: Fluorine-18 radiolabelling of peptides/proteins with fluorine-18 radiolabeled 
prosthetic groups. 
 
There is a great deal of interest in the indirect labelling approach using prosthetic 
groups, as not all biomacromolecules of interest tolerate direct radiolabelling 
conditions, for reasons highlighted above. Substrates such as peptides and proteins 
would not tolerate harsh SNAr conditions. Utilisation of a prosthetic group provides a 
flexible choice of chemical routes to the desired radiolabeled biomacromolecule, as 
the conjugation step maybe performed under relatively mild conditions. 
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1.11.1 Amine-Reactive Prosthetic Groups 
Many amine reactive prosthetic groups have been reported (Figure 25: Amine-
reactive prosthetic groups: 4-[18F]FBA,113 4-[18F]SFB,114, 115 [18F]19,116 [18F]20,117 
[18F]21,118 [18F]22,119 [18F]23,120 [18F]24,121 [18F]25110 and [18F]26.110).  
 
Figure 25: Amine-reactive prosthetic groups: 4-[18F]FBA,113 4-[18F]SFB,114, 115 [18F]19,116 
[18F]20,117 [18F]21,118 [18F]22,119 [18F]23,120 [18F]24,121 [18F]25110 and [18F]26.110 
 
4-[18F]Fluorobenzaldehyde (4-[18F]FBA) is an important prosthetic group used in 
PET and has been synthesised via several different routes. The traditional method of 
incorporating fluorine-18 onto an activated arene employs a nitro leaving group,122 
and this synthetic procedure was subsequently applied to the synthesis of 4-[18F]FBA 
using 4-nitrobenzaldeyde as the starting material. The 4-[18F]FBA was then used as 
an intermediate in the synthesis of radiolabeled 4-fluorobenzylhalides.123 Aldehydes 
undergo many established reactions with many common functional groups, including 
amine bearing amino acid residues such as arginine and lysine. Hence a labelled 
fluorobenzoyl moiety can be delivered onto many diverse substrates, from a wide 
range of peptides124 to large molecules such as the hormone leptin (Figure 26).125 
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Figure 26: A schematic of leptin labelled with 4-[18F]FBA (right), and PET scan image in ob/ob 
mice.125 
 
Recent work has utilised [18F]fluorobenzaldehydes in the convergent radiosynthesis 
of several imaging agents, by multi-component reactions, such as the Biginelli, Ugi, 
Passerini or Groebke reactions.126 An optimised Groebke-Bienaymé-Blackburn 
reaction has been performed, using 4-[18F]FBA, achieving a high RCY in accessing 
the complex target 19 (Scheme 28).126 
 
Scheme 28: Groebke-Bienaymé-Blackburn multi-component reaction affording [18F]19. 
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1.11.2 Carboxylate-Reactive Prosthetic Groups 
Amidation reactions, between carboxylate reactive synthons and carboxylic acid 
moieties present in biomacromolecules, have received considerably less attention 
than their amine counterparts. This is due to the imposition of certain requirements 
on the compound to be labelled, in particular, the compound should not possess free 
amine moieties, else inter- and intramolecular cross-linking may occur. Of course, 
the amine moiety could be protected, resulting in greater synthetic burden. An 
example of a carboxylic acid reactive prosthetic group is [18F]FMBAA (Figure 27), 
which has been used to label a protected insulin.127 
 
 
Figure 27: [18F]FMBAA – a carboxylic acid reactive prosthetic group. 
 
1.11.3 Thiol-Reactive Prosthetic Groups 
 
In nature, there is a marked lack of free sulfhydryl residues in biomacromolecules 
relative to amine and carboxylic acid residues.128 This has advantages for the 
radiochemist, as biomacromolecules can be engineered to contain sulfhydryl residues, 
thus, thiol reactive prosthetic groups can be utilised to regioselectively synthesise 
imaging agents. Many thiol-reactive prosthetic groups are known (Figure 28). 
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Figure 28: Thiol-reactive prosthetic groups: [18F]20,129 [18F]21,129 [18F]22,130 [18F]23,131 [18F]24132, 
[18F]25,133 [18F]26,134 [18F]27,135 [18F]28,136 [18F]29,137 [18F]30,138 [18F]31138 and [18F]32.138  
 
Thiol-reactive prosthetic groups often possess a maleimide moiety. Maleimides are 
Michael acceptors and will therefore react with the soft sulfhydryl nucleophile in a 
conjugate fashion. This has been demonstrated by reaction of a maleimide, 
[18F]FBEM and a sulfhydryl containing RGD peptide for the imaging of vascular 
endothelial growth factor and vascular endothelial growth factor receptor, αvβ3 
integrin (Scheme 29).130  
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Scheme 29: A RGD peptide labelled via a Michael addition using [18F]FBEM. 
 
A heteroaromatic fluorine-18 labelled prosthetic group used as a tumour imaging 
agent, [18F]FPyME, has also been synthesised, via a three step procedure (Scheme 
30).133 Due to the nature of nucleophilic heteroaromatic substitution, only the 2-
regioisomer was synthesised. 
 
 
Scheme 30: Production of [18F]FPyME. 
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1.12 Radiolabeling Small Molecules with Fluorine-18 Prosthetic 
Groups 
 
The use of prosthetic groups is not limited to the labelling of biomacromolecules; 
small molecules can also be labelled using this strategy. The labelling of small 
molecules is becoming increasingly important in the early stages of the drug 
discovery pipeline, enabling accurate selections of lead compounds for further 
evaluation.4, 139  
 
For instance, [18F]Lapatanib has recently been synthesised by labelling with the 
prosthetic group 3-[18F]fluorobenzylbromide precursor. A prosthetic group approach 
is vital for the radiolabelling of Lapatinib, as the site of the radiolabel is a meta-
substituted electron-rich aromatic. Lapatinib is approved for use in combination 
chemotherapy for the treatment of advanced metastatic breast cancer,140 and is under 
investigation for use in the treatment of other forms of cancer.141 Use of non-invasive 
preclinical imaging studies to facilitate rapid decision making regarding the efficacy 
of the treatment regimen can now be realised as a result of the use of a prosthetic 
group. 
 
A further example of prosthetic group utility is in the form of the simple aliphatic 
compound such 2-[18F]fluoroethyltosylate.142 As a result many PET imaging agents 
have a pendant [18F]fluoroalkyl group such as [18F]FECwhich has been used an 
imaging agent in a wide range of imaging studies from human,143  rodent144 and 
within cells.142  
 
 
 
 
 
 
 
 
 49 
 
1.13 Aims and Objectives 
The aims and objectives of this research are: 
 
 Develop a synthetic method to furnish the reference standard 2-
[19F]fluorothiophene 
 Synthesis and subsequently investigate the use of diaryliodonium salts as 
precursors to radiolabelled prosthetic groups  
 Develop an automated method for the synthesis of a range of radiolabelled 
prosthetic groups, taking steps to optimise the radiochemical yield and the 
reproducibility of the production of radiolabelled material 
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2 Chapter Two: ‘Cold’ Chemistry Results and Discussion  
Chapter one highlights the need for strategies to radiolabel prosthetic group 
precursors in a procedurally straight forward and reproducible manner. 
Diaryliodonium salts have herein been described as useful prosthetic group 
precursors, and hence the first aim of this research is to synthesise a range of 
prosthetic group precursors for use in subsequent radiolabelling. Furthermore, use of 
the 2-thienyl moiety to direct nucleophilic attack of [18F]fluoride ion towards the 
diaryliodonium salts so-called ‘target arene’, i.e. the arene desired to bear the 
radiolabel, may potentiate the production of the ‘off-target’ 2-[18F]fluorothiophene.           
2-[18F]Fluorothiophene is a material which is poorly characterised in the current 
literature and is to the best of the author’s knowledge commercially unavailable 
(June 2015). Hence, a further aim is to develop a synthetic methodology to afford an 
authentic standard of this key material, where such a standard is able to be used in 
subsequent radiochemical syntheses where treating a diaryliodonium salt bearing a 2-
thienyl moiety with [18F]fluoride ion. 
 
2.1 Synthesis of Diacetoxyiodoarene  
The synthesis of diacetoxyiodoarenes, as useful precursors to diaryliodonium salts, is 
well established and such compounds are used routinely in the synthesis of 
diaryliodonium salts.101 Many oxidising agents have been used in the transformation 
of iodoarenes to diacetoxyiodoarenes, including: sodium periodate,145 sodium 
percarbonate146 hydrogen peroxide–urea,147 Selectfluor™148 and m-
chloroperoxybenzoic acid.149 The most general oxidation methodology makes use of 
sodium perborate tetrahydrate (referred to herein as SPB) as the oxidant, as a 
suspension in acetic acid.102  
 
It is believed that mixing SPB and acetic acid results in the in situ formation of a 
peracetoxyborane species, which is attributed as the oxidising species in the reaction 
(Scheme 31).150 The species reacting in step (C) may be the same as that formed in 
step (B), or there may be an intermediate solvolysis of the first of the B-O-O-B 
linkages. The scheme identifies species containing the B-OOAc unit as intermediates, 
 51 
 
and it is possible that such species may act directly on organic substrates, either 
instead of, or in parallel with, their likely to be acid-catalysed hydrolysis to peracid. 
 
 
Scheme 31: Generation of the reactive peracetoxyboron species.  
 
Diacetoxyiodoarenes 33 and 34 were synthesised in moderate yields of 13-49% 
following the widely utilised methodology developed by McKillop and co-
workers.102, 150 As McKillop et al. did not specify reaction times for the oxidation of 
4-iodoanisole or 2-iodothiophene, several reactions have been carried out to 
investigate the most appropriate reaction time (Table 3). 
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Entry Ar Time (h) Yield (%) 
1 4-iodoanisyl 3 29 
2 “ 4 44 
3 “ 5 41 
4 “ 4.5 45 
5 2-iodothienyl 3 11 
6 “ 4 29 
7 “ 5 24 
8 “ 4.5 27 
9 “ 9 10 
Table 3: Variation of reaction time to optimise the oxidation process outlined by McKillop et 
al.102, 150 
 
The progress of the reaction could be followed by the formation of an off-white 
precipitate, which, with elongated reaction times (> 4 h), could also be seen to re-
dissolve into the reaction mixture. 
 
It has been reported that accelerated oxidation of electron-rich arenes is observed, 
particularly those which possess electron-donating ortho- or para-substituents, or 
electron-withdrawing meta-substituents.102 The series of reactions performed above 
supports this hypothesis. 
 
Silva et al. carried out an electrospray ionisation mass spectrometry study of the 
hydrolysis products of diacetoxyiodobenzene, 35, encountered during its 
decomposition under atmospheric conditions.151 ESI-MS studies were performed 
using a freshly prepared sample of 35, as well as sample exposed for a 24 hours to 
atmospheric conditions. The resulting spectra were found to reveal a myriad of 
decomposition products, particularly for the sample exposed to air.151 As may be 
anticipated by the study of Silva et al., comparable decomposition products have 
 53 
 
been identified in this work by ESI-MS, although the relative rates of decomposition 
were not considered in detail. Molecular ions were observed for 33 (374.9705) and 
34 (350.9159) as sodium adducts, for high-resolution ESI-MS spectra, see appendix.  
Importantly, the main conclusions identified by Silva and co-workers are that 
spontaneous decomposition of 35 occurs in solution, and that the decomposition 
process is accelerated by an increase in temperature.151 Accordingly, after work-up 
and crystallisation, 33 and 34 were dried under nitrogen and either used in 
subsequent reactions immediately or stored in a freezer to mitigate formation of 
decomposition adducts (Figure 29).   
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Figure 29: Decomposition products of 33 (top) and 34 (bottom). (ESI-MS in MeCN) 
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1H and 13C NMR were overall as expected in light of previously published 
examples,100 demonstrating the expected downfield shift of protons –ortho to the 
iodane (8.0 ppm) relative to an iodide counterpart, e.g. 4-iodoanisole (7.5 ppm). 
 
Although the process is moderate in yield, reasonable quantities of 
diacetoxyiodoarenes are required to be used in further studies, hence the reaction is 
still employed as it can be carried out on a large scale (50 mmol), is procedurally 
straight-forward; in addition to being viable (see section 2.8) across a number of 
iodoarenes.102 
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2.2 Synthesis of Substituted Arylstannanes 
 
Substituted aryl stananes have been widely used in many synthetic procedures, from 
Stille couplings152 to carbonylations.153 The purpose of using an aryl stannane is to 
provide a nucleophilic coupling partner for subsequent reaction with a 
diacetoxyiodoarene, i.e. using a general approach to the synthesis of a 
diaryliodonium salt. 
 
Diacetoxyiodoarenes are synthesised under oxidising conditions and therefore are 
often used to supply the so-called ‘non-participating arene’ of a diaryliodonium salt. 
It could be envisaged that the reactive functionality of certain substituted arenes (the 
‘target’ arene) would not tolerate such oxidising conditions, and therefore such 
functionalities could be incorporated into the other aromatic ring (as the appropriate 
arylstannane) as this can be achieved under mild reaction conditions.  
 
An example of a synthetic route to an arylstannane in the presence of reactive 
functionality is the synthesis of 4-tributylstannylbenzaldehyde 37, from a 
bromobenzaldehyde 36, where Pd(PPh3)4 was used as the catalyst, yielding 37 in 
67% yield (Scheme 32).154 The procedure requires an excess of 2 eq. hexa-n-
butylditin to 1 eq. 36 in addition to 10 mol% of an expensive palladium catalyst. 
Furthermore, the excess of the stannane, as well as the high catalyst loading, lead to 
difficulties in purification of the resultant product. A further problem associated with 
the reported purification method, is that it has been shown that normal phase column 
chromatography may lead to destannylation of the desired product,155, 156 which may 
be a factor to account for the yield of the reaction. Hence, a more efficient alternative 
was required. 
 
 
Scheme 32: Palladium catalysed synthesis of 4-tributylstannylbenzaldeyhde. 
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A method of introducing trialkylstannane functionality into a reactive arene using 
cobalt/zinc catalysis has been demonstrated by Gosmini et al.157 Importantly, half the 
amount of tin starting material, in this case Bu6Sn2, is required.
157 The initiation point 
for the catalytic cycle is the reduction of cobalt dibromide using zinc dust which has 
been activated with trace acid. Oxidative insertion of cobalt bromide into the aryl-
halide bond yields a trivalent complex, ArCoBr2. The presence of excess zinc dust 
proceeds to reduce this complex, thus facilitating a transmetallation with zinc 
dibromide, furnishing the desired arylzinc compound and regenerating copper 
dibromide (Scheme 33).158  
 
 
 
Scheme 33: The catalytic cycle which leads to the formation of an arylzinc species. 
 
The conditions set forth by Gosmini and co-workers were therefore used to facilitate 
the stannylation of 36 (Scheme 34) in a 46-67% yield (n=4), which compares 
reasonably well with the palladium mediated stannylation reaction performed above, 
given the increased economy of the process. 
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Scheme 34: Cobalt catalysed synthesis of 4-tributylstannylbenzaldeyhde, 37. 
 
The reaction progress was monitored by TLC (95:5 petrol:ether) until it was found 
that all of the starting material 36 had been consumed. Of particular note is the 
problem which has been encountered with regards the purification of 37. Some 
impurities, which have been attributed to oxidation of an organotin species (possibly 
Bu3Sn-O-SnBu3 and Bu3SnO), have proven difficult to remove using normal phase 
chromatography, resulting in an inseparable mixture of the desired product and the 
undesired impurity. One method which aided the removal of the problematic 
impurity was reverse phase chromatography, which readily separated the proposed 
highly lipophilic tin oxide from less lipophilic 37. It has been found that the 
appearance of this impurity was difficult to predict, as on occasion, normal phase 
column chromatography proved sufficient for purification. Overall, an advantage of 
reverse phase purification is that the destannylation problems attributed to the use of 
silica gel are avoided. 
 
The 3- (38) and 2- (39) regioisomers of 37 were prepared utilising the same 
chemistry; varied yields (70% for 38, 33% for 39) were obtained for these 
regioisomers.  
 
It should be noted that catalysis isn’t an essential requirement to stannylate 
benzaldehydes. For instance, a Grignard reagent can be synthesised by reaction 
between a haloaryldioxolane and magnesium, followed by quenching with tri-n-
butyltin chloride and acid catalysed removal of the protecting group (Scheme 35).159  
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Scheme 35: Non-catalytic synthesis of 38 using a Grignard reagent. N.B. protection of the 
starting material is not shown.159 
 
We did not attempt the Grignard strategy as it highly substrate dependent, i.e. 
synthesis of a Grignard reagent in the presence of many functional groups, such as 
the aldehyde, means additional protection and deprotection steps are required. 
Additionally, as we examine functionality which is more intricate than that of an 
aldehyde, the solubility of the starting material may not conform to the solvent 
requirements which are imposed upon Grignard reagents, i.e. only aprotic solvents 
are of use when synthesising the Grignard reagent. 
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2.3 Synthesis of Diaryliodonium Salts 
 
As outlined in section 1.10.2, diaryliodonium salts are useful synthetic precursors to 
radiolabeled compounds, such as prosthetic groups. By using diaryliodonium salt 
chemistry, it is possible to avoid unwanted nucleophilic substitution reactions and to 
selectively introduce fluorine into any position desired arene precursor, thus, a 
generic synthetic route to all regioisomers of a particular prosthetic group becomes 
possible. 
 
There are many synthetic strategies one could employ to synthesise a substituted 
diaryliodonium salt. The first reported regiospecific synthesis of a substituted 
diaryliodonium tosylate was carried out in 1980,160 where Koser’s reagent 40 is 
reacted with  substituted arylsilanes 41a-d. Exclusive substitution at the ipso position 
occurs, regardless of the other substituents present on 41a-d (Scheme 36).160 
 
 
 
Scheme 36: Reaction of Koser’s reagent with a substituted arylsilane. 
 
One disadvantage of using Koser’s reagent is that the counter anion generated is 
restricted to tosylate. Tosylate ion has been shown to be disadvantageous in 
radiolabelling studies of heteroaromatic iodonium salts, where it has been indicated 
that counter anions can compete as an alternative nucleophile to the fluoride ion 
during the radiolabeling process. The tosylate counter anion also performed poorest 
with respect to radiochemical yield (Scheme 37).6 
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Scheme 37: Counter anion influence when radiolabeling heteroaromatic diaryliodonium salts.6 
 
Noticeably, the common trifluoroacetate anion doesn’t appear in the study outlined 
above. Work within our group has determined that the trifluoroacetate counter anion 
provides the best balance between ease of synthesis and overall radiochemical 
yield.161  
 
We considered that a general approach (Scheme 38) would be most appropriate for 
the synthesis of the chosen diaryliodonium salts.90 The synthetic methodology 
employs anhydrous conditions, whereby the diacetoxyiodoarene (1 eq.) is dissolved 
in dry DCM and the solution cooled to −30 °C (acetone/cardice), followed by 
dropwise addition of TFA (2 eq.). The resultant solution is stirred in the dark for 30 
minutes, followed by 1 hour at room temperature. The solution is then re-cooled to 
−30 °C, when a substituted arylstannane (1 eq.) is added. The solution is warmed to 
room temperature for a second time and left to stir overnight. The reaction solvent is 
then removed in vacuo, leaving the addition of DCM/petrol to crystallise the 
diaryliodonium salt. This general approach was applied to the synthesis of the 
diaryliodonium salts discussed in this report, unless stated otherwise.  
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Scheme 38: General synthetic route to asymmetric diaryliodonium salts. 
 
It has been proposed that diaryliodonium salts can react with nucleophiles either 
through an associative, or a dissociative pathway,162 in a manner similar to that of an 
aryl-λ3-iodane bearing two labile ligands (Scheme 39). To date, experimental results 
of the associative pathway have been reported, whereas no experimental results have 
been reported regarding the dissociative pathway.97 
 
 
 
Scheme 39: Associative and dissociative nucleophilic reaction pathways of an aryl-λ3-iodane. 
 
Due to the electropositive nature of the tin atom in the arylstannane, the carbon atom 
bound to tin will be slightly δ-. Consideration of the associative pathway mechanism 
reveals the bonding pair of the carbon-tin bond acts as a nucleophile, resulting in the 
arene becoming bonded to the iodine atom, which leads to an important feature of the 
mechanism by which an aryl-λ3-iodane reacts. This feature is the ability for ligands 
to pseudo-rotate about the iodine centre. Consequently, many conformations may 
exist for a particular aryl-λ3-iodane, which highlights the conformational instability 
this type of iodane. The formal terminology for the conformational flexibility is 
termed Berry pseudorotation (denoted as Ψ), after being first described in 1960 by R. 
S. Berry.163 In the example below, Berry pseudorotation facilitates the elimination of 
a ligand from the equatorial position, a requirement imposed by both the proposed 
associative and dissociative mechanisms (Scheme 40), as well as a requirement of 
 63 
 
the diaryl-λ3-iodane itself, as the more electron-deficient and/or sterically demanding 
ligand will preferentially occupy an equatorial position.94 
 
 
Scheme 40: The proposed mechanism of diaryliodonium salt synthesis by an associative 
pathway. 
 
2.3.1 Synthesis of 4-Formylphenyl(aryl)iodonium Salts 
 
Diaryliodonium salts 43, 44 and 45 were prepared in yields of 32-48% respectively 
(Scheme 41) from an aryliodobisacetate and an arylstannane. 
 
 
 
Scheme 41: Synthesis of diaryliodonium salts 43-45. 
 
As previously reported the work-up procedure prior to crystallisation of the desired 
diaryliodonium salt is simply removal of the reaction solvent, in this instance DCM, 
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followed by the addition of a low polarity solvent, e.g. petrol, to effect 
crystallisation.67 However, crystallisation of the diaryliodonium salts 43-45 proved 
challenging. On some occasions, amorphous white powders form, on other occasions 
colourless needles form. In some instances no crystalline material is observed, 
including over extended periods (4 weeks), even where 1H-NMR of the crude 
product suggests successful diaryliodonium salt formation. A feature of the 1H-NMR 
of the crude product revealed the presence of a significant quantity of butyl groups. 
The butyl groups are attributable to stannane impurities, which have proven difficult 
to remove as the stannane impurity appears to be remarkably soluble, being present 
in both DCM/MeCN and petrol/pentane extracts from the crude material. It is 
proposed that the presence of said impurity results in a lack of crystallisation of 
suitable quality. 
 
In an attempt to evaluate the most appropriate conditions required to routinely yield 
crystals of good quality, a simple study of various solvent/anti-solvent combinations 
was undertaken using slow diffusion as well as an ‘H-tube’ ( 
Table 4). The general procedure comprised dissolution of crude material (25 mg) in 
the minimum amount of the system’s polar solvent being pipetted into its respective 
section of the container. The corresponding ratio of pentane was added to the other 
section of the container. Containers were left in the dark in an undisturbed 
environment for a given time period. 
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Entry System Ratio Result Time 
1 Pentane/MeCN 1:1 43: A 
44: X 
45: X 
10 h 
4 weeks 
4 weeks 
2 Pentane/MeCN 1:0.5 43: A 
44: A 
45: X 
10 h 
10 h 
4 weeks 
3 Pentane /MeCN 1:0.25 43: A 10 h 
   44: C 3 days 
   45: A 5 days 
4 Pentane/DCM 1:1 43: X 
44: X 
45: X 
4 weeks 
4 weeks 
4 weeks 
5 Pentane/DCM 1:0.5 43: A Immediately 
   44: C 10 h 
   45: C 4 weeks 
6 Pentane/DCM 1:0.25 43: A Immediately 
   44: C 3 days week 
   45: C 2 weeks 
7 Pentane/Ether 1:1 43: A Immediately 
   44 C 10 h 
   45: A 4 weeks 
8 Pentane/Ether 1:0.5 43: A Immediately 
   44: C 1 week 
   45: C weeks 
9 Pentane/Ether 1:0.25 43: A Immediately 
   44: C 1 week 
   45: C 9 days 
10 Pentane/TBME 1:1 43-45: X 4 weeks 
11 Pentane/TBME 1:0.5 43-45: X 4 weeks 
12 Pentane/TBME 1:0.25 43-45: X 4 weeks 
 
Table 4: Solvent systems used to crystallise 43-45 (C = crystalline material, A = amorphous 
analytically pure material, X = crude material).  
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With respect to obtaining a sample of material, albeit crystalline or otherwise, for use 
in further reactions the most efficient system was pentane/ether (1:0.25). This system 
often produced crystals of suitable quality for single crystal x-ray crystallography 
studies, yielding previously unreported x-ray crystal structures for 44 and 45        
(Figure 30). A bulk crystallisation using the same ratio also yields powders of all 
three compounds, within 10 h, which conform to the expected NMR, MS and CHN 
analyses, and is also tolerant of the use of petrol in place of pentane. Systems using 
DCM or MeCN were found to have no distinct advantages, and, in the case of or tert-
butyl methyl ether (TBME), produced no solid material of any description. 
 
Unfortunately, 43 was obtained as an amorphous white powder in all solvent systems 
tested. Powder diffraction measurements of the powder at the Diamond Light Source 
have not proven possible, as during the time required to acquire a powder diffracton 
of reasonable quality, the power of the beam destroyed the sample.   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30: X-ray crystal structures of the monomers of 44 (left) and 45 (right) drawn using 
ORTEP-3,164 plotted as thermal ellipsoids with a 50% probability, H atoms are presented as 
spheres with a constant radius, as are all further structures. Selected bond lengths and angles 
shown. 
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As discussed in the sections above, diaryliodonium salts can interact in an intra-
molecular manner thus forming dimers, trimers and so on. The interactions in 
forming a dimer have been observed for compound 44 (Figure 31).  
 
Figure 31: X-ray crystal structure of a dimer of 44. 
 
Given that in their ground states, diaryliodonium salts, e.g. 44 above, can exist 
effectively in a polymeric state, judicious selection of part of the unit cell of a 
diaryliodonium salt from a structure determined in the ground state may be 
misleading and may also be different to that encountered in a transition state              
( 
Figure 32). Selection of the blue groups places the aldehyde bearing moiety in the 
pseudo-equatorial position, whereas selection of the red groups places the aldehyde 
bearing moiety in the pseudo-axial position. Accordingly the part of the unit cell 
selected when conveying the monomer may not be representative of the actual 
conformation which is adopted during the course of a reaction with a nucleophile.  
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Figure 32: Polymeric unit selections yield different ground state structures. 
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2.4 [19F]Fluorination of 4-Fluorobenzaldehyde Precursors 
 
[19F]Fluorination, so-called ‘cold’ fluorination, of 4-formylphenyl(aryl)iodonium salt 
precursors enables the determination, and the relative extent, of fluorination between 
the 4-formylphenyl and the other aryl moieties present per diaryliodonium salt. It is 
known that the most electron-deficient arene on the diaryliodonium salt will be 
preferentially fluorinated.94 The ‘target arene,’ i.e. the arene bearing the aldehyde 
moiety, is clearly the more electron-deficient relative to the ‘non-participating arene’ 
counterparts, i.e. phenyl, 4-anisyl, and 2-thienyl arenes. Consequently, selective 
fluorination of the target arene should be observed. This data will be useful prior to 
any radiosynthetic chemistry with [18F]fluoride being carried out, as the most 
appropriate diaryliodonium salt precursor can be determined. 
 
The [19F]fluorination of 4-fluorobenzaldehyde precursors 43-45 was determined by a 
variable temperature NMR (VT-NMR) experiment observing both 1H and 19F nuclei. 
The procedure used one equivalent of diaryliodonium salt 43-45, two equivalents of 
caesium fluoride, and one equivalent of 3-methoxybenzotrifluoride as an internal 
standard, the study was conducted in deuterated dimethylformamide (d7-DMF), 
which is a useful solvent for this experiment, as DMF is the solvent which is 
typically used for fluorine-18 radiolabeling (Scheme 42). Additionally, this solvent 
will enable the study to be conducted at temperatures up to 130 °C. Caesium fluoride 
was judiciously chosen on the basis of a report from Nairne et al. where several cold 
fluorinating reagents were examined and with respect to reaction yield: CsF > 
KF(18-crown-6) > KF(K222) > KF = TBAF.
100 
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Scheme 42: [19F]Fluorination of 4-fluorobenzaldehyde precursors 43-45. 
 
The reaction was conducted over a two hour period, increasing the NMR probe 
temperature by roughly 20 ˚C every twenty minutes.  
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2.4.1 [19F]Fluorination of 4-formylphenyl(phenyl)iodonium TFA 
 
Figure 33: 1H VT-NMR experiment following the fluorination of 4-formyl(phenyl)iodonium 
trifluoroacetate, 43.
The aldehyde region 
shows clearly the 
formation of a new 
aldehyde, in addition 
to a reduction in the 
amount of aldehyde 
starting material. 
All starting material 
has been consumed 
at 130 °C. 
120 min 
20 min 
40 min 
60 min 
100 min 
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2.4.2 [19F]Fluorination of 4-formylphenyl(4-anisyl)iodonium TFA  
 
Figure 34: 1H VT-NMR experiment following the fluorination of 4-formylphenyl(4-anisyl)iodonium 
trifluoroacetate, 44.
The aldehyde region 
shows clearly the 
formation of a new 
aldehyde, in 
addition to a 
reduction in the 
amount of aldehyde 
starting material. 
All of the starting 
material has been 
consumed at 90 °C. 
100 min 
20 min 
40 min 
60 min 
80 min 
120 min 
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2.4.3  [19F]Fluorination of 4-formylphenyl(2-
thienyl)iodonium TFA 
 
Figure 35: 1H VT-NMR experiment following the fluorination of 4-formylphenyl(2-
thienyl)iodonium trifluoroacetate, 45.
The region between 
6.2–10.4 is expanded 
for clarity. The 
starting material 
seems to be fully 
consumed at around 
90 °C. Again, only one 
new aldehyde is 
observed. 
100 min 
20 min 
40 min 
60 min 
80 min 
120 min 
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There is an overall decrease in the amount of diaryliodonium salt as the reactions 
proceed (Figure 33, Figure 34 and Figure 35). It is also evident that new multiplets 
form in the aromatic region, which is consistent with what we expect regarding the 
fluorination of a diaryliodonium salt, i.e., the formation of an iodoarene and a 
fluoroarene. Note that multiplets form as a result of line broadening due to the higher 
temperatures of the NMR probe not being able to shim the sample as evenly as at 
room temperature. A 19F VT-NMR experiment which was carried out simultaneously 
found that only one new fluorinated compound was synthesised, at around −105 ppm, 
corresponding to 4-fluorobenzaldeyhde, which was observed at −104 ppm at room 
temperature (the 1H NMR spectrum does indicate the presence of an aldehyde other 
than the starting material. However, 4-iodobenzaldehyde 46 and 4-FBA appear in 
very similar regions). A problem arises at this point; this is because fluorobenzene, 
47, 4-fluoroanisole, 48 or 2-fluorothiophene, 49 were not detected. Consequently, 
upon initial examination, it would seem that selectivity towards the target arene is 
100%. However, consideration of the boiling points of fluorinated arenes 47-49 
reveals that in two instances their boiling points are lower than the highest 
temperature reached during the experiment. The boiling points of these fluoroarenes 
are; 47 85 °C (1 atm),165 48 150 °C (1 atm)166 and 49 believed to be 82 °C (pressure 
at which boiling point determined not given).167  The boiling point of 49 is higher 
than the 130 °C experiment limit, and 49 was not detected by 19F NMR at any stage 
of the 2 hour experiment. To detect the volatile arenes, a specialist sealed NMR tube 
with a pressure regulation system would be required. This would ensure that any 
volatiles potentially generated over the course of the experiment remain inside the 
NMR tube, and therefore could be detected. A specialist NMR tube of this type was 
not available at the time of the experiment. A more traditional glass sealed and 
waxed NMR tube may not be able to cope with increased pressures as a result of the 
increased temperature, therefore the risk of damaging the expensive NMR probe is 
high if the NMR tube fails and as such was not attempted.  
 
Three 4-formylphenyl(aryl)iodonium salts, 43-45, have been synthesised and 
obtained as analytically pure material from the appropriate diacetoxyiodoarene and 
an arylstannane. X-ray crystal structures have been determined for 44 and 45, and a 
‘cold’ NMR study by reaction with [19F]fluoride ion affirms that product selectivity 
cannot be ascertained by consideration of the ground state of a diaryliodonium salt. 
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2.5 Synthesis of 3-Formylphenyl(aryl)iodonium Salts 
3-Formylphenyl(aryl)iodonium salts provide a means of synthesising 3-[18F]FBA, a 
prosthetic group which cannot be synthesised via traditional nucleophilic means.168 
3-Formylphenyltributyl stannane, 38, was synthesised and purified in the manner 
described in section 2.2, affording the desired material in 46-70% yield (n=5) 
(Scheme 43). Interestingly, the purification of 38 was found to be more 
straightforward its 4-substituted counterpart 37. 
 
Scheme 43: Synthesis of 3-formylphenyltributyl stannane using the procedure of Gosmini et 
al.157 
 
The 3-formyl(aryl)iodonium trifluoroacetates 50-52 were subsequently synthesised 
in a manner akin to their regioisomeric counterparts above, in 39-47% yield    
(Scheme 44).  
 
Scheme 44: Synthesis of 3-formylphenyl(aryl)iodonium salts 50-52. 
 
A study was carried out in 2011 by Griffiths et al.to synthesise a range of 
diaryliodonium salts as precursors to the prosthetic group, 3-[18F]FBA.168 The 
reported synthetic approach followed previous work carried out by Olofsson et al.169 
whereby a non-isolated tetrafluoroborate salt is formed post oxidation of 
iodobenzene by meta-chloroperbenzoic acid (mCPBA), followed by various counter 
anion exchanges to yield a range of diaryliodonium salts (Scheme 45). 
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Scheme 45: Synthesis of diaryliodonium salts 53-56 via a non-isolated diaryliodonium 
tetrafluoroborate salt.168 
 
It has been discussed in many previous publications that unavoidable dilution of 
[18F]fluoride ion occurs when tetrafluoroborate salts are used and accordingly, use of 
tetrafluoroborate salts as precursors to high specific activity fluorine-18 labelled 
compounds is not appropriate.72, 170, 171 
 
Griffiths and co-workers proceed with counter anion exchanges to avoid this problem, 
however, the experimental evidence provided does not attempt to quantify the extent 
of any undesired fluorine-19, and hence   confirm the purity of the counter-ion, in the 
precipitated products. No 19F-NMR analyses were provided for any of the reported 
diaryliodonium salts, even in instances where fluorine-19 is present as a constituent 
of a desired counter anion, such as 53. Furthermore, identification of the bromide and 
chloride diaryliodonium salts was performed using 1H, 13C NMR and low resolution 
positive mode LC-MS only. These methods are not appropriate to identify, with any 
reasonable confidence, the presence of residual bromide or chloride. Elemental 
analysis is an analytical method which can be used to determine with a level of 
confidence the percentage of fluoride, bromide and chloride in the diaryliodonium 
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salt, such an analysis was not reported and therefore it is not possible to confirm the 
purity of the counter-ion component following these exchange reactions. 
 
Diaryliodonium salts synthesised in this study benefit from additional 
characterisation, conforming with the expected results of 1H, 13C and 19F-NMR, high 
resolution mass spectrometry, IR and elemental analysis (see appendix). Additionally, 
X-ray crystal structures of 50-52 have been determined (Figure 36). 
 
In the case of the monomer of 51, the electron-rich 4-anisyl moiety is sited in the 
equatorial position. Monomers of 50 and 52 can be seen to adopt the opposite 
structure. Analogous to their regiosiomeric counterparts reported above, selection of 
a portion of the refined unit cell determined in the ground state may result in an 
apparent ‘flip’ between arenes appearing as pseudo-equatorial or pseudo-axial. In the 
transition state, however, the relative position of the rings is likely to differ compared 
to the ground state (see section 2.3.1). 
 
 
 
Figure 36: X–ray crystal structures of 3-formylphenyl(aryl)iodonium salts 50-52. 
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2.6 Synthesis of 2-Fluorothiophene: Current Methods 
2-Fluorothiophene, 49, is an important compound from the viewpoint of the 
radiosynthetic applications of diaryliodonium salts bearing the 2-thienyl moiety. This 
importance owes to the reaction mechanism arising where Ar1≠Ar2, thus potentiating 
the production of two product pairs (Scheme 46), where selectivity is dictated by 
steric and electronic controls, i.e., fluorination occurring preferentially on the more 
sterically encumbered and/or electron-deficient of the two.92, 172 The products are 
often initially purified by HPLC, and upon further purification, e.g. solid-phase 
extraction (SPE), used as radiopharmaceuticals. 
 
Scheme 46: Steric and electronic controls result in the generation of one or two pairs of 
products. 
 
Due to its low steric encumbrance and relatively electron-rich nature, the 2-thienyl 
moiety is often used to promote fluorination of the desired arene in the 
diaryliodonium salt, especially where the target-arene, i.e. the arene intended to be 
radiofluorinated, is also electron-rich.6 Unlike the fluorination products of other 
commonly used arenes, such as 4-fluoroanisole or fluorobenzene, 2-fluorothiophene 
is not commercially available. As such the λmax, absorption coefficient and most 
importantly HPLC retention times, have never been reported, though unknown ‘hot 
peaks’ have been postulated as corresponding to the illusive 2-[18F]fluorothiophene, 
[18F]49 (see Table 5 for selected literature examples). 
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Table 5: Selected literature examples of the use of the 2-thienyl moiety in the fluorination of 
diaryliodonium salts.  
Compound 
2-
Fluorothiophene 
reported 
Analytical method λmax Ref 
 
0% 
Computer calculation, 
references that typical 
radiochemical yields have been 
reported for the process, 
although the 2-thienyl moiety 
isn’t used in the referenced 
studies. 
No 
HPLC 
data 
provided 
94 
 
Detected, % not 
provided 
HPLC 
No 
HPLC 
data 
provided 
173 
 
0% 
Reversed-phase (RP) radio-
HPLC using a Phenomenex 
Luna  C18 column (3 mm × 
250 mm) and MeCN/water 
(40/60) as eluent. 
Paper states that, ‘It proved 
that the 2-thienyl group directs 
the n.c.a [18F]fluoride to a 
regiospecific attack of the ipso-
carbon of the aryl group, and 
consequently only the desired 
[18F]fluoroarenes without any 
other radioactive side product 
were formed’. 
No 
HPLC 
data 
provided 
6, 
174 
 
No details HPLC 
No  
HPLC  
data 
provided 
105, 
175 
 
0–4% (d.c.) 
HPLC (5.0 min Luna C18 
column (250 × 4.6 mm i.d 10 
μm, 280 nm) eluted at 1.75 
mL/min with a gradient of 
MeCN/H2O with the 
percentage of MeCN increased 
linearly from 60 to 90% over 7 
min. Fluorine-18 containing 
compounds were identified by 
their comobility with the 
respective reference fluoro 
compounds. 
280 nm 
176, 
177 
 
37% 
(plus 20% 
thiophene) 
1H-NMR 
No 
HPLC 
data 
provided 
178 
 
No details No details 
No  
HPLC  
data 
provided 
179 
 
No details 
RP HPLC MeCN:H2O (1:1, 
v/v) 
No  
HPLC 
data 
provided 
180 
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It is therefore apparent that great importance is associated with the use of the 2-
thienyl moiety as a non-participating arene both for simple and complex 
diaryliodonium salts. An authentic standard of the material was sought accordingly. 
 
The earliest synthesis of 49, reported in 1949 by VanVleck, employed the reaction of 
antimony trifluoride with 2-iodothiophene in refluxing nitromethane (Scheme 47), to 
produce moderate yields of the desired compound which was characterised only by 
sulfur and fluorine elemental analysis due to technological limitations of the time.167 
 
 
Scheme 47: The earliest reported preparation of 49. 
 
A number of syntheses have since been reported for the production of 49, the most 
successful of which being the reaction of perchloryl fluoride, an extremely toxic 
(TLV 3 ppm), potentially explosive and now unobtainable gaseous reagent,182 with 
2-thienyllithium (Scheme 48).183, 184  
 
 
Scheme 48: Preparation of 49 using perchloryl fluoride. 
 
Many of the attempted syntheses have resulted in mixtures of 49 and thiophene, with 
analytically pure samples being produced only by preparative gas 
chromatography.183, 184 Other than some early work on the 1H- and 19F-NMR 
spectra183 of 49 (as well as related compounds),185-187 modern innovations are yet to 
 
No details 
UPLC, Semi preparative 
HPLC. 
No  
HPLC 
data 
provided 
181 
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prompt a synthesis to produce large quantities of pure 2-fluorothiophene and thus, 
full characterisation remains to be reported. 
 
Aryllithiums have previously been shown to be reactive towards NFSI, 
demonstrating the potential for fluorination of organometalics with NFSI188 and thus 
forming the basis of our synthetic approach. The known volatility of 49167, 184 has 
forced careful solvent choice previously, to the extent that Schuetz et. al. found it 
necessary to synthesise their own n-butyllithium in diethylether to avoid the higher 
boiling commercially available solutions in, for example, hexanes. Following these 
precautionary measures an initial approach using high boiling solvents was 
postulated. 
 
Although ionic liquids have been shown to be suitable for the synthesis of Grignard 
reagents,189 these would be an expensive solvent for performing the reaction on 
larger scales, therefore a more common ethereal solvent was preferred.  
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2.7 Synthesis and Isolation of 2-[19F]Fluorothiophene 
 
Diglyme was initially selected as the reaction solvent during early attempts to 
synthesise 2-fluorothiophene, 49, for the reasons that it is compatible with 
organolithium and Grignard reagents, it has a boiling point around        80 ˚C higher 
than that reported for 49, and it could readily dissolve NFSI. Initial experiments 
showed n-butyllithium to be incompatible with anhydrous diglyme, immediately 
forming a cloudy suspension even before the introduction of any other reagents and 
thus was deemed unsuitable for this approach. The use of diethylether also had its 
problems, showing a triplet of triplets in the 19F-NMR at -113.82 ppm in addition to 
the expected183 double, double doublet for 49. On the basis of its splitting and shift* 
the fluorinated impurity was assigned as the fluorinated hydrolysis product of 
directed 4-metalation, 4-fluorobenzenesulfonic acid, though no attempt was made to 
isolate this species (Figure 37).190 
 
Figure 37: 19F-NMR for the fluorinated impurity obtained via the organolithium reaction. 
 
In light of the results observed with organolithium species, the analogous 
organomagnesium species were investigated (Scheme 49). It was found that 2-
thienylmagnesium bromide could be synthesised more cleanly than its corresponding 
iodide. Despite quantitative formation of 2-thienylmagnesium bromide followed by 
                                         
* Shift comparison made with p-fluorobenzene sulfonic acid (110.15 ppm) 
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its subsequent conversion to 2-fluorothiophene using NFSI, none of the distillation 
techniques attempted were able to separate the product from diglyme. 
 
 
Scheme 49: Attempted synthesis of 49 using ethereal solvents diglyme and diethyl ether. 
 
Accordingly, focus therefore returned to the use of diethylether as the reaction 
solvent due to its very low boiling point and, following successful small scale 
reactions using 2-thienylmagnesium bromide and NFSI as above, the reaction was 
repeated on a 750 mmol scale. After removal of the insoluble magnesium by-
products by filtration, the product was isolated by careful distillation spanning 
several days.† 
 
In spite of our best efforts to use only low boiling point solvents it was suggested that 
the commercial NFSI contained residual traces of ethyl acetate, which was found in 
the distilled product and having ruled out the other starting materials/reagents as 
potential sources. Residual diethylether levels could be reduced marginally using 5Å 
sieves providing 35.8 g of >95% purity 2-fluorothiophene, 49, containing traces of 
ethyl acetate (<2.5%) and thiophene (<1%), as well as a separate fraction of 6.7 g of 
>70% purity material.191, 192 
 
1H- (Figure 38) and 19F-NMR spectra (Figure 39, left) of >95 % pure 49 were in 
keeping with those reported previously as a component in a mixture; in addition, 
COSY, HMQC, HMBC and 1H-decoupled-19F spectra (Figure 39, middle and right) 
were also ran to provide further structural information. 
 
 
 
                                         
† Distillation procedure performed both by Dr L. I. Dixon and the author. 
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Figure 38: 1H-NMR for 95+% pure 2-fluorothiophene, 49. 
 
Figure 39: 19F-NMR (376 MHz, d2-DCM, CFCl3) (left),193 19F-NMR (471 MHz, d2-DCM, CFCl3) 
H3 (6.48ppm) irradiated (middle) and H4 and H5 (6.68ppm) irradiated (right). 
 
Spectroscopic analysis of 49 by UV-Vis gave a molar absorption coefficient (ε) of 
5150 M-1cm-1 (λmax (EtOH)/nm 226) (Figure 40) which is of similar magnitude to the 
parent molecule thiophene (λmax(EtOH)/nm 231; ε=2232 M-1cm-1). The λmax for 49 
was also assessed for other common HPLC solvents to rule out solvatochromistic 
effects, i.e. the dependence between absorption (and emission) spectra as a 
consequence of a molecules various states of polarity in different solvents, showing 
almost no change in water or acetonitrile (λmax = 225 and 226 nm respectively). It is 
interesting to note that upon fluorination of the 2-thienyl(aryl)iodonium salts 
reported in Table 5 the HPLC analyses were performed at 254 and 280 nm 
wavelengths for which there is minimal absorbance.  
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Figure 40: Absorption spectrum for 2-[19F]fluorothiophene, 3.3×10-4 M in EtOH. 
 
Using the HPLC analysis, the detection limits for 2-fluorothiophene have been 
established by generation of a series of calibration curves, where the minimum 
detection limit is 25 µM and maximum detection limit is ≤12 mM for 10 µL injection 
volumes of the respective concentration standards (Figure 41).194 The linear portion 
of the calibration curve is taken when R2 = 1 (3 d.p.). Greater concentrations results 
in a drop in R2, revealing the detection limit. 
 
 
Figure 41: HPLC calibration curve demonstrates the detection limit for  2-[19F]fluorothiophene. 
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2.8 Synthesis of 2-Thienyl(aryl)iodonium Salts 
A radiosynthetic study was sought to determine if the corresponding                          
2-[18F]fluorothiophene, [18F]49, could be observed and quantified relative to a 2-
fluorothiophene, 49, standard. Following the procedures set forth above, a range of 
2-thienyl(aryl)iodonium trifluoroacetates, 57-59, were prepared (Scheme 50). 
 
Scheme 50: Synthesis of 2-thienyl(aryl)iodonium salts 57-59. 
 
No attempts were made to optimise the yields of the reaction, as sufficient quantities 
of the precursors could be obtained for the intended study. It is important to note that 
the more electron-rich diaryliodonium salt 59 was found to decompose to a 
brown/black tar-like substance within 48 hours, even when stored in a freezer          
(ca. -20 °C). The previously unreported X-ray crystal structures of 57-59 were 
obtained (Figure 42). 
 
 
Figure 42: X-ray crystal structures of 57-59 (left to right). 
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In summary an authentic analytically pure sample of 2-fluorothiophene, 49, has been 
prepared by a large scale synthesis from 2-thienylmagnesium bromide and NFSI and 
several key analytical parameters have been unambiguously determined. A range of 
simple diaryliodonium salts have also been synthesised and fully characterised, 
enabling a radiochemical study reported herein to determine if [18F]49 can be 
detected when using sealed microfluidic apparatus. 
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2.9 Synthesis of N-(4-fluorophenyl)maleimide and Related 
Compounds 
As discussed in section 1.11.3, current approaches to thiol reactive prosthetic groups 
focus on the use of the maleimide moiety as a Michael acceptor for the conjugation 
of free sulfhydryl residue which may be readily incorporated into biomolecules. 
However, there is a marked lack of a simple and reproducible synthetic procedure to 
yield the simple [18F]radiolabeled maleimide, N-(4-[18F]fluorophenyl)maleimide, 
[18F]60, following the first report by Shiue et al. in 1989.129 Multi-step synthetic 
procedures are the only known pathways to afford maleimide containing prosthetic 
groups. Several have postulated that the maleimide functionality does not tolerate the 
basic conditions required for the introduction of [18F]fluoride ion into the prosthetic 
group precursor.129, 133 However, the aforementioned studies have not considered the 
use of diaryliodonium salts, nor the use of microfluidic apparatus during the 
radiosynthetic procedure.  
 
Attempts were made to follow the general procedure given above for the synthesis of 
a diaryliodonium salt containing maleimide functionality, i.e. introduction of a 
stannane into the target-arene followed by reaction with preformed oxidised iodine 
species. Firstly, N-(4-halophenyl)maleimides were prepared195 (Scheme 51) to 
investigate which species is most amenable to subsequent inclusion of stannane 
functionality. The synthesis of 61-63 proceeds via non-isolated N-
halophenylmaleanic acid, which conveniently precipitates out of the reaction solvent. 
Once filtered, the acid is readily cyclised by using sodium acetate in acetic acid. 
 
 
Scheme 51: Preparation of 4-N-halophenylmaleimides 61-63.  
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An x-ray crystal structure for 63 was obtained, demonstrating that the maleimide 
functionality lies at 90° relative to the arene (Figure 43) and is therefore not 
conjugated with the π-electrons of the benzene ring.  
 
 
Figure 43: X-ray crystal structure of 63. 
 
Catalytic incorporation of stannane functionality was attempted using a range of 
catalysts and reaction conditions for precursors 62 and 63, where all reactions were 
performed under a positive pressure of nitrogen using MeCN freshly distilled over 
calcium hydride or toluene freshly distilled over sodium metal.  Unfortunately, 
however, none of the attempted procedures furnished the desired arylstannane  
(Table 6). Consequently, the general procedure outlined above could not be applied 
to the synthesis of this diaryliodonium salt. 
 
Entry Catalytic System Stannane Solvent Temperature Time Result  
1 Co/Zn, allyl- 
chloride 
Bu3SnCl MeCN 50 °C 8 h Complex mixture of 
crude material 
 
2 Pd(PPh3)4 (Bu3Sn)2 Toluene Reflux 4 h 62 and 63 decomp.  
3 Pd(dba)2 (Bu3Sn)2 Toluene Reflux 12 h Formation of an N-
phenylmaleanic acid 
 
4 Pd(OAc)2   (Bu3Sn)2 Toluene Reflux 8 h 62 and 63 decomp.  
5 Pd(dppf)Cl2 (Bu3Sn)2 Toluene Reflux 12 h 62 and 63 decomp.  
Table 6: Attempted synthesis of 64 from precursors 62 and 63 by examination of various 
catalysts and reaction conditions.  
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An early example of a diaryliodonium salt bearing maleimide functionality is 
reported in patent documentation, which describes a procedural enhancement which 
aims to improve the reproducibility of the preparation of diaryliodonium salt 
photoinitiatiors.196 Crivello et al., obtained 4,4ꞌ-bis-N-phenylmaleimidoiodonium 
bisulfate 66 by reaction of N-phenylmaleimide 65 with potassium iodate in the 
presence of acetic anhydride and sulfuric acid (Scheme 52). Conversion to the 
corresponding chloride salt was reported by addition of an excess of ammonium 
chloride, though limited analytical evidence was provided for either of the isolated 
species. Furthermore, limited experimental details were provided. 
 
Scheme 52: Synthesis of 66 from N-phenylmaleimide.196 
 
If the purpose of 66 was considered from the perspective of a prosthetic group, rather 
than a photoinitiator, the advantage of its symmetry becomes immediately apparent 
in that successful radiolabeling with [18F]fluoride ion will lead to the formation of a 
single product pair. Accordingly, attempts were made to synthesise 66 using the 
method proposed by Crivello et al., however, such endeavours were met with little 
success. Upon 1H-NMR analysis of the crude product (n = 4), only starting material 
was observed in significant quantities, in addition to a myriad of crude species. A 
suggestion of the formation of a 4-substituted diaryliodonium salt was apparent upon 
examination of the precipitated reaction output by 1H-NMR, as a diagnostic doublet 
at ~8.5 ppm was observed. However, the white powder obtained quickly 
decomposed to a black tar when attempts were made to dry the material under 
reduced in amber glass over a desiccant. An attempt to convert the potentially 
unstable bisulfate salt to the corresponding chloride species as a result of anion 
exchange by addition of an excess of ammonium chloride to the isolated precipitate 
was made. Unfortunately, however, attempts to dry the material also resulted in the 
formation of a crude tar-like product.  
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Due to the lack of reproducibility with the method outlined above, an alternative 
route to a maleimide bearing diaryliodonium salt was considered. Work by Olofsson 
et al. describes the use of m-chloroperbenzoic acid (mCPBA) as an oxidatant 
appropriate for the oxidation of a range of electron-rich and electron-poor iodoarenes, 
which when followed by treatment with an arene and trifluoromethanesulfonic acid, 
furnishes a range of symmetrical and unsymmetrical diaryliodonium triflates.169, 197 
Furthermore, molecular iodine could be used in place of an iodoarene, which greatly 
simplifies the synthesis of a symmetric salt. Accordingly, the aforementioned method 
was applied to the synthesis of a symmetric and asymmetric diaryliodonium salt 
bearing maleimide functionality.  
 
The synthesis of 67 from molecular iodine and 65 proved unsuccessful. A range of 
conditions were examined as suggested by Olofsson and co-workers, from 10 minute 
reaction times to 22 hour reaction times, to the use of either 3 or 4 eq mCPBA, or 
varying the eq of TfOH to 4 or 6 relative to 65. Care was taken using mCPBA, as 
the % of mCPBA present needs to be determined by iodometric titration prior to 
synthetic use.198 Following the procedure of Olofsson et al., in most instances, 
unreacted 65 was obtained, and following the course of the reaction by TLC (95:5, 
petrol:DCM) only 65 and m-chlorobenzoic acid were visualised (Scheme 53). 
 
 
Scheme 53: Attempted synthesis of 67 following the methodology reported by Olofsson et al.169, 
197 
 
Following the methodology for the synthesis of an asymmetric diaryliodonium salt, 
65 and 50 were mixed in the presence of mCPBA. Some slight modifications to the 
procedure, i.e. running the reaction at 0 °C, as well as using TFA in place of TfOH 
for both reaction temperatures, was also investigated (Scheme 54). No consumption 
of iodobenzene was observed when following the reaction by TLC (4:1, 
petrol:DCM) and the desired asymmetric diaryliodonium salt was not obtained. 
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Clearly, the use of the conditions above is not amenable to the production of a 
diaryliodonium salt containing maleimide functionality. 
 
 
Scheme 54: Attempted synthesis of diaryliodonium salts following the methodology reported by 
Olofsson et al.169, 197 
 
Additional synthetic methodologies were attempted, including: 
 The preformed reactive Koser’s reagent199 was used instead as the source of 
the electrophilic iodine. However, no reaction was observed and starting 
material was recovered. 
 Generation of an organolithium species at -78 °C by reaction of with 4-bromo 
and 4-iodo derivatives of N-phenylmaleimide, 62 and 63, with nBuLi in ether. 
Upon quenching with Bu3SnCl and work-up, 
1H NMR of the resultant red oil 
indicated various tin containing by-products were the only material extracted 
into the organic phase. 
 
A further method was considered, which reverses the general diaryliodonium 
synthetic strategy given in section 1.10.1, i.e. oxidation of the target arene followed 
by reaction with the non-target arene bearing a stannane. Using the procedure 
outlined in section 2.1, synthesis of diacetoxyiodoarene 68 was attempted using 
sodium perborate tetrahydrate in acetic acid (Scheme 55). Upon filtration of the 
anticipated product, the off white powder began to darken. 1H-NMR determined that 
the crude mixture consisted of roughly a 1:1  mix of starting material and 63, and that 
the sample was found to decompose to a mixture of unidentified aromatic species 
after ca. 30 min. Purification of 68 is inherently difficult by chromatographic means 
given that the sample rapidly decomposes. Elongated reaction times (12 h) did not 
facilitate complete conversion of the starting material to the desired product. 
Additionally, recrystallisation techniques failed to separate the diacetoxyiodoarene 
from the iodoarene.  
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Scheme 55: Preparation of crude diacetoxyiodoarene 68. 
 
The difficulty regarding the purification of 68, coupled with the apparent instability 
of the compound, meant that a direct synthesis of a diaryliodonium salt from crude 
68 was attempted (Scheme 56). Fortunately, diaryliodonium salt 69 was delivered in 
a 20% yield upon crystallisation as fine colourless needles. The material was found 
to be stable enough to perform a microanalysis several days post isolation, where 69 
was found to conform to the expected percentages of C, H and N. Furthermore, an X-
ray crystal structure of 69 was obtained (Figure 44).  
 
 
Scheme 56: Preparation of diaryliodonium salt 69 was achieved by use of impure 68. 
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Figure 44: X-ray crystal structure of 69. 
 
Accordingly, the synthesis of a maleimide bearing diaryliodonium salt has been 
successfully achieved after several attempted synthetic methodologies. Key to the 
synthesis, was the reversal of our general synthetic approach to diaryliodonium salts, 
which has furnished 69 as a material to be studied with respect to the first one-step 
synthesis of a maleimide bearing a fluorine-18 radiolabeled material. 
2.10 Chapter Two: Overall Conclusions 
 A range of diaryliodonium salts, precursors to  prosthetic groups bearing 
aldehyde and maleimide functionaltiy, have been prepared and characterised.   
 An authentic analytically pure sample of 2-[19F]fluorothiophene, 49, has been 
prepared by a large scale synthesis from 2-thienylmagnesium bromide and 
NFSI and several key analytical parameters have been unambiguously 
determined.  
 A range of simple diaryliodonium salts bearing the 2-thienyl moiety have 
been synthesised and fully characterised, enabling a radiochemical study, 
reported herein, to determine if [18F]49 can be detected when using sealed 
microfluidic apparatus. 
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3 Chapter Three: Radiochemistry Results and Discussion 
The aims of the radiosynthetic studies performed herein are to: 
 Determine if it is possible to detect the presence of 2-[18F]fluorothiophene 
using a sealed radiosynthetic system, by reference to the authentic standard 
2-[19F]fluorothiophene prepared above. 
 Elucidate if diaryliodonium salts are suitable precursors to the key prosthetic 
groups, 4-[18F]fluorobenzaldehyde and the counterpart 3-
[18F]fluorobenzaldehyde. 
 Optimise the radiochemical yields of radiosyntheses by varying the 
parameters used as an input to automated microfluidic apparatus. 
 Determine if a large scale radiosynthesis of 4-[18F]fluorobenzaldehyde is 
feasible using diaryliodonium salts and microfluidic apparatus. 
 
3.1 Introduction to Practical Microfluidic Apparatus used for 
Radiosyntheses 
 
Microfluidic apparatus present many advantages for the production of radiolabeled 
compounds, e.g. the ability to use milligram quantities of precursor for multiple 
reactions. In a traditional radiosynthesis, greater quantities of the precursor are used, 
much of which may be wasted during the radiosynthetic process.6 Microfluidics also 
provides an excellent degree of precision over several key reaction parameters, 
namely, temperature, stoichiometry and reaction time. Furthermore, microfluidic 
systems may operate at significantly elevated pressures (300 psi), enabling reactions 
to be carried out at temperatures above the boiling point of the reaction solvent. 
 
Relative to batch radiosynthetic apparatus (discussed in section 1.5.1.2), one delivery 
of [18F]fluoride ion can be sufficient for multiple reactions, up to 50 per delivery of a 
3 GBq is feasible. Consequently, microfluidic apparatus is often used as a first-step 
in the development of new radiolabeled compounds, as many key reaction 
parameters can be conveniently and rapidly screened. 
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In light of the advantages discussed, the remotely controlled microfluidic Advion 
NanoTek45 apparatus was used for all radiofluorination reactions performed as part 
this study (Figure 45).  
 
Figure 45: Advion NanoTek (BM bottom left, RM middle and CM right), auto-injection valve 
(blue box) and Agilent Technologies 1200 series in-line HPLC.  
 
The NanoTek system consists of a base module (BM), concentrator module (CM) 
and a reactor module (RM) with dedicated control software (Advion, LF software 
version 1.4.0) which is operable external to the hotcell housing the apparatus.  
 
The BM comprises of two reagent syringes operated separately by high pressure 
syringe pumps (P1 and P2). The syringe pump is connected to an eight way 
distribution valve which is where so-called reagent loops are installed, prior to being 
dispensed towards to RM.  
 
The CM comprises a low-pressure six-way valve, a reagent cartridge and an 
aluminium heating block. As the cyclotron produced (either delivered from Erigal200 
or prepared in-house using an ABT Biomarker Generator201) NCA [18F]fluoride ion 
is delivered ‘wet’, i.e. in a solution of the target [18O]water, a drying process is then 
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required to ensure ‘naked’ fluoride is used for radiolabelling.3 A syringe line 
connected to the CM unit is inserted into the vessel bearing the wet [18F]fluoride ion. 
The azeotropic drying procedure is then initiated. To summarise the procedure 
reported elsewhere,67 the wet [18F]fluoride ion solution is passed through a 
quaternary ammonium resin (QMA) cartridge, trapping the [18F]fluoride ion and 
facilitating the elution of the [18O]water. [18F]Fluoride ion is then sequestered from 
the QMA cartridge using a phase transfer agent (PTA), tetraethylammonium 
hydrogen carbonate (TEA·HCO3), followed by azeotropic drying with acetonitrile 
under a positive pressure of nitrogen in the CM heating block. Once the drying 
process is complete, a pre-set volume of DMF is dispensed and aspirated several 
times into the CM vial, the contents of the [18F]fluoride ion/PTA complex are swept 
to the RM (Figure 46). 
 
 
Figure 46: Decay counter attached to the P3 loop (red line) shows the repeated dispensing and 
aspiration of DMF into the concentrator vial (green line) followed by aspiration of the 
[18F]fluoride ion/PTA complex into the P3 loop. 
 
The RM houses a heating element and a microreactor, of which up to four can be 
installed per RM. Microreactors were made of fused silica tubing (internal diameter 
(⌀INT) 0.1 μm; length 4.0 m) held in a brass ring, which is filled with a 
thermoresistant polymer to fix the fragile coiled tubing in place (Figure 47). An 
additional syringe pump (P3) and distribution valve, used to direct reaction boluses 
to intended ports, is housed at the RM. The dry radioisotope complex is stored at P3 
prior to being dispensed towards the microreactor. 
 
Fluorine-18 aspirated into 
the system’s concentrator 
module (CM). 
DMF dispensed/aspirated 
into the CM after fluorine-
18 drying process. 
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Figure 47: Four microreactors, each connected to the reactor board. The red thermoresistant 
polymer can be seen at the centre of the microreactor.  
 
 
It is important to note that the PTA which has traditionally been used is a cryptand, 
e.g. K222, or tetrabutylammonium hydrogen carbonate. Work discussed herein, 
however, makes use of the PTA discussed in section 1.7, as recent studies have 
indicated that tetraethylammonium hydrogen carbonate (TEA.HCO3) is a suitable 
PTA replacement for cryptands, and does not cause blockages within microfluidic 
apparatus.202  
 
Each precursor to be radiolabeled was stored in a loop (400 µL, P1) for use in 
subsequent reactions. Once both reagents are stored in their respective loop, they are 
swept into the reactor at pre-set flow rates. The reactants rapidly mix and reach the 
pre-set reaction temperature upon entering the chemically inert coiled silica glass 
capillary tube microreactor, which can be heated to 200 °C (Figure 47).45 It is 
important to note that the microfluidic system is sealed and as such, any volatile 
material which may be lost in an open system can be detected during subsequent 
analysis.173 
 
The crude reaction mixture is then swept out of the microreactor towards an auto-
injection valve (Smartline Valve Drive: Knauer, Germany), where the crude reaction 
mixture is stored on a loop until all crude material is swept out of the microreactor, at 
which point, the valve is diverted to an in-line radio HPLC (Agilent Technologies 
1200 HPLC system, LabLogic Flow Count) for analysis. The complete set up of the 
primary components used in this study can be seen below (Figure 48). 
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Figure 48: Radiosynthesis apparatus configuration (P2 not shown for clarity).67 
  
[18O]water recovery 
MeCN 
[18F]TEAF 
Target water inlet 
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3.2 Radiosynthesis of 2-[18F]Fluorothiophene 
Methods, both ‘hot’ and ‘cold’, to synthesise 2-[18F/19F]fluorothiophene have been 
described above. However, to the best of the authors’ knowledge, no comparison to 
an authentic sample of 2-[19F]fluorothiophene has been made when the 2-thienyl 
moiety is incorporated into a diaryliodonium salt. Accordingly, 2-
[18F]fluorothiophene precursors 53-55 were subjected to a radiofluorination study, 
whereby 10 mg/mL 53-55 in DMF was stored on P1 and reacted with [18F]fluoride 
ion in an attempt to detect and characterise 2-[18F]fluorothiophene (Scheme 57). 
 
 
Scheme 57: Reaction of 53-55 with [18F]fluoride ion to generate 2-[18F]fluorothiophene, [18F]49, 
as part of product pair B. 
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The first precursor to be examined was 57, the least electron-rich precursor in the 
series. As may be expected of the directing nature of the 2-thienyl moiety, only one 
product pair, as well as decomposition products, was observed during the course of 
the fluorination reaction (n = 4, [18F]fluorobenzene  31% RCY) (Figure 49). Less 
forcing reaction conditions, 170 °C (n = 3) and 110 °C (n = 1) were also screened, 
and still only one product pair was observed. A greater range of temperatures were 
not examined as part of the study, as the radio-HPLC method time needed to be 
extremely elongated, relative to typical radio-HPLC methodologies, in order to 
separate benzene (tR 46.55 min) from 2-fluorothiophene (tR 48.42 min). 
 
Figure 49: Top HPLC spectrum shows the ‘cold’ development method to separate the range of 
potential products of the reaction, bottom spectrum shows the results obtained during the 
radiolabeling of 57.  
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The next precursor to be examined, 58, possesses two electron-rich arenes, 2-thienyl 
and 4-anisyl. Accordingly, the selectivity of the process may not be considered in 
advance to be as clear as in the above example. However, the selectivity for one 
product pair, i.e. 4-[18F]fluoroanisole and 2-iodothiophene, amongst decomposition 
products, was apparent (Figure 50). It is therefore interesting to note that this study 
suggests the inclusion of the 2-thienyl moiety will direct [18F]fluoride ion with 100% 
regioselectivity onto an electron-rich arene, which is in agreement with precedent set 
elsewhere.6, 203 RCYs of 1% (n = 3, 150-190 °C) were obtained and no [18F]labelled 
material was observed at temperatures <150 °C. No attempt was made to optimise 
the RCY for the process. 
 
Figure 50: Top HPLC spectrum shows the ‘cold’ development method to separate the range of 
potential products of the reaction, bottom spectrum shows the results obtained during the 
radiolabeling of 58.  
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The final precursor to be tested bears two 2-thienyl moieties, hence successful 
incorporation of [18F]fluoride ion will lead to the production of one product pair and 
therefore the detection of [18F]39. Gratifyingly, the radiosynthetic process was 
successful, resulting in the formation of the desired product pair and thus the 
detection of [18F]39 (Figure 51). RCYs of 1% (n = 3, 170-190 °C) were obtained and 
minute quantities of [18F]39 were observed at temperatures <170 °C. No attempt was 
made to optimise the RCY for the process. 
 
 
Figure 51: Top HPLC spectrum shows the ‘cold’ development method to separate the range of 
potential products of the reaction, bottom spectrum shows the results obtained during the 
radiolabeling of 59.  
 
The quantification of previously unaccounted for ‘hot peaks’, i.e. not assigned to 
[18F]39, may now be realised. Consequently, an accurate assessment of purity and 
RCY may now be reported by using 39 as a standard in HPLC method development 
for appropriate diaryliodonium salt precursors. These features will become of great 
importance should diaryliodonium salts bearing the 2-thienyl moiety enter routine 
pre-clinical/clinical use. 
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3.3 Radiosynthesis of [18F]Fluorobenzaldehydes: Current 
Methods 
Currently, 4-[18F]FBA is synthesised via a SNAr reaction using [
18F]fluoride ion, 
which had been sequestered using Kryptofix® (K222)/K2CO3, from a 4-substituted 
benzaldehyde. Typically, 4-nitro204 71 or 4-trimethylammonium triflate205 72 is the 
leaving group (Scheme 58). Radiochemical yields (RCYs) of 81%204 and 90%205 
have been obtained for the 4-nitro and 4-trimethylammonium precursor respectively.  
 
 
Scheme 58: Synthetic approaches to 4-[18F]FBA.204, 205 
  
Although both precursors generate 4-[18F]FBA in high yield, there are limitations 
associated with the SNAr approach. Where the leaving group is trimethylammonium 
a competing fluorination reaction may occur resulting in two additional compounds 
in the reaction mixture, [18F]methyl fluoride and 4-(N,N-
dimethylamino)benzaldehyde, 73 (Scheme 59).206  
 
 
Scheme 59: Possible by-products obtained by reaction of 72 with [18F]fluoride ion. 
 
[18F]Methyl fluoride is a flammable gaseous compound, which is generated by 
demethylation of the –NMe3+ moiety (via a reverse Menschutkin reaction) when         
-ipso substitution does not occur.206 Gaseous radioactive compounds require 
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specialist facilities to handle safely; additionally, the quantity of radioactive gas 
generated will have to be determined and in each instance comply with local 
radiation regulations.  
 
Åberg et al. performed the radiosynthesis of 4-[18F]FBA according to Scheme 58 as 
part of their investigation of chemokine receptor CXCR4 expression across a variety 
of cancers by radiolabelling a derivative of FC131,207 a potent cyclic pentapeptide 
CXCR4 inhibitor first reported in 2003.208 It was reported that the by-product 73 
could not be separated from 4-[18F]FBA during their solid phase extraction (SPE) 
workup (Figure 52). Attempts to trap the by-product 73 (with an estimated pKa ~3.5, 
i.e. 2 pH units higher than the pH of the eluent on a strong cationic exchange 
cartridge (Phenomenex SCX) eluting with phosphate buffer solution adjusted to pH 
1.5 in order to protonate the dimethylaniline moiety while keeping the solid phase 
bound sulfonic acid (estimated pKa <1) in its deprotonated state.207 However, while 
the procedure reduced the amount of by-product 73, 50% of the desired 4-[18F]FBA 
was trapped. Further attempts at purification using this approach were abandoned. 
 
 
Figure 52: 73 and 4-[18F]FBA were inseparable after attempted purification.207 
 
A critical consequence of the presence of by-product 73 was realised during the 
intended conjugation of 4-[18F]FBA to an aminooxy moiety present on the 
biomolecular substrate, that is, 73 competed in the same conjugation process.207 The 
resultant conjugates 74 and 75 were inseparable, both being identified in the final 
formulation by LC-MS, thus affecting the specific activity of the formulation which 
varied from 2-60 GBq/µmol (Figure 53).207 
73 
4-[18F]FBA 
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Figure 53: Formation of competing biomolecule 75 (top) reduces the specific activity of the 
formulated sample, as 74 and 75 could not be separated (bottom).207 
 
An alternative route to 4-[18F]FBA, the use of its corresponding 4-nitro precursor, 
has been found to be unreliable;209 therefore in the majority of cases, the 4-
trimethylammonium precursor is used. 
 
In addition to aforementioned problems, both nitro precursor 71 and dimethylamino 
precursors 72 are reliant upon SNAr chemistry, thus limiting the introduction of 
[18F]fluoride ion to the 2- and 4- positions of the arene.210 In some cases 3-substituted 
arenes have been shown to be more metabolically stable in vivo relative to their 4-
substituted counterparts. This is especially important when performing an imaging 
study with PET, as any generated [18F]fluoride can accumulate in bone, 
compromising the quality of the PET image.5 In addition, where a potential imaging 
agent is derived from a known fluorinated bioactive compound the fluorine atom 
may already be present in a position not compatible with traditional SNAr 
methodology (e.g. the 3-position) and as such alternative approaches are needed. For 
example [18F]lapatanib211 has been prepared using 3-[18F]fluorobenzaldehyde168 as 
74 and 75 
74 
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the prosthetic group. Therefore we envisage that diaryliodonium salt precursors 
could address these limitations: 
 
 All regioisomers of [18F]FBA can potentially be obtained. 
 Any competing reactions generate benign products which can be easily 
separated from [18F]FBA. 
 The same platform/kit maybe used for the synthesis of each regioisomer. 
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3.4 Synthesis of 4-[18F]Fluorobenzaldehyde Using Diaryliodonium 
Salt Precursors 
Fluorination of 4-formylphenyl(aryl)iodonium salts 43-45 (Figure 54: 
Diaryliodonium salts 43-45.) was performed using the microfluidic set up as 
described above. 
 
Figure 54: Diaryliodonium salts 43-45. 
 
The plumbing diagram, i.e. the loop sizes, sweep path lengths, reactor sizes, etc., 
associated with all radiosyntheses performed in this section can be seen below 
(Figure 55). 
 
Figure 55: Plumbing diagram for the one-step radiofluorination process. 
 
 109 
 
The following parameters were selected for the study based on optimisation of 
reaction conditions carried out elsewhere which determined that temperature has the 
greatest effect on reaction yield:202  
 
 Varied temperature: from 50-190 °C (in 20 °C increments)  
 Fixed diaryliodonium salt concentration – [10 mg/mL];  
 Fixed reactor length - 4m (coiled silica glass, ⌀INT 1.0 µm, 31.4 µL internal 
volume); 
 Fixed P1:P3 volume ratio – 1:1; 
 Fixed isotope complex volume - 10μL; 
 Fixed flow rate - 10 μL/min; 
 Fixed transfer rate – 60 μL/min. 
 
Reactions were repeated in triplicate (unless stated otherwise) to ensure the 
robustness of the process at each given temperature, with the error bars representing 
the highest and lowest yields observed (Figure 56). Note that in this section of the 
study, no [18F]fluoroarenes were isolated and the radiochemical yield (RCY) reported 
relates to the amount of radioactivity in the products relative to the total radioactivity 
detected by radio-HPLC upon analysis of the reaction mixture. 
 
Figure 56: RCY vs Temperature during the radiolabelling (n = 3) of 43 (blue), 44 (red) and 45 
(green), generating 4-[18F]FBA. The legend indicates the ‘non-participating arene’. 
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The selection of non-participating arene clearly affects the RCY, with phenyl>4-
anisyl>2-thienyl. It is known that electron-rich non-participating arenes direct the 
incorporation of the radiolabel onto the electron-deficient arene.90, 92, 94 Work 
performed herein supports this hypothesis, as the only undesired by-product formed 
was [18F]fluorobenzene, [18F]47, in < 1% RCY (Figure 57).  
 
 
Figure 57: UV trace (left) and radio-HPLC (right) demonstrates the separation of 4-[18F]FBA 
from [18F]47.  
 
Interestingly, during the [19F]CsF ‘cold’ fluorination of 43 (section 2.4), no 
[19F]fluorobenzene was detected. The reaction clearly initiated at 50 °C in both the 
case of the fluorine-18 and the cold study, however, the hot study is performed 
within a sealed system, therefore volatile by-products are not lost and can be detected. 
Although the [18F]fluorination of 43 generates an undesired by-product, 49, 
purification is quite straightforward (4-[18F]FBA tR = 325 s, [
18F]fluorobenzene tR = 
385 s).  
 
All of the compounds studied demonstrate a reasonable degree of process 
reproducibility, the largest range of ±11.8% RCY being attributable to 4-
formylphenyl(4-anisyl)iodonium trifluoroacetate 43. Ranges of ±6% RCY are 
observed for formylphenyl(phenyl)iodonium trifluoroacetate 44 and ±7% RCY for 
formylphenyl(2-thienyl)iodonium trifluoroacetate 45. 
 
Of particular note, RCY is sometimes not considered in great detail during 
radiochemical syntheses. The reason is that if one commences the process with a 
high level of radioactivity, e.g. 50 GBq, a decay corrected radiochemical yield of 
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10% affords 5 GBq of desired radiolabeled product, a more than sufficient quantity 
for a number of PET imaging studies. Consequently, there is no need to optimise the 
radiosynthetic process. However, to realise such a level of starting radioactivity, a 
powerful (i.e. large) cyclotron is required (see section 1.2). The nature of a cyclotron 
of this type is that a specialist facility is almost certainly required, e.g. a concrete 
bunker with appropriate shielding.212 As the demand for radiolabelling studies of 
promising bioactive compounds is increasing, more low power cyclotrons, which are 
more affordable and do not require such extensive infrastructure, are now being 
deployed. Concomitant with a low power unit, the starting levels of radioactivity 
achievable decrease. For instance, the ABT Biomarker Generator installed in the Sir 
Bobby Robson Foundation PET Tracer Product Unit at Newcastle University can 
generate a maximum of 2 GBq [18F]fluoride ion per run (~ 60 min). Accordingly, 
taking the example above, a decay corrected radiochemical yield of 10% would 
afford 200 MBq of radiolabeled product when commencing with 2 GBq [18F]fluoride 
ion, barely enough for one clinical PET scan.  
 
It is interesting to note that the ground state single-crystal structures obtained for 44 
and 45 (section 2.3.1) would suggest that the product of the reaction with fluoride ion 
would be 4-FBA and 2-fluorothiophene, 49, respectively, as these moieties are 
located in the pseudo-equatorial position. The work reported above supports that 
carried out elsewhere, i.e. it is the relative position of the arenes about the iodine 
atom in the transition state, which dictates the major product of the reaction.92, 93  
 
Initial findings are positive, as the RCY associated with the diaryliodonium 
radiolabeling process certainly affords 4-[18F]FBA in yields useful for subsequent 
transformations. RCYs may appear moderate relative to current synthetic procedures, 
though those procedures start with significantly greater activities of fluorine-18.  
 
As discussed in section 1.10, radical scavengers have been reported to improve the 
reproducibility of some radiosynthetic processes.100 Aromatic radicals may be 
generated in situ from a parent hypervalent iodine compound, as a consequence of 
homolytic fission of an aryl iodine bond. To mitigate the risk of such radicals 
undergoing further, undesired reactions – potentially decreasing the realised RCY, a 
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radical trap (10 mol% TEMPO), was added to the diaryliodonium salt solution prior 
to being loaded into P1. 
 
The results encouragingly demonstrate the principle that use of a radical trap when 
radiolabeling sensitive diaryliodonium salts with [18F]fluoride ion improves the 
associated reproducibility (Figure 58). 
 
Figure 58: RCY vs Temperature during the synthesis of 4-[18F]FBA with the addition of 10 
mol% TEMPO to the starting solutions of 43-45 improves reproducibility. N.B. n =2 for 44 at 70, 
130 and 170 °C. The legend indicates the ‘non-participating arene’. 
 
The hypervalent character of the iodine atom in a diaryliodonium salt, apparent due 
to the 3c-4e bond, is in the most stable relative to the equivalent λ3-bromanes and λ3-
chloranes, as the most electropositive atom increases the stability of the hypervalent 
bond to better effect.213, 214 By increasing electron density around the iodine atom, e.g. 
44 and 45, the stability afforded by the electropositive nature of the centre is 
decreased. Accordingly, the propensity for homolytic fission of the aryl-iodine bond 
increases. 
 
Indicative of the aforementioned theory, it is clear that in practice there is an increase 
in reproducibility during the radiolabeling of the more electron-rich diaryliodonium 
salts, 44 and 45, upon inclusion of a radical trap relative to the exclusion of a radical 
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trap (Figure 56). The greatest range in RCY associated with the diaryliodonium salts 
bearing 4-anisyl and 2-thienyl non-participating arenes, 44 and 45, is reduced to 
±4.5% and ±1.0% RCY, relative to the exclusion of TEMPO respectively. The range 
associated for 43, i.e. where phenyl is the ‘non-participating arene’, is the highest, 
±7.0%, which is slightly higher relative to the exclusion of a radical trap. 
Nonetheless, an overall improvement in the reproducibility profile across the range 
of screened temperatures is apparent. 
 
Although the reproducibility of the process is markedly improved upon inclusion of 
TEMPO, there is a slight determent to the RCY observed across the temperature 
profile. Accordingly, a method was sought which aimed to increase the RCY of the 
radiolabeling process. 
 
It has been reported elsewhere, that the addition of water, during nucleophilic 
fluorinations, can influence the associated RCY. Early studies in the 1980s 
determined that in a solid-liquid biphasic system, the presence of a limited amount of 
water was found to increase the rate of fluorination.215, 216 The reported affect has 
been described as a consequence of the solid-liquid system favouring extraction of 
fluoride ion into the organic phase in response to the addition of water, thus 
increasing the rate of fluorination accordingly.217 However, in a liquid-liquid system, 
the rate of fluorination has been shown to decrease the rate of fluorination due to the 
hydration of fluoride ion.218 
 
The first known of example of the addition of water to a radiofluorination process 
was reported in a patent document by Wandsworth et al.95 The document describes 
how the addition of certain ratios of water, preferably 10-30% in a mixture with a 
water miscible solvent, improves the yield of the radiofluorination of a 
diaryliodonium salt. In fact, the inventors report that radiolabeled material was 
obtained, even where the solvent system was 100% water – a feat yet, to the best of 
the authors’ knowledge, to be reproduced elsewhere. 
 
There are further reports of water being added to the radiofluorination process. Chun 
et al. reported in 2010 the addition of 0.25% water during the fluorination of several 
diaryliodonium salts.219 However, a limited comparison of one diaryliodonium salt 
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fluorination in the presence (1.5%) and  absence of water was provided, where            
2-methylphenyl(phenyl)iodonium tosylate was used as a precursor to                          
2-[18F]fluorotoluene, obtained in RCYs of 34% and 9% respectively, and 
[18F]fluorobenzene, in RCYs of 16% and 3% respectively. A further study within 
their report using several diaryliodonium chlorides in the presence of 0.25% water 
was provided, with no discussion of the results where water was absent from the 
reaction process. 
 
In 2012, we reported some of our initial findings of the work which follows in this 
section, regarding the inclusion of known quantities of water during the radiolabeling 
with fluorine-18 of a range of diaryliodonium salts.220, 221 
 
A further study reported by Chun et al. in 2013 regarded the fluorination of a range 
of diaryliodonium tosylates in where [18F]fluoride ion was derived directly from the 
cyclotron and therefore in a solution of target [18O] water (maximum of 28%).222 The 
reported methodology is advantageous as firstly time is saved as no drying of the 
[18F]fluoride ion is required to achieve moderate yields of radiolabeled product,222 
secondly as no removal of a phase transfer agent is required – a necessary procedure 
during the formulation of a radiolabeled material for a PET imaging study with 
human subjects.223 As in the previous 2010 study, there was limited discussion of the 
effect of the addition of water upon the RCY, as no studies were carried out on the 
same compounds in the absence of water. 
 
Of the diaryliodonium salts examined herein, 4-formylphenyl(phenyl)iodonium 
trifluoroacetate 43 has afforded 4-[18F]FBA in the highest RCY. Accordingly, 43 was 
subjected to a range of conditions whereby the percentage of water present in the 
starting solution, stored at P1 of the microfluidic apparatus, was examined (Figure 
59). 
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Figure 59: RCY vs Temperature during the synthesis of 4-[18F]FBA with addition of known 
quantities of water to a starting solution of 43 (n =2 for 20% water).  
 
An excellent trend was observed, whereby the addition of any of the known 
quantities of water to the starting solution outperformed the RCY obtained relative to 
the water-free counterpart; the order of RCY improvement 5% > 10% > 20%. A 
maximum RCY of 83% (n = 3, 110 °C) has been achieved, a remarkable increase of 
33% relative to water-free conditions. The errors associated with the process remain 
unchanged relative to the water-free process, showing an outstanding tolerance in 
observed RCY across all temperature ranges. However, there is a slight increase in 
off-target fluorination, i.e. the generation of [18F]fluorobenzene, in RCYs of 3%, 2% 
and 2% across 20%, 10% and 5% additions of water respectively.  
 
Whilst it is gratifying, and even in light of some known precedence, it is certainly 
surprising to observe such behaviour upon the addition of water. A practical study 
has demonstrated that the intrinsic reactivity of fluoride ion in a quaternary 
ammonium complex shows a dependence upon the degree of solvation of the 
fluoride ion, such that an increase in hydration results in a decrease in 
nucleophilicity.218 Experimental evidence reports a decrease of almost three orders of 
0
10
20
30
40
50
60
70
80
90
100
40 60 80 100 120 140 160 180 200
R
C
Y
 %
Temperature (°C)
5% Water 10% Water 20% Water No Water
 116 
 
magnitude as the number of water molecules involved in hydration is increased from 
0 to 6.218 Several theoretical studies indicate that a single fluoride ion in an aqueous 
medium may be hydrated by up to 16 water molecules, and that the hydration energy 
is exceptionally high at 367 kcal mol−1.224-226 Theoretically, the nucleophilicity of 
fluoride ion has an inverse relationship with the number of water molecules 
associated with its hydration.227  
 
Separate studies have been concerned with the fact that so-called ‘naked’ fluoride ion, 
i.e. fluoride determined to possess and extremely low degree of hydration, and 
therefore a high nucleophilicity, can go on to perform undesired sided reactions.228-
230 Control of the degree of hydration of fluoride ion mitigated the effect of unwanted 
side reactions.217 It may be considered that the effect of the degree of hydration is 
being observed in the work reported herein, i.e., a balance of the hydration of 
[18F]fluoride ion is necessary to realise the optimum RCY. 
 
As the addition of 5% water to the starting diaryliodonium salt solution appears to be 
the most beneficial to the RCY obtained, the same amount of water was added to 44 
and 45 to determine if a similar advantage could be realised (Figure 60).  
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Figure 60: RCY vs Temperature during the synthesis of 4-[18F]FBA is impacted by the addition 
of 5% water to starting solutions of 44 and 45. 
 
A significant 31% increase in RCY relative to water-free conditions was observed 
for 44, with a maximum RCY of 78% (n = 3, 190 °C). The RCYs obtained under 
these conditions appear to plateau in the 150-190 °C range and that the errors are 
reduced relative to water-free conditions. It would be interesting to ascertain the 
effects of temperatures beyond 190 °C, however, the microfluidic apparatus limited 
such as study as the thermoresistant polymer holding the silica glass coil in place 
within the reactor can degrade at temperature exceeding 190 °C.  
 
Although the reproducibility profile of 45 was reduced, a significant increase in RCY 
relative to water-free conditions was not apparent, with an increase in RCY of 8% (n 
= 3, 130 °C). As with the water-free and radical scavenger conditions reported above, 
no off-target fluorination products were detected during the process. 
 
The optimum quantity of water along with 10 mol% TEMPO was added to a starting 
solution of 43, the best performing diaryliodonium salt studied thus far with respect 
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to the RCY of 4-[18F]FBA obtained, to determine if a synergistic effect, i.e. a 
significant increase in RCY whilst maintaining a tight reproducibility profile, could 
be realised (Figure 61). 
 
 
Figure 61: RCY vs Temperature during in the presence of simultaneous addition of 5% water 
and 10 mol% TEMPO to a solution of 43 generates 4-[18F]FBA. 
 
It is apparent that although the results are positive relative to water-free and 10 mol% 
TEMPO conditions, the addition of 10 mol% TEMPO to the system is detrimental to 
the RCY observed when 5% water is the sole additive in the process. The combined 
additives do appear to stabilise the reaction such that the RCY profile remains 
somewhat consistent between 110-190 °C. 
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3.5 Synthesis of 3-[18F]Fluorobenzaldehyde Using Diaryliodonium 
Salt Precursors 
As determined above, the optimum conditions with respect to RCY for 
diaryliodonium salts 43-45 is the addition of 5% water to the starting solution and a 
reaction temperature of between 90-190 °C. Accordingly, the same conditions were 
applied to the 3-[18F]FBA precursors 50-52 (Figure 62). 
 
 
Figure 62: Synthesis of 3-[18F]FBA from 50 in the presence of 5% water. 
 
The RCY of the 3-[18F]FBA precursor 50 appears to follow a different reaction 
profile to it 4-[18F]FBA counterpart 43, as higher temperatures appear to favour an 
increase in RCY. It would be interesting to examine temperature beyond 190 °C to 
determine where the plateau with respect to RCY lies, however, as discussed above, 
the microfluidic apparatus places a restriction on reaching such temperatures. An 
impact upon the RCY of 3-[18F]FBA relative to 4-[18F]FBA could be attributed to the 
ipso position of 43 is markedly more δ- than counterpart 50 due to 3-substitution of 
the aldehyde moiety. Hence, when the turnstile mechanism (section 1.10) approaches 
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the elimination step, [18F]fluoride ion is less likely to favour ipso incorporation onto 
the target arene, thus impacting the RCY obtained.  
 
A significantly increased quantity of [18F]fluorobenzene, [18F]47, was obtained 
across the reaction series, where an increased RCY of 3-[18F]FBA is concomitant 
with an increased RCY of [18F]fluorobenzene. In addition to the reason highlighted 
above, the 3-position of the aldehyde moiety on the target arene results in a lack of 
delocalisation of electron density out of the arene (the opposite of its 4-substituted 
counterpart 43). Accordingly, the selectivity associated with electronic directing 
effect of unsymmetrical diaryliodonium salts is less pronounced, resulting in an 
increase in off-target fluorination. [18F]Fluorobenzene has been obtained in yields of 
up to 12%, compared with RCY of <1% for the 4-substituted counterpart. As in the 
example above, it is procedurally straight forward to separate 3-[18F]FBA from the 
non-target product in addition to adducts arising from decomposition/side reactions, 
as can be seen, a mixture of 3-iodobenzaldehyde, iodobenzene and decomposition 
products are readily separated from the desired compound (Figure 63). 
 
 
Figure 63: Generation of off-target [18F]47.  
 
In the case of 51, the diarylidodonium salt bearing the 4-anisyl non-participating 
arene, useful RCYs of 3-[18F]FBA have been obtained (Figure 64). Higher reaction 
temperatures result in an increase in RCY, and RCYs of up to 48% have been 
achieved where the reactor is set to 190 °C. The range of RCYs observed across the 
temperature profile remain pleasingly consistent, apart from the reactions performed 
at 150 °C, although the range of RCY is only ± 12%. Importantly, and as may be 
expected, no 3-[18F]fluoroanisole was detected at any of the temperatures examined 
throughout the study. 
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Figure 64: An increase in the temperature during the radiolabeling of 51 generates 3-[18F]FBA 
in greater RCYs. 
 
In the case of 52, the diarylidodonium salt bearing the 2-thienyl non-participating 
arene, the results of the radiolabeling study were somewhat disappointing (Figure 65). 
The range of RCY associated with the radiolabeling procedure is markedly increased 
across the temperature profile relative to the regioisomer 4-formylphenyl(2-
thienyl)iodonium trifluoroacetate, 45, although the range of ±7% RCY is in keeping 
with expectations based upon the study above. An important advantage associated 
with 52 is that no off-target fluorination, i.e. 2-[18F]fluorothiophene, [18F]39, was 
observed, a point which may now be accurately ascertained by comparison to the 
authentic sample of 2-[19F]fluorothiophene, 39, prepared as described above (section 
2.6). 
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Figure 65: Radiolabeling of 52 affords a varied range of RCY for 3-[18F]FBA. 
 
In summary, the greatest average RCY of 17% (n = 3, 170 °C) is achieved with 51, 
but is less than that obtained for its regioisomer 44 without the addition of water, 
29% (n = 3, 150 °C) or with the addition of water, 37% (n = 3, 130 °C). Taking into 
account the RCY obtained by use of 52 as a precursor to 3-[18F]FBA, it is difficult to 
consider using 52 as a precursor relative to 50 and 51. 
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3.6 Batch Synthesis of 4-[18F]FBA Using Microfluidic Apparatus 
The optimisation of the radiolabeling procedure has determined that the addition of 
5% water to the starting diaryliodonium salts solution is greatly beneficial to the 
resulting RCY, a production of 4-[18F]FBA, on a scale suitable for routine production, 
was attempted using the optimal conditions. 
 
The diaryliodonium salt used in the study was chosen as 4-formylphenyl(4-
anisyl)iodonium trifluoroacetate, 44. Even though in the optimisation study above 
the phenyl bearing counterpart 43 slightly outperformed with respect to RCY, 
however 44 did not facilitate the production of a non-target radiolabeled product. 
 
Accordingly, whilst maintaining the aforementioned reaction conditions a slight 
modification was made to the microfluidic apparatus, as both loops are dispensed 
entirely through the microreactor during the large scale process; the resultant bolus 
being collected at a large (1000 µL) loop connected to the auto-injector. Radio-
HPLC was scaled up to semi-preparative scale to accommodate the increased volume 
of material to be analysed. Over the course of two runs, 4-[18F]FBA was obtained in 
an RCY of 96% determined by radio-HPLC, from starting activities 1.3-1.5 GBq 
fluorine-18 (Figure 66), clearly indicating the extend increased starting activities has 
upon the RCY. 
                          
Figure 66: A radio-HPLC obtained during batch production of 4-[18F]FBA from 43 in 96% 
RCY (n = 2, 190 °C). 
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3.7 Chapter Three: Overall Conclusions 
A summary of the conclusions arising from chapter three are given below: 
 
 It is possible to detect 2-[18F]fluorothiophene generated in a sealed system 
upon reaction of a diaryliodonium salt bearing the 2-thienyl moiety with 
[18F]fluoride ion, by reference to an authentic standard of 2-
[19F]fluorothiophene. 
 In general, increasing temperatures increase the RCY associated with the 
production of 4-[18F]FBA and 3-[18F]FBA from a range of diaryliodonium 
salt precursors. 
 Inclusion of 5% water into a starting solution of a diaryliodonium salt has a 
positive effect upon the RCY achieved, whereas the additive TEMPO has a 
positive effect upon the reproducibility of the process.  
 4-[18F]FBA can be synthesised in batch in excellent RCY using microfluidic 
apparatus. 
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4 Final Conclusions and Future Work 
There have been several key conclusions from the work reported herein, namely: 
 Successful preparation of substituted diacetoxyiodoarenes and substituted 
aryl stannanes. 
 Preparation of a range of diaryliodonium salts bearing aldehyde and 
maleimide functionality, as well as simple electron-rich species such as the 
dithienyliodonium trifluoroacetate. X-ray crystal structures have been 
determined for many diaryliodonium salts following a robust investigation 
into the conditions requisite for single crystal growth. 
 A cold fluorine-19 study of selected diaryliodonium salts has been performed 
as a prologue to a fluorine-18 study to ascertain in advance a selectivity 
profile. 
 2-[18F/19F]Fluorothiophene have been prepared and unambiguously 
characterised for the first time. 
 The effect of water upon the radiolabeling process has been investigated 
using the 4-[18F]FBA precursors diaryliodonium salts 43-45, resulting in an 
observation that the presence of water is both well tolerated and beneficial to 
the RCYs which are obtained. 
 The effect of TEMPO has been investigated, which confirms that the range of 
RCYs observed decreases upon its inclusion although no benefit to the 
overall RCY obtained. 
 Simultaneous use of water and TEMPO as additives to the radiolabeling 
process is not as beneficial as the sole addition of water. 
 4-[18F]FBA and 3-[18F]FBA have been obtained in RCYs which are suitable 
for routine clinical production. 
 
Future work should be directed to consider the conjugation of the prosthetic groups 
synthesised herein to a range of biomacromolecules, such as peptides/antibodies, 
using the optimised prosthetic group production conditions reported here.  
 
Batch production of 3-[18F]FBA should be examined to determine if, as is the case 
for its regioisomer, the starting activity can profoundly affect the RCY. 
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Radiolabeling of the maleimide containing diaryliodonium salt 69 should be 
examined, and the optimised conditions reported herein applied to determine the 
tolerance of a separate species of diaryliodonium salt to the presence of water. 
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5 Notes Added in Proof 
Articles related to work reported herein have recently been published by others since 
cessation of this project in 2013. 
 
Recent synthesis of 3-[18F]FBA, has been achieved by the manual, i.e. by hand rather 
than using automated apparatus, radiolabeling of mesityl(3-formylphenyl)iodonium 
tetrafluoroborate by Scott and co-workers, via a copper catalysed process        
(Scheme 60).231  
 
 
Scheme 60: Synthesis of 3-[18F]FBA via a catalytic procedure.231 
 
Recent synthesis of 3-[18F]FBA and 4-[18F]FBA have been reported by Gouverneur 
and co-workers, by a copper catalysed manual radiofluorination of arylboronic acids 
(Scheme 61).232 
 
 
Scheme 61: Synthesis of 4-[18F]FBA and 3-[18F]FBA via a catalytic procedure.232 
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6 Experimental 
All manipulations involving air-sensitive materials were carried out using standard 
Schlenk line techniques under a nitrogen atmosphere, using oven dried glassware.233 
Anhydrous DCM and MeCN were prepared by refluxing over CaH2. 
1H and 13C 
NMR spectra were recorded on a Bruker 300 MHz, JEOL 400 MHz, or a JEOL 500 
MHz spectrometer at room temperature. 1H and 13C shifts were relative to 
tetramethylsilane. 19F spectra were recorded on either a JEOL 400 MHz, or a JEOL 
500 MHz spectrometer at room temperature. 19F shifts were relative to CFCl3. Thin-
layer chromatography was carried out on aluminum sheets pre-coated with silica gel 
60F 254, and performed using Merck Kieselgel 60. Melting points were determined 
with a Gallenkamp MF-370 and are uncorrected. Automated flash chromatography 
was performed using a Varian IntelliFlash 971-FP discovery scale flash purification 
system. Mass spectrometry data was obtained from the EPSRC National Mass 
Spectrometry Service Centre, Swansea. Microanalysis data was obtained from the 
London Metropolitan University Elemental Analysis Serivce and Medac Ltd. 
 
Practical considerations: Hypervalent iodine compounds are potentially explosive 
and should be handled taking appropriate precautions.234, 235 
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6.1 4-Anisyliodobisacetate (33)100, 236 
 
 
4-Iodoanisole (12.15 g, 50 mmol) was added to glacial acetic acid (500 mL), and the 
solution stirred at 45 °C. Sodium perborate tetrahydrate (76.93 g, 500 mmol) was 
carefully added to the reaction mixture over 30 minutes, followed by 4.5 hours 
stirring. The crude mixture was left to cool to room temperature. Water (500 mL) 
was added, followed by extraction with DCM (3 × 150 mL). The combined organic 
layers were washed with water (3 × 500 mL). The washed organic layer was then 
concentrated in vacuo to afford a pale yellow oil. 33 was obtained as colourless 
crystals by crystallisation from DCM/Petrol (8.23 g, 45%). Mp 89-93 °C (from 
DCM/Petrol) (lit:236 mp 92.4-96 °C); IR νMAX/cm-1 (neat) 1648, 1576,1487, 1354, 
1290, 1250, 1189; 1H NMR (400 MHz, CDCl3) δ 7.96 (2H, d, H2/H6 J = 9.1 Hz), 
6.92 (2H, d, H3/H5 J = 9.1 Hz), 3.81 (3H, s, OCH3), 1.94 (6H, s, Me); 
13C NMR 
(101 MHz, CDCl3) δ 176.49 (CO), 137.22 (C4), 135.50, 116.74, 116.47 (C1), 55.65 
(OMe), 20.49 (OAc); HRMS (NSI positive) found: M+Na+, 374.9696. C11H13IO5Na
+ 
requires 374.9705; Anal. Calcd. for C11H13IO5: C, 37.52; H, 3.72. Found: C, 37.35; H, 
3.73. 
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6.2 2-Thienyliodobisacetate (34)237 
 
2-iodothiophene (12.15 g, 50 mmol) was added to glacial acetic acid (500 mL), and 
the solution stirred at 45 °C. Sodium perborate tetrahydrate (76.93 g, 500 mmol) was 
carefully added to the reaction mixture over 30 minutes, followed by 4 hours stirring. 
The crude mixture was left to cool to room temperature, and the product was 
extracted with DCM (3 × 500 mL). The combined organic layers were washed with 
water (3 × 500 mL). The washed organic layer was then concentrated in vacuo to 
afford a pale oil. 34 was crystallised as off-white crystals from DCM/Petrol obtained 
by filtration (4.74 g, 29%). Mp 123-127 °C (decomp. from DCM/petrol/ether) (lit:237 
119-125 °C); IR νMAX/cm-1 (neat) 1646, 1389, 1349, 1262, 1219, 1037, 1014; 1H 
NMR (400 MHz, CDCl3) δ 7.76 (1H, dd, J = 3.9, 1.2 Hz), 7.62 (1H, dd, J = 5.4, 1.2 
Hz), 7.11 (1H, dd, J = 5.4, 3.9 Hz), 1.99 (6H, s); 13C NMR (101 MHz, CDCl3) δ 
177.10 (CO), 139.17, 134.96, 128.72, 106.31 (C2), 20.45 (OAc); HRMS (NSI 
positive) found: M+Na+, 350.9159. C8H9IO4SNa
+ requires 350.9158; Anal. Calcd. 
for C8H9IO4S: C, 29.28; H, 2.76. Found: C, 29.32;  H, 2.69. 
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6.3 4-Tributylstannylbenzaldehyde (37)157 
 
A flask was charged with zinc dust (6.14 g, 93.8 mmol), MeCN (70 mL) was added. 
Trifluoroacetic acid (0.13 g, 1.15 mmol) was carefully added, and the solution stirred 
for 5 minutes. Cobalt dibromide (1.38 g, 6.25 mmol) was added, the resultant blue 
solution was stirred for a further 5 minutes. Addition of allyl chloride (1.44 g, 18.8 
mmol) turned the solution red upon 10 minutes stirring. 4-Bromobenzaldeyhde (9.25 
g, 50.0 mmol) was added, followed immediately by tri-n-butylstannyl chloride (22.3 
g, 68.5 mmol). The reaction was heated to 50 °C and monitored by TLC (95:5 
petrol:ether) until all of the starting material had been consumed. Once cooled to RT, 
aqueous saturated ammonium chloride (50 mL) was added and the mixture extracted 
with ether (3 × 50 mL). The organic fractions were combined and dried over MgSO4, 
filtered and concentrated in vacuo. The crude orange oil was purified by column 
chromatography on SiO2 (petrol, then 90:10 petrol:ether) or using automated flash 
reverse phase chromatography (neat MeCN) obtaining 37 as a clear oil (10.86 g, 
55%). Rf 0.46 (95:5 petrol:ether); IR νMAX/cm-1 (neat) 2957, 2925, 1704, 1587, 1379, 
1174; 1H NMR (300 MHz, CDCl3) δ 9.86 (1H, s, CHO), 7.67 (2H, d, H2/H6 J = 8 
Hz), 7.53 (2H, d, H3/H5 J = 8 Hz), 1.49 – 1.34 (6H, m), 1.20 (6H, m), 1.03 – 0.93 (m, 
6H), 0.76 (9H, t, CH2CH3 J = 7 Hz); 
13C NMR (75 MHz, CDCl3) δ 190.89 (CHO), 
150.86 (C1), 135.37, 134.60, 126.84 (C4), 27.45 (SnCH2), 25.67 (SnCH2CH2), 11.93 
(CH2CH2CH2), 8.27 (CH2CH3); HRMS (ESI positive) found: M+H
+, 395.1549. 
C19H33O
117Sn+ requires 395.1551; Anal. Calcd. for C19H32SnO: C, 57.75; H, 8.16. 
Found: C, 57.93; H, 8.07. 
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6.4 3-Tributylstannylbenzaldehyde (38)159 
 
A flask was charged with zinc dust (6.14 g, 93.8 mmol), MeCN (70 mL) was added. 
Trifluoroacetic acid (0.13 g, 1.15 mmol) was added carefully, and the solution stirred 
for 5 minutes. Cobalt dibromide (1.38 g, 6.25 mmol) was added, the resultant blue 
solution was stirred for a further 5 minutes. Addition of allyl chloride (1.44 g, 18.8 
mmol) turned the solution red upon 10 minutes stirring. 3-Bromobenzaldeyhde (9.25 
g, 50.0 mmol) was added, followed immediately by tributylstannyl chloride (22.3 g, 
68.5 mmol). The reaction was heated to 50 °C and monitored by TLC (95:5 
petrol:ether) until all of the starting material had been consumed. Once cooled to RT, 
aqueous saturated ammonium chloride (50 mL) was added and the mixture extracted 
with ether (3 × 50 mL). The organic fractions were combined and dried over MgSO4, 
filtered and concentrated in vacuo.  The crude orange oil was purified by column 
chromatography on SiO2 (petrol, then 90:10 petrol:ether) or using automated flash 
reverse phase chromatography (neat MeCN) obtaining 38 as a clear oil (13.8g, 70%). 
Rf 0.44 (95:5 petrol:ether);  IR νMAX/cm-1 (neat) 2956, 2923, 2361, 1701, 1580, 1377, 
1203; 1H NMR (300 MHz, CDCl3) δ 10.00 – 9.89 (1H, s, CHO), 7.97 – 7.81 (1H, s, 
H2), 7.75 – 7.68 (1H, dt, J = 8, 2 Hz), 7.68 – 7.62 (1H, dt, J = 7, 1 Hz), 7.46 – 7.34 
(1H, m), 1.58 – 1.38 (6H, m), 1.31 – 1.23 (6H, m), 1.19 – 0.88 (6H, m), 0.85 – 0.71 
(9H, m); 13C NMR (75 MHz, CDCl3) δ 193.01 (CHO), 143.94, 142.72, 137.89, 
136.21, 129.62, 128.64, 29.34 (SnCH2), 27.53 (SnCH2CH2), 13.78 (CH2CH2CH2), 
10.17 (CH2CH3); Anal. Calcd. for C19H32SnO: C, 57.75; H, 8.16. Found: C, 57.88; H, 
8.00. 
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6.5 4-Formylphenyl(phenyl)iodonium trifluoroacetate (43) 
 
Diacetoxyiodobenzene (3.34 g, 10.4 mmol) was dissolved in DCM (40 mL). The 
solution was cooled to 30 °C. TFA (2.37 g, 20.8 mmol) was added dropwise, the 
yellow solution was stirred at 30 °C for 30 minutes, followed by 1 hour stirring at 
room temperature. The reaction mixture was recooled to 30 °C, 4-
tributylstannylbenzaldehyde (4.11 g, 10.4 mmol) was added, and stirred for 30 
minutes. The reaction was warmed to room temperature and stirred overnight. The 
solvent was removed in vacuo, affording a yellow oil, which was triturated with 
DCM/petrol/ether to given the crude product as an off-white powder. 43 was 
obtained by recrystallisation (DCM/Petrol) as a white powder (1.36 g, 32%). Mp 
159163 °C (from DCM/Petrol); IR νMAX/cm-1 (neat) 1707, 1648, 1581, 1175, 1181; 
1H NMR (300 MHz, CD3CN) δ 10.01 (1H, s, CHO), 8.25 (2H, d, H2/H6 J = 8.4 Hz), 
8.13 (2H, d, H2′/H6′ J = 7.4 Hz), 7.94 (2H, d, H3/H5 J = 8.6 Hz), 7.68 (1H, t, H4′ J 
= 7.5 Hz), 7.52 (2H, t, H3′/H5′ J = 7.7 Hz); 13C NMR (75 MHz, CD3CN) δ 191.31 
(CHO), 138.33 (C4), 135.47 (C2/C6), 135.24 (C2′/C6′), 132.15 (C4′), 131.75 
(C3/C5), 131.59 (C3′/C5′), 122.05 (C1), 116.50 (C1′); 19F NMR (376 MHz, CD3CN) 
δ 75.51 (s); HRMS (ESI) found: M+, 308.9766. C13H10IO+ requires 308.9771; Anal. 
Calcd. for C15H1F3IO3: C, 42.68; H, 2.39. Found: C, 42.56; H, 2.45. 
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6.6 4-Formylphenyl(4-anisyl)iodonium trifluoroacetate (44) 
 
4-Anisyliodobisacetate (5.61 g, 15.9 mmol) was dissolved in dry DCM (50 mL). The 
solution was cooled to -30 °C in a dry ice/acetone bath. TFA (3.63 g, 31.8 mmol) 
was added dropwise, the yellow solution was stirred at -30 °C for 30 minutes, 
followed by 1 hour stirring at room temperature. The reaction mixture was recooled 
to -30 °C, 4-tributylstannylbenzaldehyde (6.28 g, 15.9 mmol) was added, and stirred 
for 30 minutes. The reaction was warmed to room temperature and stirred overnight. 
The solvent was removed in vacuo, affording an orange oil, which was triturated 
with DCM/petrol/ether and placed in the freezer. 44 was obtained by filtration as a 
white powder (3.43 g, 49%). Mp 149-151 °C (from DCM/Petrol); IR νMAX/cm-1 
(neat) 1701, 1660, 1582, 1487, 1262, 1174; 1H NMR (300 MHz, CD3CN) δ 10.01 
(1H, s, CHO), 8.21 (2H, d, H2/H6 J = 8.4 Hz), 8.04 (2H, d, H2′/H6′ J = 9.2 Hz), 7.93 
(2H, d, H3/H5 J = 8.6 Hz, 2H), 7.04 (2H d, H3′/H5′ J = 9.2 Hz), 3.84 (3H, s, Me); 
13C NMR (101 MHz, CD2Cl2) δ 190.72 (CHO), 162.78 (C4′), 137.99 (C4), 137.31 
(C2′/C6′), 134.67 (C2/C6), 131.78 (C3/C5), 123.31 (C1), 117.70 (C3′/C5′), 105.27 
(C1′), 55.79 (OMe); 19F NMR (376 MHz, CD2Cl2) δ -75.44 (s); HRMS (ESI 
positive) found: M+, 338.9877. C14H12IO2
+ requires 338.9876; Anal. Calcd. for 
C16H12F3IO4: C, 42.5; H, 2.67. Found: C, 42.35; H, 2.60. For X-ray crystal structure 
data, see appendix. 
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6.7 4-Formylphenyl(2-theinyl)iodonium trifluoroacetate (45) 
 
2-Thienyliodobisacetate (2.96 g, 7.49 mmol) was dissolved in dry DCM (30 mL). 
The solution was cooled to -30 °C in a dry ice/acetone bath. TFA (1.71 g, 15.0 
mmol) was added dropwise, the resultant yellow solution was stirred at -30 °C for 30 
minutes, followed by 1 hour stirring at room temperature. The reaction mixture was 
recooled to -30 °C, 4-tributylstannylbenzaldehyde (2.96 g, 7.49 mmol) was added, 
and stirred for 30 minutes. The reaction was warmed to room temperature and stirred 
overnight. The solvent was removed in vacuo, affording a yellow oil, which was 
triturated with DCM/petrol/ether and placed in the freezer. Pure 45 was obtained by 
filtration as an off-white powder (1.21 g, 38%). Mp 155-159 °C (from DCM/Petrol); 
IR νMAX/cm-1 (neat) 2981, 1702, 1645, 1381, 1190, 1141; 1H NMR (400 MHz, 
CD3CN) δ 9.95 (1H, s, CHO), 8.23 (2H, d, H2/H6 J = 8.5 Hz), 7.92 – 7.83 (3H, m), 
7.74 (1H, dd, H5′ J = 5.3, 1.2 Hz), 7.10 (1H, dd, H4′ J = 5.2, 3.8 Hz). 13C NMR (101 
MHz, CD3CN) δ 191.60 (CHO), 140.87 (C4), 138.26, 137.27, 134.80, 131.83, 
129.83, 125.50 (C1), 101.97 (C1′). 19F NMR (376 MHz, CD3CN) δ -75.62 (s); 
HRMS (ESI positive) found: M+, 314.9333. C8H11IOS
+ requires 314.9335; Anal. 
Calcd. for C13H8F3IO3S: C, 36.47; H, 1.88. Found: C, 36.36; H, 1.73. For X-ray 
crystal structure data, see appendix. 
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6.8 3-Formylphenyl(phenyl)iodonium trifluoroacetate (50) 
 
Diacetoxyiodobenzene (1.30 g, 4.05 mmol) was dissolved in dry DCM (15 mL). The 
solution was cooled to -30 °C in a dry ice/acetone bath. TFA (2.37 g, 20.8 mmol) 
was added dropwise, and the yellow solution was stirred at -30 °C for 30 minutes, 
followed by 1 hours stirring at room temperature. The reaction mixture was then 
recooled to -30 °C, 3-tributylstannylbenzaldehyde (1.60 g, 4.05 mmol) was added, 
and stirred for 30 minutes. The reaction was warmed to room temperature, and 
stirred overnight. The solvent was removed in vacuo, affording a pale yellow oil, 
which was triturated with DCM/petrol/ether and placed in the freezer. Pure 50 was 
obtained by filtration as a white powder (804 mg, 47%). Mp 150-153 °C 
(decomp.)(from DCM/Petrol); IR νMAX/cm-1 (neat) 1707, 1648, 1581, 1175, 1128; 1H 
NMR (500 MHz, d6- DMSO) δ 10.00 (1H, s, CHO), 8.74 (1H, s, H2), 8.53 (1H, d, 
H6 J = 8.0 Hz), 8.30 (2H, d, H2′/H6′ J = 8.4 Hz), 8.17 (1H, d, H4 J = 7.7 Hz), 7.76 
(1H, t, H5 J = 7.8 Hz), 7.67 (1H, t, H4′ J = 7.5 Hz), 7.54 (2H, t, H3′/H5′ J = 7.8 Hz); 
13C NMR (101 MHz, d2-DCM) δ 189.90 (CHO), 139.91 (C3), 135.19, 135.11, 
132.48, 132.19, 132.06, 131.84, 117.70 (C1), 116.86 (C1′); 19F NMR (376 MHz, d2-
DCM) δ -75.47; HRMS (ESI) found: M+, 308.9768. C13H10IO+ requires 308.9771; 
Anal. Calcd. for C15H1F3IO3: C, 42.68; H, 2.39. Found: C, 42.81; H, 2.29. For X-ray 
crystal structure data, see appendix. 
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6.9 3-Formylphenyl(4-anisyl)iodonium trifluoroacetate (51) 
 
 
4-Diacetoxyiodoanisole (1.60 g, 4.56 mmol) was dissolved in dry DCM (15 mL). 
The solution was cooled to -30 °C in a dry ice/acetone bath. TFA (1.04 g, 9.12 
mmol) was added dropwise, the yellow solution was stirred at -30 °C for 30 minutes, 
followed by 1 hour stirring at room temperature. The reaction mixture was recooled 
to -30 °C, and 3-tributylstannylbenzaldehyde (1.80 g, 4.56 mmol) was added, and 
stirred for 30 minutes. The reaction was warmed to room temperature and stirred 
overnight. The solvent was removed in vacuo, affording a pale yellow oil, which was 
triturated with DCM/petrol/ether and placed in the freezer. Pure 51 was obtained by 
filtration as a white powder (803 mg, 39%). Mp 148-158 °C (decomp.)(from 
DCM/Petrol). IR νMAX/cm-1 (neat) 1703, 1650, 1571, 1489, 1254, 1176, 1130; 1H 
NMR (500 MHz, DMSO-d6) δ 9.99 (1H, s, CHO), 8.69 (1H, s, H2), 8.47 (1H, d, H6 
J = 8.1 Hz), 8.22 (2H, d, H2′/H6′ J = 9.0 Hz), 8.16 (1H, d, H4 J = 7.6 Hz), 7.75 (t, 
H5 J = 7.8 Hz), 7.09 (2H, d, H3′/H5′ J = 9.0 Hz), 3.79 (3H, s, OMe); 13C NMR (75 
MHz, DMSO) δ 191.34 (CHO), 162.11 (C4), 139.80 (C6), 138.38 (C3), 137.36 
(C2′/C6′), 134.56 (C2), 132.75 (C4), 132.19 (C5), 117.71 (C1), 117.52 (C3′/C5′), 
105.55 (C1′), 55.70 (OMe); 19F NMR (471 MHz, DMSO-D6) δ -73.27; HRMS (ESI 
positive) found: M+, 338.9875. C14H12IO2
+ requires 338.9876; Anal. Calcd. for 
C16H12F3IO4: C, 44.06; H, 2.77. Found: C, 43.93; H, 2.69. For X-ray crystal structure 
data, see appendix.  
 
 
 
 
 
 
 138 
 
6.10 3-Formylphenyl(2-thienyl)iodonium trifluoroacetate (52) 
 
2-Diacetoxyiodothiophene (1.33 g, 4.05 mmol) was dissolved in dry DCM (15 mL). 
The solution was cooled to -30 °C in a dry ice/acetone bath. TFA (924 mg, 8.10 
mmol) was added dropwise, the yellow solution was stirred at -30 °C for 30 minutes, 
followed by 1 hour stirring at room temperature. The reaction mixture was recooled 
to -30 °C, and 3-tributylstannylbenzaldehyde (1.60 g, 4.05 mmol) was added, and 
stirred for 30 minutes. The reaction was warmed to room temperature and stirred 
overnight. The solvent was removed in vacuo, affording a yellow oil, which was 
triturated with DCM/petrol/ether and placed in the freezer. 52 was obtained by 
filtration as a white powder (744 mg, 43%). Mp 134-141 °C (decomp.)(from 
DCM/petrol/ether); IR νMAX/cm-1 (neat) 1705, 1644, 1588, 1423, 1384, 1185, 1132; 
1H NMR (400 MHz, DMSO-d6) δ 9.95 (1H, s, CHO), 8.69 (1H, s, H2), 8.49 (1H, d, 
H6 J = 8.5 Hz), 8.11 (1H, d, H4 J = 8.6 Hz), 8.07 (1H, d, J = 3.7 Hz), 7.92 (1H, d, J 
= 5.4 Hz), 7.70 (1H, t, J = 7.9 Hz), 7.16 – 7.09 (1H, m); 13C NMR (101 MHz, 
DMSO-D6) δ 192.12 (CHO), 158.65 (q, CF3(O)CO JC–F = 30.7 Hz), 141.06, 140.26, 
138.76, 137.84, 134.83, 133.59, 132.78, 130.13, 121.04 (C1), 102.28 (C1′); HRMS 
(ESI positive) found: M+, 314.9331. C8H11IOS
+ requires 314.9335; Anal. Calcd. for 
C13H8F3IO3S: C, 36.47; H, 1.88. Found: C, 36.34; H, 1.81; For X-ray crystal 
structure data, see appendix. 
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6.11 2-Fluorothiophene (49) 
 
Magnesium turnings (18.45 g, 759 mmol) were stirred for 24 h using a glass‡ stirrer 
bar under argon in a dry 3-necked 3 L round bottomed flask fitted with a double 
walled water condenser and a dropping funnel. Freshly distilled, dry diethylether (1.5 
L) was then transferred to the reaction vessel by cannula. 2-Bromothiophene (72.6 
mL, 750 mmol) was loaded into the dropping funnel then around 100 drops were 
added to the reaction vessel without stirring and left for 1 h. Stirring was then started 
and the remainder of the 2-bromothiophene added to the vessel at a rate which 
maintained a steady reflux (ca. 3 h); following addition, residual 2-bromothiophene 
was washed into the reaction mixture with dry diethylether (20 mL). An increase in 
the lustre of the magnesium turnings could be observed upon initiation accompanied 
by their gradual consumption. The reaction mixture was left overnight, after which 
the mixture was pale brown and slightly cloudy in appearance with a few small 
flakes of magnesium remaining. In a separate dry, single-necked 3 L round bottomed 
flask fitted with a water condenser, NFSI (237.72 g, 754 mmol) was dissolved in dry 
diethylether (750 mL, transferred to the flask as before) and the suspension cooled to 
0 ˚C. The Grignard solution was then transferred by cannula (12 gauge) to the NFSI 
suspension with vigorous stirring. Consumption of the NFSI was accompanied by the 
formation of a large amount of white precipitate and a slight exotherm. The 
suspension was stirred at 0 ˚C for 5 h then at room temperature for a further 3 h. A    
1 mL sample was taken from the reaction mixture, quenched with a few drops of 
methanol then mixed with D6-DMSO and analysed by 
1H- and 19F-NMR showing all 
the NFSI to be consumed but around 10% thiophene to be present relative to 2-
fluorothiophene. The condenser was quickly removed, more NFSI added (11.70 g, 
37.1 mmol) and the condenser replaced. The reaction was left for 48 h then analysed 
as before showing only one fluorinated product, 2-fluorothiophene. The reaction 
mixture was filtered through a pad of Celite (3 cm depth, 10 cm diameter) and silica 
(7 cm depth, 10 cm diameter) and the white residue washed with diethylether (2 x 
200 mL). The solvent was carefully removed from the reaction mixture by 
                                         
‡ Previous activation of magnesium turnings using a PTFE stirrer bar resulted in reaction with the PTFE coating, 
visible by the formation of ‘soot’ 
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distillation over several days, analysing the fractions by 19F- and 1H-NMR. Fractions 
of similar purity were combined to give 2-fluorothiophene as a clear colourless liquid 
(35.8 g, 47%). bp 82-84 °C (lit: 82 ˚C); λmax (EtOH)/nm 226 (ε/dm3 mol-1 cm-1 5150; 
IR νmax/cm-1 (neat) 1556, 1451, 1229, 1187, 1085, 1027, 843, 807, 705, 673; 1H 
NMR (500 MHz, D2-DCM) δ 6.71 (1H, ddd, H4 3J4,5 6.0, 3J4,3, 3.9, 4J4,F 3.1), 6.66 
(1H, ddd, H5 3J5,4 6.0, 
4J5,3 1.8, 
4J5,F 3.1), 6.48 (1H, dt, H3 
3/4J3,4/5 2.0, 
3J3,F 1.8); 
13C 
NMR (125 MHz, D2-DCM) δ  168.06 (d, C2 1J2,F 286.4)125.69 (d, C4 3J4,F 286.4), 
115.70 (d, C5 3J5,F 1.5), 109.03 (d, C3 
2J3,F 11.1);
 19F NMR (376 MHz, D2-DCM) δ 
135.05 (1F, dt, 4JF,4/5 3.2, 
3JF,3 1.6); Mass spec. (HRMS) Found: M
+, 101.9933. 
C4H3FS requires 101.9934. Anal. Calcd. for C5H3FS: C, 47.04; H, 2.96, found C, 
47.43; H, 2.95. 
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6.12 2-Thienyl(phenyl)iodonium trifluoroacetate (57)238 
 
Phenyliodobisacetate (1.28 g, 5 mmol) was dissolved in dry DCM (25 mL), and the 
solution was cooled to -30 °C in a dry ice/acetone bath. TFA (0.57 g, 10 mmol) was 
added dropwise, the yellow solution was stirred at -30 °C for 30 minutes, followed 
by 1 hour at room temperature. The reaction mixture was recooled to -30 °C, 2-
thienyltributylstannane (1.87 g, 5 mmol) was added and stirred for 30 minutes. The 
reaction was then warmed to room temperature and stirred overnight. The solvent 
was removed in vacuo, affording a pale yellow oil, which was triturated with 
DCM/petrol/ether and placed in a freezer. Pure 57 was obtained by filtration as a 
white crystalline solid (434 mg, 28%). Mp 147-153 °C (decomp.)(from 
DCM/petrol/ether); IR νmax/cm-1 1651, 1577, 1488, 1259, 1173, 1137; 1H NMR (400 
MHz, CDCl3) δ 7.95 (2H, dd, J = 8.5, 0.9 Hz), 7.71 (1H, dd, J = 3.7, 1.1 Hz), 7.58 
(1H, dd, J = 5.3, 1.1 Hz), 7.50 (1H, t, J = 7.4 Hz), 7.41 – 7.34 (2H, m), 7.04 (1H, dd, 
J = 5.3, 3.8 Hz); 13C NMR (101 MHz, DMSO-d6) δ 158.50 (q,  JC-F = 30.8 Hz) 
140.72, 137.62, 135.10, 132.44, 132.11, 130.09, 122.19, 120.19, 119.20, 116.21, 
101.95; 19F NMR (376 MHz, CDCl3) δ -75.33; HRMS (ESI positive) found: M+, 
286.9378. C10H8IS
+ requires 286.9366. Anal. Calcd. for C12H8F3IO2S: C, 36.30; H, 
2.34. Found: C, 36.49; H, 2.25. For X-ray crystal structure data, see appendix.  
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6.13 2-Thienyl(4-anisyl)iodonium trifluoroacetate (58)239 
 
4-Anisyliodobisacetate (1.76 g, 5 mmol) was dissolved in dry DCM (25 mL), and the 
solution was cooled to -30 °C in a dry ice/acetone bath. TFA (0.57 g, 10 mmol) was 
added dropwise, the yellow solution was stirred at -30 °C for 30 minutes, followed 
by 1 hour at room temperature. The reaction mixture was recooled to -30 °C, 2-
Thienyltributylstannane (1.87 g, 5 mmol) was added and stirred for 30 minutes. The 
reaction was then warmed to room temperature and stirred overnight. The solvent 
was removed in vacuo, affording a pale yellow oil, which was triturated with 
DCM/petrol/ether and placed in a freezer. 58 was obtained by filtration as a white 
crystalline solid (839 mg, 39%). Mp 147-153 °C (decomp.)(from DCM/petrol/ether); 
IR νmax/cm-1 1650, 1572, 1488, 1259, 1174, 1137, 1016; 1H NMR (400 MHz, 
DMSO-d6) δ 8.14 (2H, d, H2′/H6′ J = 9.0 Hz), 8.00 – 7.95 (1H, m), 7.90 (1H, dd, J = 
5.3, 1.0 Hz), 7.13 – 7.10  (1H, m), 7.02 (2H, d, H3′/H5′ J = 9.0 Hz). 13C NMR (101 
MHz, DMSO-d6) δ 162.39, 140.26, 137.35, 137.27, 130.01, 117.82, 109.03, 102.30, 
56.23; 19F NMR (376 MHz, CDCl3) δ -75.25; HRMS (ESI positive) found: M+, 
316.9485. C10H11IOS
+ requires 316.9492. Anal. Calcd. for C13H10F3IO3S: C, 36.30; 
H, 2.34. Found: C, 36.22; H, 1.92. For X-ray crystal structure data, see appendix. 
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6.14 2-Thienyl(2-thienyl) trifluoroacetate (59)178, 238 
 
2-Thienyliodobisacetate (1.64 g, 5 mmol) was dissolved in dry DCM (25 mL), and 
the solution was cooled to -30 °C in a dry ice/acetone bath. TFA (0.57 g, 10 mmol) 
was added dropwise, the yellow solution was stirred at -30 °C for 30 minutes, 
followed by 1 hour at room temperature. The reaction mixture was recooled to -
30 °C, 2-Thienyltributylstannane (1.87 g, 5 mmol) was added and stirred for 30 
minutes. The reaction was then warmed to room temperature and stirred overnight. 
The solvent was removed in vacuo, affording a pale yellow oil, which was triturated 
with MeCN/ether and placed in a freezer. Pure 59 was obtained by filtration as a 
white crystalline solid (103 mg, 19%). Mp 123-125 °C (decomp.)(from MeCN/ether). 
IR νmax/cm-1 1645, 1420, 1386, 1180, 1137, 947, 831, 797, 699; δH (400 MHz, D3-
MeCN, Me4Si) 7.80 (2 H, d, H-3 
3J3/4 3.20), 7.69 (2 H, d, H-5 
3J5,4 5.20), 7.04 (2 H, 
tapp, H-4 
3J3,5/4 4.80); δC (100 MHz, D3-MeCN, Me4Si) 139.50 (C3), 136.26 (C5), 
129.27 (C4), 104.57 (C2); δF (376 MHz, CDCl3, CFCl3) -75.36; Mass spec. (High 
Res. LCMS) m/z (ESI) 292 (M-TFA)+, 100%), 239 (12), 210 (27), 166 (15). Found: 
(M-TFA)+ 292.8950. C8H6IS2 requires 292.8950. Anal. calcd. for C10H6F3IO2S2:       
C, 29.57; H, 1.49. Found: C, 29.61; H, 1.45. For X-ray crystal structure data, see 
appendix. 
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6.15 N-4-(Fluoro)phenylmaleimide (61)195 
 
Maleic anhydride (19.62 g, 200 mmol) was added to a dry flask equipped with a 
dropping funnel, and dissolved in dry ether (240 mL). 4-Fluoroaniline (22.22 g, 200 
mmol) was placed in the dropping funnel and dissolved in dry ether (40 mL), the 
resultant solution was added dropwise to the reaction flask, forming a thick 
green/yellow solution, which was stirred at room temperature for 1.25 hr. Upon 
filtration and drying a yellow/green solid was obtained, the solid was placed in a dry 
flask, equipped with a condenser, containing NaOAc (6.56 g, 80 mmol). Upon 
dissolution with acetic anhydride (70 mL), and heating at 100 °C a clear 
yellow/brown solution formed after 0.5 hr stirring. The reaction mixture was cooled 
to room temperature; the resultant yellow/brown precipitate was collected by 
filtration. Washing with ice cold water (2 × 50 mL) followed by recrystallisation 
(from EtOH/water) and drying afforded 61 as a fluffy orange/yellow crystalline 
powder (34.61 g, 91%). Mp 136-143 °C (from EtOH/water) (lit:195 146-148 °C); IR 
νMAX/cm-1 (neat) 3104, 1708, 1514, 1390, 1230, 1148;  1H NMR (400 MHz, CDCl3) 
δ 7.29 (2H, m), 7.18 – 7.10 (2H, m), 6.84 (2H, s, H6). 13C NMR (101 MHz, CDCl3) 
δ 169.51 (C5), 161.89 (C1, d, JC–F = 247.8 Hz), 134.32 (C6), 128.00 (C2, d, JC–F = 
8.7 Hz), 127.17 (C4, d, JC–F = 3.0 Hz), 116.26 (C3, d, JC–F = 23.0 Hz). 
19F NMR (471 
MHz, Chloroform-d) δ -113.01. HRMS (ESI positive) found: [M+H]+, 192.0455. 
C10H7FNO2
+ requires 192.0453; Anal. calcd. for C10H6FNO2: C, 47.65; H, 2.40; N, 
5.56. Found: C, 47.48; H, 2.23; N, 5.56.  
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6.16 N-4-(Bromo)phenylmaleimide (62) 
 
 
Maleic anhydride (19.62 g, 200 mmol) was added to a dry flask equipped with a 
dropping funnel, and dissolved in dry ether (240 mL). 4-Bromoaniline (34.40 g, 200 
mmol) was placed in the dropping funnel and dissolved in dry ether (50 mL) forming 
a dark purple solution, which upon addition to the reaction flask generated a thick 
yellow/green mixture. The mixture was stirred at room temperature for one hour. 
Upon filtration a yellow/green solid was obtained, dried, and placed in a dry flask, 
equipped with a condenser, containing NaOAc (6.56 g, 80 mmol). Upon dissolution 
with acetic anhydride (70 mL), and heating at 100 °C a clear yellow/brown solution 
formed after 30 minutes stirring. The reaction mixture was cooled to room 
temperature, and poured onto a water/ice mixture (200 mL), the resultant 
yellow/brown precipitate was collected by filtration. Washing with ice cold water (3 
× 100 mL) followed by recrystallisation (from EtOH/water) and drying afforded 62 
as a yellow powder (33.78 g, 98%). Mp 130-134 °C (from EtOH/water) (lit:195 128-
130 °C); IR νMAX/cm-1 (neat) 3090, 2981, 1716, 1490, 1383, 1146; 1H NMR (400 
MHz, CDCl3) δ 7.62 – 7.47 (2H, d, J = 8.7 Hz), 7.29 – 7.15 (2H, d, J = 8.7 Hz), 6.88 
– 6.69 (2H, s, H6). 13C NMR (101 MHz, CDCl3) δ 169.16 (CO), 134.39, 132.39, 
130.37, 127.45, 121.69. HRMS (ESI positive) found: [M+H]+, 283.9919. 
C10H7BrNO2
+ requires 283.9917. Anal. calcd. for C10H6BrNO2: C, 47.65; H, 2.40; N, 
5.56. Found: C, 47.48; H, 2.23; N, 5.56. 
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6.17 N-4-(Iodo)phenylmaleimide (63)195 
 
Maleic anhydride (9.81 g, 100 mmol) was added to a dry flask equipped with a 
dropping funnel, and dissolved in dry ether (40 mL). 4-Iodoaniline (21.90 g, 100 
mmol) was placed in the dropping funnel and dissolved in dry ether (40 mL), the 
resultant solution was added dropwise to the reaction flask, forming a thick 
green/yellow solution, which was stirred at room temperature for 1.25 hr. Upon 
filtration and drying a yellow/green solid was obtained, the solid was placed in a dry 
flask, equipped with a condenser, containing NaOAc (3.28 g, 40 mmol). Upon 
dissolution with acetic anhydride (34 mL), and heating at 100 °C a clear 
yellow/brown solution formed after 0.5 hr stirring. The reaction mixture was cooled 
to room temperature, and poured onto a water/ice mixture (200 mL), the resultant 
yellow/brown precipitate was collected by filtration. Washing with ice cold water (2 
× 50 mL) followed by recrystallisation (from EtOH/water) and drying afforded 63 as 
a yellow crystalline powder (18.06 g, 61%). Mp 139-144 °C (from EtOH/water) 
(lit:195 145-147 °C); IR νMAX/cm-1 (neat) 2981, 1703, 1485, 1388, 1152; 1H NMR 
(300 MHz, CDCl3) δ 7.80 (2H, d J = 8.6 Hz), 7.14 (2H, d J = 8.6 Hz), 6.87 (2H, s, 
H6); 13C NMR (75 MHz, CDCl3) δ 168.82 (CO), 138.22, 134.23, 131.27, 127.51, 
92.77 (C1); HRMS (ESI positive) found: [M+H]+, 299.9522. C10H7INO2
+ requires 
299.9516. Anal. calcd. for C10H6INO2: C, 40.16; H, 2.02; N, 4.68. Found: C, 40.05; 
H, 2.07; N, 4.74. For X-ray crystal structure data, see appendix. 
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6.18 4-N-phenylmaleimide(phenyl)iodonium trifluoroacetate (69) 
 
4-N-phenylmaleimideiodobisacetate (1.8 g, 4.31 mmol as a 50% mixture determined 
by 1H-NMR with 4-iodo-N-phenylmaleimide, 63) was dissolved in dry DCM (25 
mL). The solution was cooled to -30 °C in a dry ice/acetone bath. TFA (0.98 g, 8.61 
mmol) was added dropwise, the yellow solution was stirred at -30 °C for 30 minutes, 
followed by 1 hour stirring at room temperature. The reaction mixture was recooled 
to -30 °C, and phenyltributylstannane (1.58 g, 4.31 mmol) was added, and stirred for 
30 minutes. The reaction was warmed to room temperature and stirred overnight. 
The solvent was removed in vacuo, affording a pale yellow oil, which was triturated 
with DCM/petrol/ether and placed in the freezer. 69 was obtained by filtration as 
colourless needles (422 mg, 20%). Mp 123-134 °C (decomp.)(from 
DCM/petrol/ether); 1H NMR (400 MHz, DMSO-d6) δ 8.31 (2H, d, J = 8.7 Hz, 1H), 
8.24 (d, J = 8.1 Hz, 1H), 7.64 (t, J = 7.3 Hz, 1H), 7.56 – 7.44 (m, 4H), 7.19 (s, 1H). 
13C NMR (101 MHz, DMSO-D6) δ 169.87 (CO), 136.39 (C7), 135.72, 135.48, 
135.23, 132.55, 132.25, 129.68, 117.64, 115.29. 19F NMR (376 MHz, DMSO-D6) δ -
68.36; HRMS (ESI positive) found: [M]+, 375.9827. C16H11NIO2
+ requires 375.9829; 
Anal. Calcd. for C16H11F3IO3S: C, 44.20; H, 2.27 N, 2.86. Found: C, 44.08; H, 2.34 
N, 2.98. For X-ray crystal structure data, see appendix. 
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7 Appendix 
Note that further appendices may be found on the accompanying CD.  
7.1 Crystal data and structure refinement for 4-formylphenyl(4-
anisyl)iodonium trifluoroacetate (44) 
Chemical formula (moiety) C16H12F3IO4 
Chemical formula (total) C16H12F3IO4 
Formula weight  452.16 
Temperature  150(2) K 
Radiation, wavelength   Å 
Crystal system, space group  monoclinic, P121/c1 
Unit cell parameters a = 5.7022(4) Å  = 90° 
 b = 17.4185(13) Å = 97.454(7)° 
 c = 16.6821(11) Å  = 90° 
Cell volume 1642.9(2) Å3 
Z 4 
Calculated density  1.828 g/cm3 
Absorption coefficient  1.998 mm1 
F(000) 880 
Reflections for cell refinement 2037 (range 3.4 to 28.6°) 
Data collection method Xcalibur, Atlas, Gemini ultra 
 thick-slice  scans 
 range for data collection 3.4 to 25.0° 
Index ranges h 6 to 6, k 17 to 20, l 16 to 19 
Completeness to  = 25.0° 99.8 %  
Reflections collected 7100 
Independent reflections 2887 (Rint = 0.0646) 
Reflections with F2>2 1957 
Absorption correction semi-empirical from equivalents 
Min. and max. transmission 0.63325 and 1.00000 
Structure solution direct methods 
Refinement method Full-matrix least-squares on F2 
Weighting parameters a, b 0.0646, 0.0000 
Data / restraints / parameters 2887 / 0 / 218 
Final R indices [F2>2] R1 = 0.0625, wR2 = 0.1277 
R indices (all data) R1 = 0.1019, wR2 = 0.1492 
Goodness-of-fit on F2 1.034 
Largest and mean shift/su 0.000 and 0.000 
Largest diff. peak and hole 1.39 and 1.97 e Å3 
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7.2 Crystal data and structure refinement for 4-formylphenyl(2-
thienyl)iodonium trifluoroacetate (45) 
Chemical formula (moiety) C13H8F3IO3S 
Chemical formula (total) C13H8F3IO3S 
Formula weight  428.15 
Temperature  150(2) K 
Radiation, wavelength  MoK, 0.71073 Å 
Crystal system, space group  monoclinic, C2/c 
Unit cell parameters a = 23.0590(13) Å  = 90° 
 b = 8.0398(3) Å          = 110.324(6)° 
 c = 16.4429(8) Å  = 90° 
Cell volume 2858.6(2) Å3 
Z 8 
Calculated density  1.990 g/cm3 
Absorption coefficient  2.426 mm1 
F(000) 1648 
Reflections for cell refinement 9027 (range 2.9 to 28.6°) 
Data collection method Xcalibur, Atlas, Gemini ultra 
 thick-slice  scans 
 range for data collection 2.9 to 28.6° 
Index ranges h 30 to 29, k 10 to 10, l 17 to 20 
Completeness to  = 25.0° 99.8 %  
Reflections collected 15278 
Independent reflections 3274 (Rint = 0.0381) 
Reflections with F2>2 2852 
Absorption correction semi-empirical from equivalents 
Min. and max. transmission 0.72172 and 1.00000 
Structure solution direct methods 
Refinement method Full-matrix least-squares on F2 
Weighting parameters a, b 0.0205, 5.1722 
Data / restraints / parameters 3274 / 0 / 209 
Final R indices [F2>2] R1 = 0.0248, wR2 = 0.0503 
R indices (all data) R1 = 0.0335, wR2 = 0.0539 
Goodness-of-fit on F2 1.066 
Largest and mean shift/su 0.001 and 0.000 
Largest diff. peak and hole 1.12 and 0.72 e Å3 
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7.3 Crystal data and structure refinement for                                   
3-formylphenyl(phenyl)iodonium trifluoroacetate (50) 
Chemical formula (moiety) C15H10F3IO3 
Chemical formula (total) C15H10F3IO3 
Formula weight  422.13 
Temperature  150(2) K 
Radiation, wavelength  MoK, 0.71073 Å 
Crystal system, space group  triclinic, P1 
Unit cell parameters a = 8.1943(4) Å   = 98.177(4)° 
 b = 8.2924(5) Å    = 103.038(4)° 
 c = 11.7005(6) Å  = 101.490(4)° 
Cell volume 744.30(7) Å3 
Z 2 
Calculated density  1.884 g/cm3 
Absorption coefficient  2.193 mm1 
F(000) 408 
Crystal colour and size colourless, 0.20  0.20  0.15 mm3 
Reflections for cell refinement 4414 ( range 2.8 to 28.6°) 
Data collection method Xcalibur, Atlas, Gemini ultra 
 thick-slice  scans 
 range for data collection 2.8 to 28.6° 
Index ranges h 10 to 10, k 10 to 9, l 15 to 15 
Completeness to  = 26.0° 97.3 %  
Reflections collected 6132 
Independent reflections 3093 (Rint = 0.0271) 
Reflections with F2>2 2900 
Absorption correction semi-empirical from equivalents 
Min. and max. transmission 0.6682 and 0.7345 
Structure solution direct methods 
Refinement method Full-matrix least-squares on F2 
Weighting parameters a, b 0.0306, 1.5647 
Data / restraints / parameters 3093 / 0 / 200 
Final R indices [F2>2] R1 = 0.0289, wR2 = 0.0727 
R indices (all data) R1 = 0.0314, wR2 = 0.0744 
Goodness-of-fit on F2 1.101 
Extinction coefficient 0.0016(7) 
Largest and mean shift/su 0.000 and 0.000 
Largest diff. peak and hole 1.42 and 0.56 e Å3 
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7.4 Crystal data and structure refinement for 3-formylphenyl(4-
anisyl)iodonium trifluoroacetate (51) 
Chemical formula (moiety) C14H12IO2
+·C2F3O2
 ·CH2Cl2 
Chemical formula (total) C17H14Cl2F3IO4 
Formula weight  537.08 
Temperature  150(2) K 
Radiation, wavelength  MoK, 0.71073 Å 
Crystal system, space group  triclinic, P1 
Unit cell parameters a = 5.9676(3)         = 91.507(4)° 
 b = 12.4791(5) Å    = 93.060(4)° 
 c = 13.5288(7) Å    = 95.936(4)° 
Cell volume 1000.15(8) Å3 
Z 2 
Calculated density  1.783 g/cm3 
Absorption coefficient  1.915 mm1 
F(000) 524 
Crystal colour and size colourless, 0.34  0.30  0.10 mm3 
Reflections for cell refinement 4163 ( range 3.0 to 29.6°) 
Data collection method Xcalibur, Atlas, Gemini ultra 
 thick-slice  scans 
 range for data collection 3.0 to 29.7° 
Index ranges h 6 to 8, k 15 to 17, l 17 to 17 
Completeness to  = 26.0° 99.9 %  
Reflections collected 9247 
Independent reflections 4734 (Rint = 0.0323) 
Reflections with F2>2 4188 
Absorption correction semi-empirical from equivalents 
Min. and max. transmission 0.5621 and 0.8316 
Structure solution direct methods 
Refinement method Full-matrix least-squares on F2 
Weighting parameters a, b 0.0326, 1.3833 
Data / restraints / parameters 4734 / 6 / 273 
Final R indices [F2>2] R1 = 0.0347, wR2 = 0.0783 
R indices (all data) R1 = 0.0430, wR2 = 0.0840 
Goodness-of-fit on F2 1.047 
Largest and mean shift/su 0.003 and 0.000 
Largest diff. peak and hole 1.54 and 0.80 e Å3 
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7.5 Crystal data and structure refinement for 3-formylphenyl(2-
thienyl)iodonium trifluoroacetate (52) 
Chemical formula (moiety) C13H8F3IO3S 
Chemical formula (total) C13H8F3IO3S 
Formula weight  428.15 
Temperature  150(2) K 
Radiation, wavelength  MoK, 0.71073 Å 
Crystal system, space group  monoclinic, C2/c 
Unit cell parameters a = 23.0590(13)  Å  = 90° 
 b = 8.0398(3) Å   = 110.324(6)° 
 c = 16.4429(8) Å  = 90° 
Cell volume 2858.6(2) Å3 
Z 8 
Calculated density  1.990 g/cm3 
Absorption coefficient  2.426 mm1 
F(000) 1648 
Reflections for cell refinement 9027 ( range 2.9 to 28.6°) 
Data collection method Xcalibur, Atlas, Gemini ultra 
 thick-slice  scans 
 range for data collection 2.9 to 28.6° 
Index ranges h 30 to 29, k 10 to 10, l 17 to 20 
Completeness to  = 25.0° 99.8 %  
Reflections collected 15278 
Independent reflections 3274 (Rint = 0.0381) 
Reflections with F2>2 2852 
Absorption correction semi-empirical from equivalents 
Min. and max. transmission 0.72172 and 1.00000 
Structure solution direct methods 
Refinement method Full-matrix least-squares on F2 
Weighting parameters a, b 0.0205, 5.1722 
Data / restraints / parameters 3274 / 0 / 209 
Final R indices [F2>2] R1 = 0.0248, wR2 = 0.0503 
R indices (all data) R1 = 0.0335, wR2 = 0.0539 
Goodness-of-fit on F2 1.066 
Largest and mean shift/su 0.001 and 0.000 
Largest diff. peak and hole 1.12 and 0.72 e Å3 
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7.6 Crystal data and structure refinement for                                   
2-thienyl(phenyl)iodonium trifluoroacetate (57) 
Empirical formula  C12H8O2F3SI  
Formula weight  400.14  
Temperature/K  0.0  
Crystal system  monoclinic  
Space group  P21/n  
a/Å  9.9078(7)  
b/Å  22.2153(13)  
c/Å  12.2494(7)  
α/°  90  
β/°  90.845(2)  
γ/°  90  
Volume/Å3  2695.9(3)  
Z  8  
ρcalcg/cm3  1.972  
μ/mm-1  2.559  
F(000)  1536.0  
Crystal size/mm3  0.336 × 0.146 × 0.145  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  4.502 to 50.694  
Index ranges  -11 ≤ h ≤ 11, 0 ≤ k ≤ 26, 0 ≤ l ≤ 14  
Reflections collected  4944  
Independent reflections  4944 [Rint = ?, Rsigma = 0.0503]  
Data/restraints/parameters  4944/1149/516  
Goodness-of-fit on F2  1.133  
Final R indexes [I>=2σ (I)]  R1 = 0.0624, wR2 = 0.1568  
Final R indexes [all data]  R1 = 0.0672, wR2 = 0.1621  
Largest diff. peak/hole / e Å-3  5.63/-1.55  
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7.7 Crystal data and structure refinement for                                  
2-thienyl(4-anisyl)iodonium trifluoroacetate (58) 
Empirical formula  C13H10O3F3SI  
Formula weight  430.17  
Temperature/K  120.0(2)  
Crystal system  triclinic  
Space group  P-1  
a/Å  8.2626(5)  
b/Å  9.2855(5)  
c/Å  11.5270(6)  
α/°  67.2341(15)  
β/°  80.1262(15)  
γ/°  65.0867(14)  
Volume/Å3  739.56(7)  
Z  2  
ρcalcg/cm3  1.932  
μ/mm-1  2.345  
F(000)  416.0  
Crystal size/mm3  0.23 × 0.11 × 0.09  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  5.168 to 50.698  
Index ranges  -9 ≤ h ≤ 9, -11 ≤ k ≤ 11, -13 ≤ l ≤ 13  
Reflections collected  9049  
Independent reflections  2706 [Rint = 0.0218, Rsigma = 0.0211]  
Data/restraints/parameters  2706/289/225  
Goodness-of-fit on F2  1.100  
Final R indexes [I>=2σ (I)]  R1 = 0.0183, wR2 = 0.0447  
Final R indexes [all data]  R1 = 0.0196, wR2 = 0.0454  
Largest diff. peak/hole / e Å-3  0.49/-0.49  
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7.8 Crystal data and structure refinement for                                   
2-thienyl(2-thienyl)iodonium trifluoroacetate (59) 
Empirical formula  C10H6O2F3IS2 
Formula weight  406.17  
Temperature/K  150.0(2)  
Crystal system  triclinic  
Space group  P-1  
a/Å  7.1291(4)  
b/Å  8.3112(5)  
c/Å  11.9268(7)  
α/°  103.2231(16)  
β/°  104.6033(15)  
γ/°  105.3008(17)  
Volume/Å3  625.73(6)  
Z  2  
ρcalcg/cm3  2.156  
μ/mm-1  2.919  
F(000)  388.0  
Crystal size/mm3  0.27 × 0.19 × 0.07  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  5.356 to 55.146  
Index ranges  -9 ≤ h ≤ 9, -10 ≤ k ≤ 10, -15 ≤ l ≤ 15  
Reflections collected  8948  
Independent reflections  2893 [Rint = 0.0200, Rsigma = 0.0183]  
Data/restraints/parameters  2893/210/189  
Goodness-of-fit on F2  1.065  
Final R indexes [I>=2σ (I)]  R1 = 0.0175, wR2 = 0.0446  
Final R indexes [all data]  R1 = 0.0182, wR2 = 0.0449  
Largest diff. peak/hole / e Å-3  1.06/-0.48  
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7.9 Crystal data and structure refinement for 4-iodo-N-
phenylmaleimide (63) 
Chemical formula (moiety) C10H6INO2 
Chemical formula (total) C10H6INO2 
Formula weight  299.06 
Temperature  150(2) K 
Radiation, wavelength  MoK, 0.71073 Å 
Crystal system, space group  orthorhombic, P212121 
Unit cell parameters a = 6.6205(5) Å  = 90° 
 b = 7.4850(6) Å  = 90° 
 c = 19.7683(13) Å  = 90° 
Cell volume 979.61(13) Å3 
Z 4 
Calculated density  2.028 g/cm3 
Absorption coefficient  3.239 mm1 
F(000) 568 
Crystal colour and size  , 0.30  0.04  0.04 mm3 
Reflections for cell refinement 1547 ( range 4.1 to 27.6°) 
Data collection method Xcalibur, Atlas, Gemini ultra 
 thick-slice  scans 
 range for data collection 2.9 to 28.7° 
Index ranges h 8 to 6, k 10 to 9, l 25 to 20 
Completeness to  = 25.0° 99.9 %  
Reflections collected 4151 
Independent reflections 2064 (Rint = 0.0283) 
Reflections with F2>2 1878 
Absorption correction semi-empirical from equivalents 
Min. and max. transmission 0.4432 and 0.8813 
Structure solution direct methods 
Refinement method Full-matrix least-squares on F2 
Weighting parameters a, b 0.0099, 0.0000 
Data / restraints / parameters 2064 / 0 / 128 
Final R indices [F2>2] R1 = 0.0275, wR2 = 0.0440 
R indices (all data) R1 = 0.0354, wR2 = 0.0485 
Goodness-of-fit on F2 1.067 
Absolute structure parameter  0.03(3) 
Extinction coefficient 0.0013(3) 
Largest and mean shift/su 0.001 and 0.000 
Largest diff. peak and hole 0.59 and 0.63 e Å3 
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7.10 Crystal data and structure refinement for                                 
4-N-phenylmaleimide(phenyl)iodonium trifluoroacetate (69) 
Empirical formula  C18H13NO3F3I  
Formula weight  508.09  
Temperature/K  150.00(10)  
Crystal system  monoclinic  
Space group  P21/n  
a/Å  11.7417(4)  
b/Å  6.62347(19)  
c/Å  27.4536(9)  
α/°  90  
β/°  93.635(3)  
γ/°  90  
Volume/Å3  2130.80(12)  
Z  4  
ρcalcmg/mm3  1.584  
m/mm-1  1.778  
F(000)  992.0  
Crystal size/mm3  0.8315 × 0.1191 × 0.04  
2Θ range for data collection  7.066 to 58.14°  
Index ranges  -15 ≤ h ≤ 15, -8 ≤ k ≤ 8, -36 ≤ l ≤ 36  
Reflections collected  29746  
Independent reflections  4513[R(int) = 0.0471]  
Data/restraints/parameters  4513/0/281  
Goodness-of-fit on F2  1.165  
Final R indexes [I>=2σ (I)]  R1 = 0.0418, wR2 = 0.0837  
Final R indexes [all data]  R1 = 0.0514, wR2 = 0.0873  
Largest diff. peak/hole / e Å-3  0.88/-0.74  
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7.11 Macros  
The following bespoke macros were used to control various stages of the 
microfluidic preparation of radiolabeled compounds using the Advion NanoTek LF 
software.  
 
7.11.1 Fluorine-18 Drying Macro 
0 Wait Drying macro. Ensure needle is fully inserted into 
target water vial. Ensure QMA cartridge is loaded. Ensure all 
solutions are prepared and installed. Ensure all plumbing is correct.
  
1000
 L37020000800054                         L3602000300004E
                         Set Conc 1 to 80oC  
2000 /5o1V1200A6000M3000o5V1200A0M2000R Load target water  
15000 /5o6V1200A6000M2000o3V1200A0R Remove target water  
15000
 L3702000100004D                         L3602000300004E
                         Set Conc 1 to 100oC  
2000 /7U2M5000U1M5000u2R Turn on the Nitrogen  
10000 /5o2V1000P5000M2000go5V400D750M15000G4o2V2000A0R Add 400 
uL of PTA  
105000 /5M90000R Wait 100s for conc vial to dry PTA solution
  
100000
 /5o4V1000P6000M2000o5V75D3600M2000o6V75D1200M2000o2V2000A0R
 Add 400 uL of MeCN (1) and flush back PTA line  
75000 /5M30000R Wait 20s for conc vial to dry MeCN (1)  
20000 /5o4V1000P6000M2000o6V75D3600M2000o2V2000A0R Add 400 uL of 
MeCN (2) and flush back PTA line  
45000 /5M30000R Wait 20s for conc vial to dry MeCN (2)  
20000 /7u1R Turn off the Nitrogen  
2000 /3o1V2000A0M2000o8V2000A15600M2000o6V800A0R Add 325 uL of 
DMF  
40000 /3go4V1600A19200M2000V3200A0M2000G6o8V3200A3600M2000o4V3200A0R
 Mix the solvent with the fluoride. Add 75 uL of DMF to flush 
line F  
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140000
 L37020000250053                         L3602000300004E
                         Set Conc 1 to 25oC  
2000 Wait End of drying macro. Pump 3 can now be prepared.  
 
7.11.2 Autodiscovery Mode Cleaning 
2000 Wait P1,2,3 reagent lines will be back-flushed. Place Reactor 
outlet into waste   
1000    
/1o1V3200A0o8A48000M1000o1A0o8A48000M1000o4V1600A0o8V3200A48000M1000
o3V100A0R P1, Clean reagent line, loop and load line  
5000    
/2o1V3200A0o8A48000M1000o1A0o8A48000M1000o4V1600A0o8V3200A48000M1000
o3V100A0R P2, Clean reagent line, loop and load line 
2000 /7o1R Hub to Waste (A) 
5000    
/3o1V3200A0o8A48000M1000o1A0o8A48000M1000o4V1600A0o8V3200A24000o3V10
0A0R P3, Clean reagent line, loop and load line Sweep 
1000 /6go4V600P3600M10006o2V60D3600G2R Flush APT line x2 
160000 /6go4V600P3600M10006o5V60D3600G2R Flush QMA x2 
160000 /6go4V600P3600M10006o6V60D3600G2R Flush line F x2 
230000 /3o8V3200A24000M1000o2V100A0R P3, Sweeps reactor 
contents to waste 
